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5 Resumo 
A glicosilação é a modificação pós-traducional de proteínas mais abundante em eucariotas e 
pode estar envolvida numa multiplicidade de funções. No entanto, as ferramentas disponíveis 
para estudar tipos raros ou incomuns de glicosilação, são limitadas. A N-glicosilação consiste 
num tipo de glicosilação onde o glicano é sempre adicionado a um resíduo de asparagina da 
proteína. Este tipo de glicosilação inicia-se no retículo endoplasmático onde um glicano 
precursor é sintetizado por glicosiltransferases, sendo posteriormente antes transferido para 
a proteína alvo pelo complexo enzimático da oligosacariltransferase (OST). A glicoproteína é 
então transferida para o Golgi onde o glicano é ainda modificado por glicosidases ou 
glicosiltransferases. O conjunto de glicosiltransferases presentes em cada organismo sintetiza 
uma vasta diversidade de glicanos, muitos dos quais são específicos de cada organismo. Desta 
forma as vias de síntese e funções dos glicoconjugados fornecem informações importantes 
sobre como certos organismos patogénicos proliferam e causam doenças. Neste contexto, 
novas ferramentas para estudar a síntese dos glicanos e as enzimas processadoras de glicanos 
poderão abrir caminho para novas terapêuticas. Nesta tese são descritos três métodos 
químicos para explorar a N-glicosilação nos parasitas Trypanosoma brucei e Plasmodium 
falciparum. 
 
O primeiro objetivo do meu trabalho de doutoramento foi o desenvolvimento de um novo 
método para enriquecimento seletivo de UDP-galactosil transferases, isto é 
glicosiltransferases que catalizam a transferência de uma molécula de galactose da UDP-
Galactose (UDP-Gal) para a molécula substrato. Embora a UDP-agarose sirva para enriquecer 
seletivamente para glicosiltransferases a partir de misturas complexas, esta não é específica 
para UDP-galactosil transferases. As enzimas desta família de enzimas são responsáveis por 
catalizar a formação de ligações em muitos glicanos exclusivos de T. brucei. Desta forma, e 
devido à sua ausência em seres humanos, representam potencias alvos de fármacos combater 
a tripanossomíase. Devido à sua natureza incomum, nenhum gene homólogo deste 
galactosiltransferases presentes noutros eucariotas foi identificado até hoje em T. brucei. A 
primeira parte do meu projeto de doutoramento teve por objetivo sintetizar uma sonda 
baseada em atividade enzimática para isolar seletivamente as UDP-galactosil transferases de 
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 T. brucei. Esta sonda baseou-se na funcionalização com análogos do nucleótido de açúcar 
dador desta classe de enzimas, a UDP-GalGal. Partindo de uma via de de síntese recentemente 
desenvolvida, a UDP-Gal e UDP-(4F)-Gal foram  conjugados a uma resina de TentaGel™. Tanto 
quanto conhecemos, estes são os primeiros nucleótidos de açúcar acoplados a uma resina. 
Após um processo de otimização na qual foram testadas várias vias de síntese, a resina 
conjugada com a UDP-Gal foi sintetizada em nove passos a partir da metil-α-D-Gal com 
rendimentos de 71% até quantitativo. A resina conjugada com UDP-(4F)-Gal foi sintetizada em 
treze passos a partir da glicose com rendimentos 48% até quantitativo. 
 
 A metodologia de enriquecimento para galactosiltransferases utilizando a resina sintetizada 
foi inicialmente testada com uma galactosiltranferase comercialmente disponível, em 
conjunto com outras proteínas não específicas, para comprovar a sua seletividade. Uma vez 
comprovada a seletividade, realizou-se um ensaio para isolar galactosiltransferases a partir de 
lisados de T. brucei. A resina com UDP-GalGal não permitiu o enriquecimento em 
galactosiltransferases a partir dos lisados, provavelmente devido a uma baixa afinidade da 
UDP-Gal e à complexidade das proteínas presentes na mistura. A resina com UDP-(4F)-Gal 
revelou maior afinidade, permitindo enriquecer para uma galactosiltransferase recentemente 
descoberta em T. brucei: a TbGT3. Apesar destes resultados sugerirem uma boa seletividade 
da resina UDP-(4F)-Gal,  estes ensaios beneficiariam  de experiências adicionais e etapas de 
otimização para aumentar a capacidade de enriquecimento e permitir a identificação de novas 
UDP-galactosiltransferases do parasita. 
 
A segunda parte do meu trabalho doutoral consistiu em testar o uso de pequenas moléculas 
inibidoras de N-glicosilação, nomeadamente de NGI-1, para estudar os efeitos da deficiência 
em N-glicosilação em T. brucei. A NGI-1 está descrita como inibidora da STT3B, a subunidade 
catalítica da OST, em células de mamíferos. Caso esta molécula tenha efeito em T. brucei, 
prevê-se que iniba apenas a transferência de glicanos com alto teor de manose, uma vez que 
estes são adicionados às glicoproteínas exclusivamente pela STT3B. A NGI-1 poderia então ser 
usada como uma ferramenta para a redução da glicosilação sem a necessidade de recorrer a 
técnicas de RNA de interferência para o gene de STT3B em T. brucei. De fato, o tratamento 
com NGI-1 revelou-se tóxico para T. brucei. No entanto, a droga apresentou uma 
concentração inibitória média (CI50) muito alta de 75,73 μM comparativamente com as drogas 
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normalmente usadas para tratar tripanossomíase. No entanto foi possível observar uma 
redução na glicosilação com concentrações sub-tóxicas de NGI-1. A deteção de glicoproteínas 
por imunoblot com lectinas, sugere um efeito do fármaco na N-glicosilação, com um aumento 
em glicanos complexos e uma diminuição em glicanos com alto teor de manose. De forma a 
investigar com maior detalhe os efeitos de NGI-1 na glicosilação, foi analisadapor 
espectrometria de massa a glicoproteína variável de superfície (VSG) de T. brucei, por forma 
a determinar operfil exato de N-glicosilação após o tratamento com NGI-1. 
 
O terceiro objetivo deste trabalho consistiu na identificação de glicoproteínas N-glicosiladas 
no parasita que causa a malária, o Plasmodium falciparum. Com este objetivo procurou-se 
enriquecer para glicoproteínas N-glicosiladas de P. falciparum, usando vários métodos 
baseados em separação por lectinas e análise por espectrometria de massa. Inicialmente, as 
glicoproteínas foram enriquecidas a partir de lisados de P. falciparum usando o protocolo 
FASP FACE e as lectinas GSL II e WGA. Embora os resultados da espectrometria de massa 
tenham indicado a presença de glicoproteínas com GlcNAc ou GlcNAc2, o método utilizado 
não foi suficientemente preciso para determinar a sua natureza. Um analisador de massa 
Orbitrap foi então utilizado, o que melhorou a precisão e confirmou a presença dos 
glicopéptidos. Infelizmente, os péptidos encontrados não possuíam uma resolução 
suficientemente alta para serem identificados. Os iões para HexNAc2Fuc foram observados 
indicando a presença de proteínas modificadas por fucosilação, mas a sequência de tais 
proteínas não pôde ser identificada. Na tentativa de melhorar o passo de enriquecimento, foi 
testado um protocolo de separação com as lectinas GSL II e WGA acopladas a microesferas 
magnéticas. Houve, contudo dificuldades em conjugar estas lectina com as microesferas. 
Testou-se outra abordagem em que se submeteram as glicoproteínas a de P. falciparum a 
modificação química por adição de uma molécula de galactose a GlcNac com uma 
galactosiltransferase.  Desta forma, as proteínas N-glicosiladas poderiam ser enriquecidas com 
a lectina ricina, que reconhece moléculas de galactose. Por análise em espectrometria de 
massa concluiu-se que este método de enriquecimento não foi eficaz e, portanto, métodos 
alternativos devem ser investigados no futuro. 
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 Em suma, ao longo do meu trabalho doutoral foram explorados novos métodos para estudar 
a N-glicosilação nos parasitas T. brucei e P. falciparum. Desenvolvi uma via de síntese que 
permite pela primeira vez a conjugação de uma resina a um nucleótido de açucar. Em termos 
funcionais, a seletividade da resina funcionalizada com UDP-(4F)-Gal ficou comprovada pelo 
enriquecimento de uma galactosiltransferase bona fide recentemente caracterizada em T. 
brucei, a TbGT3. Para além disso, a nova via de síntese que desenvolvi tem a vantagem de 
poder ser utilizada no futuro para produzir outros nucleótidos de açúcar ligados à resina de 
TentaGel™. 
 
Em P. falciparum foram testados diferentes métodos de separação por lectinas e identificação 
por espectrometria de massa, com o objetivo de estudar as glicoproteínas N-glicosiladas. 
Foram encontrados péptidos glicosilados com GlcNAc ou GlcNAc2, embora a identificação das 
proteínas modificadas tenha sido impossibilitada pela falta de resolução dos péptidos 
produzidos. 
 
Em suma, este trabalho permitiu o desenvolvimento de novos métodos para a descoberta de 
enzimas modificadoras de glicanos e de proteínas N-glicosiladas, em dois parasitas com vias 
de glicosilação bastante divergentes dos outros eucariotas. Estes métodos requerem ensaios 
futuros de otimização mas, considerando que estes parasitas possuem vias de glicosilação 
não-canónicas, as abordagens experimentais seguidas neste trabalho serão uma forma eficaz 
de descobrir e caracterizar a N-glicosilação das suas proteínas. 
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6 Summary 
Glycosylation is the most abundant post translational modification in eukaryotic cells and can 
be accredited to an enormous variety of functions. Yet the tools used to study rare or unusual 
glycosylations are limited. N-Glycosylation, glycosylation of an asparagine residue, begins in 
the endoplasmic reticulum where a glycan precursor is synthesised by glycosyltransferases 
before it is transferred to a protein by an oligosaccharide transferase. The protein is then 
transferred to the Golgi where the glycan is further modified by glycosidases or 
glycosyltransferases. During this process, the array of glycosyltransferases present in each 
organism serves to produce a range of glycans, many of which are organism specific. Their 
formation and functions provide valuable information as to how certain parasites proliferate 
and cause disease. Therefore, new tools to study glycans and glycan processing enzymes could 
pave the way towards new therapeutics. Within this thesis, three chemical methods to explore 
glycosylation in Trypanosoma brucei and Plasmodium falciparum are described. 
 
Although UDP-agarose serves to enrich glycosyltransferases from complex mixtures, it is not 
specific towards UDP-galactosyltransferases. This particular family of enzymes forms linkages 
in many unique glycans of T. brucei and represent interesting drug targets due to their absence 
in humans. Due to their unusual nature, no homologues have been identified. The majority of 
this PhD project was aimed at synthesising an activity based probe to selectively enrich 
galactosyltransferases from T. brucei using analogues of the donor sugar nucleotide, UDP-
galactose. In a newly developed synthetic route, UDP-galactose and UDP-(4F)-galactose were 
attached to tentagel resin. To our knowledge, these are the first resin bound sugar-
nucleotides. After initial method development with a commercially available 
galactosyltranferase along with other proteins, the resins were proven to bind with the 
desired selectivity. They were then used in an assay to enrich galactosyltransferases from T. 
brucei lysates. UDP-Galactose was unable to enrich galactosyltransferases from this 
complicated mixture, most likely due to a low affinity and the complexity of the proteins it 
was submitted to. UDP-(4F)-Galactose showed a higher affinity but was only able to enrich 
one galactosyltransferase: TbGT3. The assay was only performed once, therefore with 
repeated experiments this result may improve. 
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 The second tool described in this thesis is the use of the small molecule inhibiter of N-
glycosylation, NGI-1. From published data, this small molecule was predicted to only inhibit 
the transfer of high mannose glycans in T. brucei. In doing so, the effect of reduced 
glycosylation could be studied without the need for RNAi knock down of STT3B. NGI-1 was 
toxic to T. brucei but had a very high IC50 of 75.73 µM. Therefore, at lower concentrations the 
effect of the drug could be observed. By lectin blots, there appeared to be an effect of the 
drug on N-glycosylation with an increase in complex glycans and a decrease in high mannose. 
However, the results were not clear so mass spectrometry analysis of T. brucei’s variant 
surface glycoprotein were sought to determine the exact N-glycosylation profile. 
 
The third tool described is to enrich glycoproteins from Plasmodium falciparum lysates using 
various lectin based methods and mass spectrometry analysis. Initially, glycoproteins were 
enriched using the FASP FACE protocol and lectins GLS II and WGA. Although the mass 
spectrometry results indicated the presence of glycoproteins, the method used was not 
accurate enough to determine their nature. An Orbitrap mass analyser was then used, which 
improved the accuracy so that the presence of glycopeptides was confirmed. Unfortunately, 
these peptides were not of high enough resolution to be identified. Magnetic bead bound GSL 
II and WGA enrichment was tested, but there were difficulties in conjugating the lectin to the 
beads. Chemically modifying the glycoproteins with a galactoslytransferase so that they could 
be enriched with ricin (instead of GSL II and WGA) was also tested. Mass spectrometry showed 
that the enrichment was not successful and alternate methods must be investigated. 
 
These new methods to study N-glycosylation in T. brucei and P. falciparum require some 
optimisation. However, since both parasites synthesise unique (and in the case of P. 
falciparum, disputed) N-glycans, tools such as the ones described will be the most effective 
way to profile their N-glycosylation. 
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7 Introduction 
7.1 Glycosylation and the importance of glycosyltransferases 
7.1.1 Glycans and the way they shape our world 
A glycan, or polysaccharide, is a compound consisting of a number of linked monosaccharides. 
Nature synthesises an enormous variety of glycans; from the large polysaccharide, starch, 
containing up to 10,000 -glucose monomers, to the simple disaccharide sucrose. The most 
abundant compound on earth is cellulose (polymerised -glucose); a glycan crucial for the 
strength and rigidity of plant cell walls (O’Sullivan, 1997). Moreover, many cells are coated by 
glycosylated proteins, which can mediate cell adhesion. This is common in the case of cancer 
cells that express altered glycans on their surface. A number of cancerous cells express 
proteins glycosylated with sialyl Lewisa and sialyl Lewisx glycans which adhere to endothelial 
cell walls via E-selectin (Kannagi et al., 2004). Anaplastic large cell lymphoma express sialic 
acid enabling them to adhere to galectin 8, without which growth is inhibited (Kannagi et al., 
2004; Suzuki, Abe and Hashimoto, 2015). In some artic fish, antifreeze glycoproteins (AFGPs) 
circulate in their blood allowing them to survive in sub-zero temperatures. These proteins are 
N-glycosylated with the disaccharide GlcNAc-Gal which allows them to behave in a non-
colligative manner, disrupting ice crystal formation and inhibiting crystal growth. Without the 
glycans, these proteins lose their antifreeze properties (Harding, Anderberg and Haymet, 
2003). Glycans can also act as a shield against the immune system for some pathogens as is 
the case for influenza and HIV (Baum and Cobb, 2017). Ultimately, their abundance and 
diversity permit them to play important roles in processes that are essential for life (Easton, 
2011; Varki, 2017). Understanding how these glycans are built is important if we are to 
understand the many processes that they mediate. 
 2 
Figure 1 - Types of lipid and protein glycosylation adapted from Gloster, 2012  
Glycosylation of proteins and lipids can occur via five main glycosylation pathways, figure 1 
(Spiro, 2002; Gloster, 2012): 
- O-Glycosylation: occurs primarily where an N-acetylgalactosamine is attached to the 
hydroxl group of a protein’s serine or threonine residue. The simple O-GlcNAc 
modification is the most abundant posttranslational modification in metazoans and is 
a transient modification (Yeh and Feeney, 1996). From this N-acetylgalactosamine, 
galactosyltransferases (enzymes that transfer donor monosaccharides to acceptor 
structures) can build larger structures. In mammals, these structures tend to be small 
(three to six monosaccharides) (Spiro, 2002; Easton, 2011). 
- N-Glycosylation: occurs when a pre-made polysaccharide structure is added to an 
aspargine residue of a protein in the ER when the sequon N-X-S/T is present (but not 
all N-X-S/Ts are glycosylated), where X is any amino acid except proline (Spiro, 2002). 
This pre-made polysaccharide can be modified by glycosidases or glycosyltransferases 
in the Golgi to create a variety of glycan structures. N-glycosylation will be discussed 
in more detail later in this section and is the focus of this thesis. 
- C-Mannosylation: present when an -mannosyl group is bound to a Trp residue via a 
carbon-carbon bond (Spiro, 2002). 
- Phosphoglycosylation: this is when a glycan is attached to a protein via a 
phosphodiester bond on a serine of threonine residue. Their structures vary widely in 
terms of size and motif (Haynes, 1998). 
- Glypiation: this is when a glycosylphosphatidylinositol moiety is attached to the C-
terminal of a protein. This modification was first described in Trypanosoma brucei and 
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 has a number of different roles in membrane-bound proteins of higher eukaryotes and 
protozoa (Ferguson et al., 1988; Ferguson, 1991; Ikezawa, 2002). 
 
Glycans can be represented by their chemical structure or by symbolic nomenclature. 
Although there are many types of nomenclature, the most commonly used is the Consortium 
for Functional Glycomics (CFG) nomenclature, figure 2 (Varki, 2017). For the remainder of my 
thesis, I will use this nomenclature to simplify the chemical representation of glycans. 
 
Figure 2 – CFG glycan symbol nomenclature adapted from Essentials of Glycobiology (Varki et al., 
2009) 
Below is an example diagram of the chemical representation of a glycan and its equivalent 
structure in glycan symbol nomenclature (figure 3). 
Figure 3 – Diagram displaying a typical glycan in chemical formula and glycan symbol nomenclature 
 4 
7.1.1.1 Formation and diversity of N-Glyans 
There are three types of N-glycans; high mannose (oligomannose), complex and hybrid and 
these are represented below, figure 4. 
Figure 4 – Types of glycans, adapted from Essentials of glycobiology (Varki et al., 2009) 
High mannose glycans are characterised by containing between 5 and 9 terminal mannose 
residues attached to a GlcNAc2 core. When the GlcNAc2Man3 core is glycosylated with any 
monosaccharide except mannose a complex glycan is formed. Hybrid glycans contain a 
mixture of terminal mannose and any other monosaccharide (Varki et al., 2009). 
 
N-glycosylation occurs in the endoplasmic reticulum (ER) where a glycan precursor is added 
to an asparagine residue of a protein by an oligosaccharide transferase (OST, step 9 in figure 
5). A sequon is a sequence of amino acids where glycosylation can occur, most often N-linked 
(Varki, Cummings and Esko, 2009). The most common sequon for N-glycosylation is N-X-T 
followed by N-X-S, where X is any amino acid except proline (Aebi, 2013). However, not every 
protein containing these sequons are glycosylated. Less common sequons include N-X-C and 
N-X-G (Lowenthal et al., 2016). 
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Figure 5 – Typical mechanism of N-glycosylation adapted from Juan et al., 2016. 
The glycan precursor is synthesised by the sequential addition of monosaccharides on to 
phosphorylated dolichol by glycosyltransferases (GTs). When the glycan reaches 
Man5GlcNAc2, a flipase translocates it from the cytosol to the lumen of the ER. Here it is 
further glycosylated by other GTs. Only when the glycan reaches Glc3Man9GlcNAc2 may it be 
transferred to a protein by an OST (figure 5) (Varki, Cummings and Esko, 2009). From here, 
the correctly folded proteins move to the Golgi and misfolded folded proteins are retained (an 
important quality control step). The Golgi is an organelle found in most eukaryotic cells and is 
named after the nobel prize winning Italian scientist Camillo Golgi who identified it in 1897 
(Fabene and Bentivoglio, 1998). It is comprised of two networks – the cis and the trans. 
Proteins from the ER first enter the cis network where glycosidases can remove mannose 
residues from or glycosyltransferases add GlcNAC to N-glycans and phosphorylation can 
occur. In the trans network, GTs can add galactose or sialic acid residues forming complex or 
hybrid glycans (Alberts et al., 2002). This generalised mechanism can differ slightly depending 
on the organism. 
7.1.2 Small molecule probes of N-glycosylation 
The function of protein N-glycosylation has been studied mainly with pathway inhibitors. The 
structures of small molecule inhibitors are shown in figure 6 and their uses are described 
below. 
 
 
Tunicamycin
NGI-1
GTs
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Figure 6 - Small molecule inhibitors of glycosylation 
 Tunicamycin is a well-known inhibitor of glycosylation that inhibits the transfer of the first 
GlcNAc onto phosphorylated dolichol, mediated by DPAGT1 (figure 5). Drug resistant ovarian 
and colorectal tumour cells were found to be more susceptible to chemotherapy when treated 
with tunicamycin. Studies showed that the inhibition of glycosylation disrupted the 
localisation and function of transporter proteins increasing their sensitivity (Wojtowicz et al., 
2015). 
 
The small molecule castanospermine, found in black beans, is an inhibitor of -glucosidases 
that are essential for the processing of N-glycans. The structural proteins prM and E of the 
dengue virus are N-glycosylated with complex glycans that require -glucosidases for their 
formation. In vitro and in vivo studies of dengue with castanospermine showed that inhibiting 
the virus’s -glucosidases lead to the misfolding of these proteins which in turn inhibited the 
infection of the virus (Whitby et al., 2005). There are currently no treatments or vaccines for 
the dengue virus therefore insights in to the effect of N-glycosylation inhibition could lead to 
new therapies. 
 
Similarly, swainsonine, found in locoweed, inhibits Golgi -mannosidase II whose inhibition 
leads to the production of hybrid glycans over complex. It is toxic and cattle who eat locoweed 
suffer a range of symptoms from ataxia and emaciation to abortion. Swainsonine was used to 
study the importance of glycosylation in pregnancy in cattle. Luteal steroidogenic cells (LSCs, 
responsible for the production of progesterone) were cultured in vitro with swainsonine. This 
showed that although there was no effect on the viability of LSCs, the change in glycosylation 
7 
 did affect luteinising hormone (LH) which in turn reduced progesterone production which 
would cause problems in fertility (Sano et al., 2015). 
 
More recently, the small molecule named N-Linked Glycosylation Inhibitor-1 (NGI-1) was 
found to reduce the ability of the OST of lung cancer cells in transferring Glc3Man9GlcNAc2 to 
proteins (Lopez-Sambrooks et al., 2016). In mammalian cells, OST is not one single protein, 
but is a complex of 7 (Ribophorin II, OST48, Ribophorin I, DAD1, Stt3A or Stt3B, OST4 and N33 
or 1AP) and can exist in 4 isoforms as the pairs STT3A/ STT3B and N33/1AP are mutually 
exclusive. Stt3 is the largest of these proteins and is the catalytic unit that transfers the 
oligosaccharide to the asparagine residue. The functions of the remaining proteins are less 
described but they are associated with protein translocation, recognition of glycosylation sites 
and may have oxidoreductase activity (Mohorko, Glockshuber and Aebi, 2011). NGI-1 is a 
reversible inhibitor of STT3 with a higher affinity for STT3B, stabilising it at high temperatures 
and inhibiting the growth of cancer cells. STT3A is incompletely blocked so reduced N-
glycosylation remains present and the cells are viable (Lopez-Sambrooks et al., 2016). 
Consequently, this small molecule represents a powerful tool for the study of glycosylation 
with its reduced toxicity compared to tunicamycin and swainsonine. 
 
A number of monosaccharide analogues have been used to study N-glycosylation either 
through inhibition of GTs or by utilising the flexibility of GTs to incorporate labelled isoforms 
allowing protein visualisation, purification or the effects of  a sugar modification (Hang et al., 
2004; Dube et al., 2006; Breidenbach et al., 2010; Gloster, 2012). Inhibitors of GTs will be 
described in more detail in section 7.3.1. 
 
If the GT has a homologue, then techniques such as protein over expression, gene knock down 
or knock out can help characterisation. For example, Wang et al. over-expressed the putative 
GT PtGT1 in the tobacco plant resulting in a plant that had a higher lignin content and an early 
flowering phenotype (Stanley and Cummings, 2009). Ramírez et al. characterised STT3A from 
Trypanosoma brucei by recombinantly expressing the protein, purifying it and screening its 
activity with a range of substrate peptides and lipid-linked oligosaccharides (LLOs). In doing so 
they found certain motifs were favoured and that phosphonate analogues of LLOs were 
competitive inhibitors (Ramírez et al., 2017). Several mice knock downs or knock outs have 
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been made for specific GTs allowing for the confirmation of several candidates and describing 
their functions (Stanley, 2016). The knock down of sialyltransferase, ST6GAL1, in human 
pluripotent stem cells showed for the first time  an association of ST6GAL1 with pluripotency 
and differentiation of these cells (Wang et al., 2015). Rare diseases in humans caused by 
defects in glycosylation are classified as human congenital disorders of glycosylation or CDGs. 
These diseases manifest in a wide range of symptoms and severity from mental illness to 
muscular dystrophy, illustrating the systemic influence that the GTs have on humans (Leuven, 
2002; A. D. Shaw et al., 2014; Nigro and Savarese, 2014). 
7.1.3 Visualising and identifying N-glycans 
In order to characterise glycans or identify glycoproteins, the first step is to enrich for 
glycoproteins as they are often present in very low amounts. HILIC columns can be used to 
separate hydrophilic glycopeptides from the non-glycosylated (Gilar et al., 2011). If a 
particular glycan motif is sought, a specific lectin can be used. Lectins are proteins that bind 
to glycans and each lectin has its own substrate specificity. Although they bind weakly to their 
substrates, they are very specific and the accumulation of these interactions between a 
surface with carbohydrates and a lectin is strong (Berg, Tymoczko and Stryer, 2002). Legume 
lectins bind to glycans found on the surface of rhizobial bacteria enabling the plant to move 
the bacteria to its routes where it can carry out nitrogen fixation, maintaining their symbiotic 
relationship (Van Rhijn et al., 2001). A well-studied and commonly used lectin is ricinus 
communis agglutinin I. Extracted from castor beans, this lectin binds to terminal galactose 
residues (Lord, 1995). Biotinylated lectins can be used to visualise glycoproteins by western 
blot or can be bound to agarose or magnetic beads for use in pull downs. Alternatively, lectins 
can be used in conjunction with Filter Aided Capture and Elution (FACE). This method uses the 
lectin to capture peptides on top of a filter, allowing non-captured peptides to be washed 
away (Ongay et al., 2012). These captured peptides can be released by blocking the lectin with 
its natural substrate. They can then be analysed by mass spectrometry with or without their 
glycan. For glycoprotein determination, if PNGase or Endo-H were used, there will be a 
detectable weight difference between the glycosylated and nonglycosylated forms of the 
peptide (Asn vs Asp and glycan vs a single GlcNAc respectively), see below. 
 
To determine the structure of the glycan, they must be cleaved from the peptide. The choice 
of glycan cleaving method depends greatly on the type of glycan to be cleaved. For example, 
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 Endo-H cleaves high-mannose (and some hybrid) N-glycans in the middle of the GlcNAc2 core 
(Koide and Muramatsu, 1974). PNGase F can cleave high mannose, complex and hybrid N-
glycans at the base of the glycan (between the GlcNAc and asparagine residue) only if they 
have the GlcNAc2Man3 core unless α(1,3)-linked core fucose is present (Tarentino, Trimble 
and Plummer, 1989). PNGase A is the same as PNGase F, except it can also cleave N-glycans 
with α-(1,3)-linked core fucose present (figure 7). 
Figure 7 - Diagram to illustrate specificity of glycan cleaving enzymes 
On cleavage, the asparagine residue is converted to an aspartic acid (Tarentino, Trimble and 
Plummer, 1989). Hydrazinolysis is a chemical method of glycan release that is non-specific and 
will release N and O-glycans (Takasaki, Mizuochi and Kobata, 1982). After they have been 
released from the peptide, their structures can be determined with monosaccharide analysis 
or NMR (Takasaki, Mizuochi and Kobata, 1982). 
7.1.4 Glycosyltransferases: mechanisms and roles 
Nature relies on subtle differences between carbohydrate building blocks to synthesise 
complex glycan structures. These are built by glycosyltransferases (GTs), which transfer a 
specific donor monosaccharide (eg. UDP-galactose) on to an acceptor, which is typically 
another monosaccharide, protein or glycan (Rini, Esko and Varki, 2009).  
 
ER GTs are multi-transmembrane proteins and Golgi GTs are type II membrane proteins. There 
are 104 GT families classified by short sequence motifs, mostly grouped by their donor 
specificity (Lombard et al., 2014). All glycosyltransferases contain the DXD motif – a metal ion 
binding site required for their activity (Rini, Esko and Varki, 2009). The largest database of 
carbohydrate active enzymes is the CAZy database which, in 2013, contained 119 910 GTs. 
However, only 1.6% of these had been characterised with biological studies (Lombard et al., 
2014). Now there are 346,702 GTs associated to a family and 7,563 that are not classified in 
the CAZy database (Lombard et al., 2017). 
 
PNGase F (or A)  Endo-H 
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The donor sugar is often activated by a nucleotide diphosphate and the reaction is mediated 
by a metal cation, for example Mn2+ or Mg2+. The mechanism of the reaction can proceed in 
two ways either inverting or retaining the stereochemistry at the anomeric centre of the 
donor sugar. The inverted mechanism proceeds by an SN2 attack at the anomeric centre via 
an oxonium intermediate, figure 8 (Lairson et al., 2008). 
 
Figure 8 – Mechanism of glycosylation with stereochemistry inversion 
The mechanism for the retention of the stereochemistry has been debated. However, the 
most widely accepted mechanism is the double displacement mechanism (figure 9) (Lairson 
et al., 2008). 
Figure 9 - Mechanism of glycosylation with stereochemistry retention. 
In both the retaining and inverting mechanisms, the GT first binds to the donor. The GT can 
then change its conformation to bind to the acceptor (Taylor and Drickamer, 2011). Most GTs 
are highly specific for one donor and one acceptor. However, there are some that catalyse the 
same reactions or can catalyse more than one. For example, in the presence of -lactalbumin, 
-1,4-galactosyltransferase (-1,4-GalT) catalyses the addition of galactose to glucose 
producing lactose. In the absence of this protein -1,4-GalT adds galactose to N-
acetylglucosamine (Taylor and Drickamer, 2011). 
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7.1.4.1 ABO blood groups and glycosyltransferases 
The makeup of your personal GT repertoire will decide your blood group. The AB0 blood 
grouping system is based on glycans covering the surface of red blood cells. If you are 0 type, 
you have the basic glycan coating. If you are A, you have an extra N-acetylglucosamine 
transferase. If you are type B, you have an extra galactosyltransferase. Types AB have both of 
these extra GTs. These subtle differences in surface glycans impart massive differences for the 
recognition of red blood cells (RBCs). They are antigenic which explains why there are blood 
transfusion incompatibilities as reactions to antigenic glycans on the red blood cells that are 
non-self (Stanley and Cummings, 2009) (Stanley and Cummings, 2009). Furthermore, those 
with type 0 are more likely to be infected with norovirus than any other blood group and type 
AB or B are unlikely to develop symptoms if infected. The blood group antigens are highly 
expressed in the gastro intestinal tract suggesting that this effect could be due to adhesion of 
the virus to the glycans (Hutson et al., 2002). 
 
There are different GTs in different organisms and even between individuals, complicating 
their characterisation. Their existence can be predicted by observing the linkages they form 
using mass spectrometry. This implies that homology based approaches can only contribute 
to a certain point in the characterisation of predicted GTs. For those without a clear 
homologue there are no standard techniques. 
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7.2 Trypanosoma brucei 
Trypanosoma brucei (T. brucei) is a protozoan parasite endemic to sub-Saharan Africa. It has 
three sub species: T. brucei brucei, T. brucei gambiense and T. brucei rhodesiense all of which 
are transmitted by the tsetse fly. The first (T. b. brucei) infects non-human vertebrates and the 
latter two infect humans; with gambiense being the most abundant and rhodesiense the most 
virulent. In cattle and horses, the resulting disease is called “nagana” taken from the Zulu word 
for powerless. Nagana halts the development of farming, with large economic losses in cattle 
production of approximately $2.5 billion per year (A. P. M. Shaw et al., 2014). Although 
gambiense and rhodesiense do not cause disease in cattle, they are able to infect them. Thus, 
cattle are a large reservoir of human infecting trypanosomes and are able to promote their 
transmission (Kennedy, 2013; Sutherland et al., 2015). 
 
In humans, the disease is called African Sleeping Sickness or Human African Trypanosomiasis 
(HAT). HAT occurs in two stages; stage one infects the bloodstream and lymphatic system. In 
stage two (CNS stage), the parasite moves to the central nervous system infecting 
cerebrospinal fluid and neural tissue. Stage one presents as weight loss, chills, fatigue, 
headache, and lymphadopathy. These symptoms are often mistaken for malaria. Stage 2 
causes severe headaches, nocturnal insomnia, hallucinations, anxiety, progressive mental 
deterioration and motor system disturbances. Eventually the host falls into a coma and dies 
(Kennedy, 2013). 
 
Only two new treatments for HAT have been developed since the 1950s putting the total 
available drugs at 5. There are two strains of parasite and two stages to the disease. Each drug 
is only effective against one form of the disease leaving little to no choice in treatment, table 
5 (Bacchi, 2009). 
 
 
 
 
Table 1 – Drug specificity dependant on species and stage of HAT (Bacchi, 2009) 
 
Stage Rhodesiense Gambiense 
Early Suramin Pentamidine 
Late Melarsoprol Eflornithine/Nifurtimox-Eflornithine 
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 Current treatments must be administered intravenously and have extreme side effects 
including severe diarrhoea, organ damage and pulmonary oedema (Bacchi, 2009). 
Pentamidine can cause diabetes and Melarsoprol kills 5% of its patients. The combinatorial 
drug Nifurtimox-Eflornithine was developed with reduced side effects, although 
gastrointestinal and neuropsychiatric problems still occur (Franco et al., 2012). All of the 
current treatments for HAT have ill-defined modes of action. However, we know that 
Eflornithine inhibits ornithine decarboxylase, Suramin targets glycolytic enzymes and 
Pentamidine disrupts the structure of kinetoplastic DNA (Fairlamb, 2003; Bacchi, 2009; 
Kennedy, 2013). In vitro, trypanosomes have an intrinsic circadian rhythm affecting 10% of 
their genes that makes them more susceptible to Suramin at certain times of day (Rijo-Ferreira 
et al., 2017). In summary, the development of a treatment designed specifically for HAT, with 
reduced side effects and an easier method of administration is highly sought after. 
7.3 Glycosylation in T. brucei  
Trypanosoma brucei life cycle involves two proliferative stages: the procyclic form (pcf) in the 
tsetse fly midgut and the bloodstream slender form (bsf) in the blood of a mammal (Kennedy, 
2013). In between these proliferative stages, the metacyclic and stumpy forms are produced 
for transmission between the two hosts, figure 10. Recently, a new form of the parasite has 
been described that occupies the adipose tissue of the mammalian host (Trindade et al., 
2016). 
 Figure 10 –Lifecycle of T. brucei taken from Trindade, 2016 
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There are a number of important glycosylated proteins and lipids in both the pcf and bsf. In 
the pcf, the parasite is coated in a layer of glycoproteins called procyclins. In the bsf, its surface 
membrane is coated in Variant Surface Glycoproteins (VSGs) (Pays et al., 1989). Both procyclin 
and VSG (along with other proteins) are anchored to the surface membrane via GPI anchors – 
glycolipids that can be anchored to the C terminus of a protein. The first complete GPI 
structure was elucidated in 1988 from the VSG of T. brucei. Each bsf trypanosome has 
approximately 1x107 GPI-linked VSGs on its surface and the biosynthesis of GPI is essential to 
bsf, but not to pcf, potentially due to its importance in the assembly of VSG (Ferguson et al., 
1988; Rini, Esko and Varki, 2009). 
7.3.1 Surface glycoproteins and glycans of T. brucei 
VSG elicits an immune response from its host, which destroys the parasite using anti-VSG 
antibodies. Initially, trypanosomes are cleared by IgMs then as the infection becomes 
established B-cells play a larger role (Stijlemans et al., 2016). The parasite can change its VSG 
coating sequentially, a process known as antigenic variation. Trypanosomes that have 
switched to an alternate VSG survive and are able to proliferate until the next antibody 
response is triggered. This leads to peaks and troughs in the numbers of trypanosomes 
present in the host. This change in the VSG coating enables the parasite to evade the immune 
system and establish an infection, figure 11 (Marcello and Barry, 2007; Matthews et al., 2015).  
Figure 11 - Antigenic variation of T. brucei adapted from Matthews, 2015 
The VSG coat is tightly packed, (covering 90% of the cell surface) acting as a barrier to immune 
factors released by the host. It has also been hypothesised that glycans on the VSG add to this 
barrier, filling gaps and aiding protein folding (Mehlert et al., 1998). Each VSG has between 0 
and 5 N-glycosylation sites linked to high mannose or complex glycans, figure 12 (Schwede et 
al., 2011). For example, VSG MITat.1.5 has three glycosylation sites and its glycosylation was 
shown to be required so that the VSG can be transported to the cell surface (Ferguson et al., 
Time 
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 1986; Mehlert, Bond and Ferguson, 2002). Computer modelling of this VSG is shown in figure 
12 (Mehlert, Bond and Ferguson, 2002) which demonstrates the packing and size of the N-
linked glycans. 
Figure 12 - Computer modelling of VSG MITat1.5 (A) VSG MITat.1.5 with attached, energy-
minimised, N-linked oligosaccharides and (B and C) the cell surface coat, viewed from the side and 
above without (right) and with (left) attached N-linked oligosaccharides from Mehlert, 2002. 
Castillo-Acosta et al. showed that carbohydrate binding agents are trypanocidal, inducing 
mutation after prolonged exposure. The mutants displayed different glycosylation patterns 
on their VSG and were less virulent (Castillo-Acosta et al., 2013). After exposure to the lectin 
HHA (which binds to high mannose glycans) the parasites stopped expressing the 
oligosaccharide transferase TbSTT3B: an enzyme essential to the addition of high mannose 
glycans to proteins (Izquierdo, Schulz, et al., 2009). These parasites were less infective 
implying that the high mannose glycans are important for virulence. 
 
Once uptaken by the tsetse fly, VSG is replaced by procyclin – an antigenically conserved 
protein. There are three types of procyclin: two types of “EP” and a “GPEET”. The EP forms 
contain between 22 and 30 Glu-Pro repeats and GPEET contains six repeats of Gly-Pro-Glu-
Glu-Thr followed by three repeats of Glu-Pro. Although some forms of EP can be glycosylated, 
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GPEET cannot (Acosta-Serrano, 1999). Furthermore, EP only has one N-glycosylation site and 
is only glycosylated with one glycan: Man5GlcNac2 (Mehlert et al., 1998), figure 13. The GPI 
anchor of procyclin differs greatly from that of VSG as it contains a long polyLacNAc side chain, 
(Pearson and Republic, 1989; Acosta-Serrano, 1999) figure 13.  
Figure 13 - Structures of VSG, procyclin and GPI anchors adapted from Izquierdo, 2009. 
These glycans are built sequentially by a number of glycosyltransferases (GTs). There are at 
least 38 distinct glycosidic linkages in T. brucei glycans (as highlighted in figure 13), suggesting 
that there are at least 38 GTs present – probably many more. A number of these have been 
identified by homology, but many are unique to the parasite. No homologue has been found 
in T. brucei for the GT responsible for the linkages that are highlighted with a wavy red line in 
figure 13. The majority of these highlighted linkages require a galactosyltransferase and the 
donor UDP-Gal. 
 
The flagellar pocket of T. brucei contains large, compact poly-N-acetyllactosamine 
(PolyLacNAc) glycans, with unclear roles in the parasite, figure 13. These glycans are composed 
of Man, Gal and GlcNAc residues and have an unusually high number of repeats compared to 
other known PolyLacNAcs (on average 54 repeats per glycan – twice the size of the largest 
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 reported mammalian PolyLacNAc) (Atrih et al., 2005). The flagellar pocket is the only site of 
endocytosis and exocytosis, therefore, due to the essentiality of the flagellar pocket to the 
parasite and the unusual nature of the glycans, it is proposed that their synthesis is also 
essential. 
7.3.2 Sugar metabolism of T. brucei 
Nearly all sugar metabolism occurs in the glycosome; an organelle in which glycolytic 
processes and purine salvage occurs (Colasante et al., 2006; Haanstra et al., 2008). Sugar 
metabolism is an important part of the glycosylation machinery. Monosaccharides must either 
be synthesised de novo or up-taken by salvage pathways and converted to nucleotide sugars. 
Glucose and fucose are energy stores but they are also required to synthesise other 
monosaccharides (Freeze and Elbein, 2009). In T. brucei there have been many studies 
surrounding its sugar metabolism, discussed below, figure 14. 
Figure 14 - Sugar metabolism of T. brucei adapted from Turnock and Ferguson, 2007 
UDP-Gal is synthesised by the parasite from UDP-Glc using UDP-Glc-4’-epimerase (TbGALE) 
and is not taken up from the environment. Down regulation of TbGALE lead to cell death in 
both procyclic and blood stream forms, indicating that UDP-Gal is essential to T. brucei. 
Curiously, TbGALE is unable to epimerase UDP-GlcNAc to/from UDP-GalNAc unlike its human 
equivalent (Roper et al., 2002, 2005; Urbaniak, Turnock and Ferguson, 2006). 
 
To date, no fucosylated glycans have been identified in T. brucei. However, it expresses two 
enzymes in the GDP-Fuc biosynthesis pathway: GMD and GMER, figure 14. Procyclic TbGMD 
null mutants have almost no GDP-Fuc in their intracellular pools, grow slower and their flagella 
detached before they died. Blood stream form null mutants also grew slower and eventually 
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lost their flagella and died (Turnock and Ferguson, 2007; Turnock, Izquierdo and Ferguson, 
2007). These mutants showed that TbGMD is essential and therefore that GDP-Fucose is also. 
Although knock down of TbGMER was not performed, it is most likely also essential. 
 
Knockouts of TbPMI were only able to grow if the medium was supplemented with mannose. 
Equally, T. brucei is able to grow without mannose in the medium so long as it has TbPMI, 
therefore the parasite is able to use de novo or salvage pathways to access GDP-mannose 
(Kuettel et al., 2012). RNAi induced knock downs in blood stream forms in vitro showed that 
TbGD-MP is also essential (Denton, Fyffe and Smith, 2010). These results show that GDP-
mannose itself is essential – either because GDP-mannose itself is or because it is needed to 
access GDP-Fucose. 
 
The gene TbUAP encodes for the enzyme that converts GlcNAc-1-P to UDP-GlcNAc and it is 
essential in blood stream forms in vitro and in vivo. In mammals UAP also converts GalNAc- 1-
P to UDP-GalNAc, but, like TbGALE, TbUAP does not process GalNAc derived sugars (Stokes et 
al., 2008). TbGNA1 conditional null mutants showed that this gene is also essential. Addition 
of GlcN to the medium of these parasites does not rescue them suggesting that only the de 
novo pathway to UDP-GlcNAc exists in T. brucei (Mariño et al., 2011). These results are not 
surprising since GlcNAc is present in all GPI anchors and N-glycans. 
 
T. brucei phosphomutases are restricted to just TbPAGM and TbPMM who catalyse the 
transfer of phosphate from the C6 position to the C1 of GlcNAc and mannose respectively. 
The phosphomutase that would catalyse this transfer in glucose (PGM) is not present in T. 
brucei; instead, PAGM and PMM perform the role of PGM. RNAi induced knock downs of these 
two showed that TbPMM is essential but was not able to show that TbPMM is (Bandini et al., 
2012). 
7.3.3 T. brucei and its large repertoire of N-glycans 
The generalised mechanism of N-glycosylation was described in 7.1.1.2, however there are 
some differences in T. brucei. The parasite has three paralogous genes for the OST: TbSTT3a, 
TbSTT3b and TbSTT3c. The single subunit TbSTT3a and TbSTT3b have distinct roles, but in 
blood stream and procyclic forms STT3c is not transcribed. STT3a transfers Man5GlcNAc2 to 
acceptor proteins and leads to complex glycans. STT3b transfers Man9GlcNAc2 to acceptor 
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 proteins which leads to high mannose glycans. The substrate specificity of STT3a and STT3b 
is correlated with the amino acid sequence prior to the N-glycosylation sequon. STT3a 
recognises more acidic sequences containing aspartic acid or glutamic acid residues whereas 
STT3b recognises basic or neutral residues. Although the parasite can survive in vitro without 
STT3a or STT3b, it cannot survive without  both and in vivo both are required (Izquierdo, 
Schulz, et al., 2009). 
 
TbALG3 is the mannosyltransferase that converts Man5GlcNAc2-PP-Dol to Man6GlcNAc2-
PP-Dol. Null mutants of this gene clearly show the specificity of STT3a and b. The glycans that 
would have become Man9GlcNAc2, and thus transferred by STT3b, are stuck at Man5GlcNAc2 
and are instead processed by STT3a. In the mutants, the glycans that should be high mannose 
are now complex in structure (Manthri et al., 2008).  
 
The gene rft1 encodes for the protein that flips Man5GlcNAc2-PP-dolichol (M5-DLO) from the 
cytosol to the lumen of the ER (figure 5 in 7.1.1.1). In humans, mutations of this gene lead to 
glycosylation defects (Haeuptle et al., 2008). Imhof et al. showed that knocking out rft1 in 
procyclic forms of trypanosoma affects its social motility. This can clearly be seen in figure 15 
where the knock out remains at the site of inoculation and the wild type was able to spread. 
They also showed that the knock out was unable to establish infection in the fly mid gut. This 
all points to the importance of glycosylation in T. brucei (Imhof et al., 2015). 
 Figure 15 – Comparison of mobility in wild type (WT) and knock out (KO), (Imhof et al., 2015) 
Inhibition of N-glycosylation in T. brucei by tunicamycin in vivo appears to be lethal (Casero, 
Porter and Bernacki, 1982) although it is also toxic to the mammalian host. 
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7.3.4 T. brucei glycosyltransferases: the known and the as yet unknown 
A comprehensive list of predicted GTs based on known linkages, generated by  (Izquierdo, 
Nakanishi, Mehlert, Machray, Geoffrey J Barton, et al., 2009), is available in an annex along 
with homologues, if they have been assigned, figure 68 and 69. From this list of linkages and 
associated transferases, there are 7 retaining and 5 inverting predicted galactosyltransferases 
whose character is unknown. 
 
From BLAST searches of human -1,3-N-acetylglucosaminyltransferase there are 21 putative 
UDP-Gal or UDP-GlcNAc transferases. From this list, what is now known as TbGT8 was chosen 
and null mutants produced. These mutants grew normally in vitro and were able to infect 
mice. The study proved that TbGT8 encodes for a UDP-GlcNAc: -Gal-GPI -1,3 GlcNAc 
transferase. This is involved in the synthesis of GPI-linked glycans in the procyclic form and N-
linked glycans in the blood stream form of T. brucei (Izquierdo, Nakanishi, Mehlert, Machray, 
Geoffrey J Barton, et al., 2009; Nakanishi et al., 2014). More examples of characterized 
homologous GTs are below” 
- TbGT3, the only galactosyltransferase characterised in T. brucei, encodes for a UDP-Gal: 
β-GlcNAc-GPI β-1,3-Gal transferase, expressed in both bsf and pcf of the parasite. 
Izquierdo et al. produced TbGT3 conditional null mutants that are infectious to tsetse 
flies and whose growth is not affected in either bloodstream or procyclic form. In the 
procyclic form they observed that procyclin had a lower molecular weight because the 
GPI anchors were altered (Izquierdo, Nakanishi, Mehlert, Machray, Geoffrey J. Barton, 
et al., 2009). The remaining uncharacterised galactosyltransferases are involved in the 
synthesis of glycans on GPI anchors, bsf VSGs and the PolyLacNAc structure. 
- TbGT11 codes for UDP-GlcNAc:-D-mannoside -,2-N-acetylglucosaminyl 
transferase. Damerow et al. produced bloodstream-form null mutants that grew 
normally in vitro and no change in infecting rodents was seen despite producing 
significantly different protein N-glycans (Damerow et al., 2014). 
- TbGT15 encodes for a -1,2-GlcNAc transferase that transfers a GlcNAc to the 6-arm of 
Manα1-6(Manα1-3)Manβ1-4GlcNAcβ1-4GlcNAc. This GT does not seem to be essential 
and its deletion did not affect infectivity although mutants grew slower in vitro 
(Damerow et al., 2016). 
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 In conclusion, glycans play a large role in the survival of T. brucei in both the tsetse and 
mammalian host. Their structures are well characterised, but a number of the 
glycosyltransferases responsible for their synthesis are not known and cannot be found by 
homology. The majority of unique linkages are built by galactosyltransferases and are present 
in both life stages. We also know that UDP-Gal uptake is essential. Therefore, we used our 
probes that are designed to target galactosyltransferases to capture and enrich candidate 
GalTs, in order to characterise and better understand the mechanisms behind the production 
of galactose containing glycans. 
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7.4 Plasmodium falciparum 
Plasmodium parasites are apicomplexan and cause malaria. In 2015, a staggering 212 million 
people worldwide were infected, of which 400,000 died. Although there are 5 species of 
Plasmodium that are able to infect humans, Plasmodium falciparum is the most virulent and 
is prevalent in sub-Saharan Africa (WHO, 2016). Malaria first presents as a fever, headache 
and chills before progressing to severe anaemia, respiratory distress and occasionally cerebral 
malaria. There are many anti-malarial drugs available but if left untreated it is fatal. Although 
mortality rates have dropped by 29% since 2010, malaria remains an enormous public health 
problem particularly in Africa where 90% of cases and 92% of deaths occurred in 2015 (WHO, 
2016). 
 
Like Trypanosoma brucei, P. falciparum has a complex lifecycle, figure 16. It is transmitted to 
humans via the bite of an Anopheles mosquito and in each host it changes to different life 
stages to adapt to the new environment. The bite of the mosquito transmits the parasite in 
its sporozoite form. After entering the blood of the human host, sporozoites infect liver cells 
replicating and maturing into merozoites. This liver stage of the disease is asymptomatic 
making early diagnosis difficult. Merozoites leave the liver and invade red blood cells where 
they undergo continuous rounds of replication as blood stage asexual forms. During this 
phase, some parasites can differentiate into sexual gametocytes. When a female mosquito 
takes a blood meal, gametocytes can be transferred to the fly’s midgut where fertilisation of 
gametes occurs and a zygote is formed. This in turn produces an ookinete which migrates 
through the mosquito gut wall and forms oocysts. The oocysts contain sporozoites which 
migrate to the salivary glands of the mosquito, ready to be transmitted during the next blood 
meal. The asexual trophozoites cause the symptoms of malaria as they mature to schizonts, 
replicating and bursting red blood cells before reinvading and starting a new cycle (Prevention, 
2016). 
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Figure 16 –Life cycle of P. falciparum adapted from (Pasvol, 2010) 
In the 1950s, the front-line treatment for malaria was chloroquine. This compound was first 
discovered by Hans Andersag in Bayer’s laboratories. However, Hans declared it too toxic for 
human use and it was not validated until 1947 (Coatney, 1963). Since then, P. falciparum and 
P. vivax have become resistant to chloroquine and nearly all other anti-malarial treatments 
(Wellems and Plowe, 2001). Artemisinin and its derivatives in combination therapies are used 
to treat chloroquine resistant malaria. These compounds were discovered by Youyou Tu 
during the 1960s and 70s. She used her knowledge of traditional Chinese medicine to screen 
thousands of plants and identified 640 that had anti-malarial activity. From these, the plant 
qinghao, whose use has been documented since 1596 AD, was the only one to show inhibitory 
effect on P. falciparum but the activity was very low. Youyou then realised that the extraction 
method they had been using could be destroying the active compound. From here, she used 
cold extraction techniques and was able to isolate and identify the active compound as 
artemisinin. The new extraction vastly improved the activity and the new anti-malarial was 
identified. She was awarded with the 2015 Nobel prize in Physiology or Medicine for her work 
(Tu, 2011). 
 
Now there are also strains of P. falciparum resistant to artemisinin and there is an urgent need 
to produce new treatments or better yet, vaccines or a new more specific target. A number 
of successful vaccines for influenza and meningitis are based on glycoproteins, due to the 
antigenic nature of surface protein glycosylation (Adamo et al., 2013). Creating a vaccine 
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based on a glycoprotein of P. falciparum could be effective, however the glycosylation of this 
parasite is largely unknown and a controversial topic. 
7.5 Glycosylation in P. falciparum: To be or not to be? 
Whether any type of glycosylation is present in P. falciparum has been debated since the early 
1980s and the full picture still remains unclear. Initial evidence showed that the parasite only 
synthesises O-glycans (Dayal-Drager et al., 1991; Dieckmann-Schuppert, Bause and Schwarz, 
1993). This shifted to the acceptance that GPI anchors are the predominant glycosylation and 
that O-glycosylation does not exist (Gowda, Gupta and Davidson, 1997). Both the presence 
and absence of N-glycosylation has been reported (Dieckmann-Schuppert et al., 1992; Kimura 
et al., 1996). The uncertainty is predominantly born from the fact that the parasite is 
intracellular and separation of parasite proteins from host proteins is technically challenging. 
Metabolic labelling is also difficult as the parasite uses monosaccharides and amino acids from 
the host red blood cell as well as culture medium (Nirmalan, Sims and Hyde, 2004). There is 
also always the potential that modifications seen are not from the parasite but from induced 
effects on the red blood cell (Macedo et al., 2010). 
7.5.1 GPI anchors of Pf are its only resolved glycosylation 
Glycosylphosphatidylinositol anchors (GPI anchors) are glycolipids shared by many 
eukaryotes. They comprise of a phosphatidylinositol linked to ethanolamine phosphate by a 
glycan, which in P. falciparum is Man4GlcN (figure 17). They are conjugated to proteins in the 
ER and anchor them to the surface of lipid membranes via the protein’s carboxyl terminal 
(Varki et al., 2009). GPI anchors remain the only well characterised glycosylation in P. 
falciparum. A number of GPI-anchored proteins were characterised in the 90s, but it was not 
until 2000 that the definitive structures of P. falciparum GPI anchors were published (Naik et 
al., 2000). There are at least 5 GPI structures as the length of the fatty acid tail can differ, 
figure 17. Naik et al. also reported the presence of anti-GPI IgGs in people from malaria 
endemic areas of Kenya. This was significant because it indicated that GPIs are antigenic 
despite being at the base of a protein. Naik et al. went further to propose that, because GPIs 
are pathogenic, these antibodies can confer protection to malaria pathogenesis (Naik et al., 
2000). 
 
25 
 
Figure 17 – General GPI anchor of P. falciparum adapted from (Boutlis et al., 2005) 
7.5.2 P. falciparum sugar metabolism 
Sugar nucleotides are important as they are the donor substrates required for building glycans 
by glycosyltransferases. A summary of P. falciparum sugar metabolism is shown in figure 18, 
(Sanz et al., 2013; Cova et al., 2015). Pools of UDP-Gal, UDP-Glc, UDP-GlcNAc, GDP-Man and 
GDP-Fuc were found in the blood stage of P. falciparum. In the case of UDP-Gal, no candidate 
genes have been identified for GALE (to convert UDP-Glucose to UDP-Galactose) or Galactose-
1-phosphate uridylyltransferase (to convert Gal1P to UDP-Gal) and so far, it has not been 
identified in any glycans. The authors suggest that PF3D7_0517500 is an orthologue of L. 
major UDP-sugar pyrophosphorylase which is able to produce UDP-galactose from galactose-
1-phosphate. This would require a galactokinase to form galactose-1-phosphate from 
galactose and there is no candidate for this enzyme in the Plasmodium genome (Sanz et al., 
2013). 
 
P. falciparum does not uptake fucose as it produces it via a de novo pathway converting GDP-
Man with GMD followed by FS (figure 18). Neither enzyme is essential to the parasite and no 
glycoconjugates containing fucose have so far been identified (Sanz et al., 2013, 2016). 
However, the fucosyltransferase POFUT2 is present in the genome and potential fucosylation 
was observed in sporozoite surface proteins CSP and TRAP (Swearingen et al., 2016). POFUT2 
deficient sporozoites display a reduced gliding motility but no effect was seen in blood stage 
forms (Lopaticki et al., 2017). 
 
150 C. S. Boutliset al.
Fig. 1 Schematic representation of P. falciparum GPI. The lipid moieties are incor-
porated into the plasma membrane and joined via glycerol and phosphate (P) to
an inositol ring. A conserved core glycan chain composed of glucosamine and three
mannose residues isattached at the inositol 6 position. Theterminal third conserved
mannose residue is joined via a P ester to thanolamine, which facilita es link ge to
theC-terminusof aprotein viaan amidegroup.P. falciparumGPI remainsacylated at
the inositol 2-position, and a f urth side-chain mannose i typically attached to the
ethanolamine-linked mannose
no side-chain modifications of the first two mannose residues have been
described in P. falciparum. A side-chai fourth mannose (Man4) is typically
attached to the terminal mannose in P. falciparum and yeast, whereas this
was thought to be uncommon until recently in mammals. It has now been
demonstrated that hSMP3 is the human homologue for yeast SMP3, and
that it encodes the mannosyltransferase responsible for addition of Man4
to GPIs (Taron et al. 2004). Although the gene is nly weakly expressed in
many cultured mammalian cell lines, it is expressed in most human tissues,
challenging the previous paradigm that Man4-GPI formation is relatively
unimportant in mammalia.
Mammalian GPI inositol ringsmay beacylated by palmitatein somecases,
although it iscommon for mammalian inositol tobedeacylated followingGPI
biosynthesis (Chen et al. 1998). In contrast, P. falciparum inositol remains
acylated, most often with palmitate (90%) but occasionally with myristate
(10%) (Naik et al.2000a).Thephosphorylated lipidmoietyattached toinositol
in P. falciparum is invariably diacylglycerol in structure (Naik et al. 2000a),
but in mammalian cells is predominantly 1-alkyl, 2-acyl glyce ol. Recent
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Figure 18 - Sugar metabolism of P. falciparum adapted from (Cova et al., 2015) 
P. falciparum does not synthesise or use GalNAc (Sanz et al., 2013). UDP-GlcNAc is most likely 
made de novo from G6P although it could be made from a salvage pathway via GlcN. Both 
pathways require GNA to convert GlcN6P to GlcNAc6P, of which there is no candidate gene. 
Glucose metabolism of P. falciparum was reported as early at 1983 and although the parasite 
clearly synthesises UDP-Glc, there are no obvious glucosyltransferases present in the genome 
(Sanz et al., 2013; Cova et al., 2015). All enzymes required to produce GDP-Man both by a de 
novo or salvalge pathway are present in P. falciparum. Mannose is well used in the parasite’s 
GPI anchors, but is not believed to be present in N-glycans (Naik et al., 2000; Sanz et al., 2013). 
 
7.5.3 Current evidence of N-Glycosylation 
In P. falciparum, only 3 homologues of the 14 ALG genes required to make the 
Glc3Man9GlcNAc2 precursor of N-glycans are present in the genome: ALG7, ALG13 and ALG14. 
ALG7 is responsible for the addition of GlcNAc onto the dolicholphosphate precursor and 
ALG13 and ALG14 work as a complex to add a second GlcNAc forming GlcNAc2-PP-Dolichol. 
STT3 is also present in the genome, suggesting that the parasite is able to transfer these short 
N-glycans to proteins, figure 19 (Samuelson et al., 2005; Bushkin et al., 2010). 
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Figure 19 – Stunted N-glycosylation in P. falciparum adapted from Juan et al., 2016. 
 
Plasmodium’s “cousin” Giardia Lamblia synthesises stunted N-glycans just two GlcNAcs in 
length (Samuelson et al., 2005). The group of J. Samuleson used WGA affinity columns to pull 
down glycoproteins from both P. falciparum and G. Lamblia. They characterised a number of 
short N-glycans in Giardia but the poor peptide coverage meant they could not do the same 
for Plasmodium (Ratner et al., 2008; Bushkin et al., 2010). They use PNGaseF to show the 
reduction in binding from WGA on cleavage of N-glycans by this enzyme. However, PNGase 
only cleaves glycans when there is at least GlcNAC2Man3 present therefore should not affect 
these predicted short glycans. It is possible in fact that, in the case of P. facliparum, they 
observed a reduction of glycans from the host cell. However, Bushkin et al. were able to 
selectively label Plasmodium with GSL II whilst inside a red blood cell, indicating the presence 
of these short N-glycans and suggesting that they are not from the host (Bushkin et al., 2010). 
Further evidence for the presence of N-glycans is the toxic effect that tunicamycin, the N-
glycosylation inhibitor, has on the parasite which blocks its development after a 48 h cycle 
(Dieckmann-Schuppert, Hensel and Schwarz, 1992; Naik et al., 2001). However, both these 
studies attributed the effect to non-specific toxicity. 
  
Tunicamycin
NGI-1
GTs
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7.6 Activity based proteomic profiling probes (ABPP probes)  
Activity based proteomic-profiling (ABPP) uses chemical probes to target active sites of 
enzymes, figure 20. ABPP has a wide range of applications including finding inhibitors, target 
discovery and characterising enzyme active sites. 
Figure 20 - Illustration of ideal activity-based probing 
ABPP probes are small-molecules that bind to the active site of a given enzyme or class of 
enzymes. Most probes consist of a reactive group, a linker and a tag. Targeting a family of 
enzymes is achieved by tailoring the reactive group using transition state mimics or analogues 
of known substrates.  
 
The reactive group must bind specifically and irreversibly in order to be an effective probe. 
The purpose of the linker is to create space between the reactive group and the tag. This 
reduces steric hindrance caused by the tag, which, if not reduced, could decrease binding to 
the target. The tag enables visualisation of the probe after reaction for characterisation. It 
could also be in the form of a click handle for visualisation after binding (Speers and Cravatt, 
2004; Cravatt, Wright and Kozarich, 2008; Li, Overkleeft and Florea, 2012). 
 
Hesek et al. developed a resin bound inhibitor of free active matrix metalloproteinases 
(MMP). They chose an inhibitor that was specific to MMPs, but broad enough to target a 
number of them. They then chemically modified it so they could tether it to an epoxy-activated 
sepharose resin and used it to purify MMPs from cancer patient samples. In doing so they 
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 were able to show the presence of MMP-2 and MT1-MMP in breast carcinoma and MT1-
MMP in laryngeal cancer tissue (Hesek et al., 2006). 
 
UDP-hexanolamine has long been described to enrich for glycosyltransferases. It consists of 
Uridine diphosphate immobilised on agarose via a hexanolamine chain (Barker et al., 1972). 
However, this probe is non-specific in terms of the UDP-sugar transferase it enriches for (Khan 
et al., 1994; Sindhuwinata et al., 2010). The same group also developed a galactosyl and N-
acetylglucosamine based resin. Galactose alone failed to capture any GTs, but the N-acetyl-
glucosamine did, especially in the presence of UDP (Barker et al., 1972). The creation of a 
probe that can differentiate between, for example, galactosyltransferases and N-acetyl-
glucosamine transferases would be of great benefit to the discovery of new GTs. 
 
We envisage using a similar method to capture glycosyltransferases by immobilising a sugar-
nucleotide based inhibitor on a solid support. By incorporating both the sugar and the 
nucleotide and considering inhibitors that bind tightly to the active site, we hope to increase 
the specificity of the resin. It is my opinion that by using a tailored ABPP approach we can find 
uncharacterised GTs that are unique to an organism like T. brucei. 
 
7.7 Design of affinity-based probes for glycosyltransferases 
7.7.1 Inhibitors of glycosyltransferases 
In order to design an activity based probe against a glycosyltransferase (GT) with unknown 
character (i.e. no homolog) we must consider their general mechanism of action and known 
inhibitors. The transition state of the reaction is complex, comprising of four components, 
making it a difficult target (see section 7.1.4 Glycosyltransferases). Since GTs bind to the 
donor first and change their conformation to then bind to the acceptor, it makes sense to 
design probes around the donor (Taylor and Drickamer, 2011). Furthermore, acceptors can 
take many complex forms therefore if the probe were modelled around the acceptor it would 
only be useful for one specific GT. The donor is common to all within a family. In general, the 
affinity for GTs to the donor nucleotide sugar lies with the nucleotide and the phosphate 
backbone, but the specificity lies with the sugar. This makes designing a broad affinity probe 
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challenging. We will be targeting galactosyltransferases (GalTs), which require a UDP-Gal 
donor. 
 
In 1999, Takayama et al. published an extensive study on inhibitors of -1,4 and -1,3-
galactosyltransferases (-1,4-GalT and -1,3-GalT) (Takayama et al., 1999). The two chosen 
enzymes differ in mechanism; -1,4-GalT is inverting and -1,3-GalT is retaining. However, 
both use the UDP-Gal donor. After screening 56 compounds (mimics of uridine or galactose) 
for inhibitory action against -1,4-GalT they found 5 strong inhibitors. These were UDP, UTP, 
UDP-2F-Gal and two diphosphate mimics: pyrophosphate and methylene diphosphonate. 
From these results, they were able to infer that the uridine moiety was important for 
inhibitory action, monophosphates showed little inhibitory affects and negative charge is 
important. Negative charge mimics the transition state promoting binding to the enzyme. 
They propose that UDP-2F-Gal is a good inhibitor because the fluorine could be involved in 
hydrogen bonding in the active site and it strengthens the glycosidic bond effectively blocking 
the enzyme from proceeding. To summarise, the important features of UDP-Gal in binding to 
-1,4-GalT are highlighted below, figure 21.  
 
Figure 21 - Important parts of UDP-Gal for binding to -1,4-GalT 
When Takayama et al. tested these 5 inhibitors against -1,3-GalT they saw that only UDP 
showed similar levels of inhibition. However, an iminocyclitol, despite its poor activity against 
-1,4-GalT, was shown to be a highly potent inhibitor (Takayama et al., 1999). 
 
In 2006, Vidal et al. studied C-glycosyl analogues of three nucleotide diphosphate sugars, 
including UDP-Gal (Vidal et al., 2006). They focussed on inverting GalTs that use UDP-Gal 
and synthesised the below analogue. C-glycosyls are more resistant to hydrolysis due to the 
relative strength of the C-C bond compared to C-O making them more practical to work with 
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 and more stable in vivo. Replacing an oxygen with an ethylene forms a mimic for the SN2 
intermediate in the inverting mechanism of GalTs, which inhibits -1,4-GalT (figure 22). 
Figure 22 –Structure of UDP-Gal analogue that inhibits -1,4-GalT 
Descroix et al. also studied the inhibitory properties of donor analogues of 
galactosyltransferases (GalTs) (Descroix et al., 2012; Jingqian Jiang et al., 2016). They found 
that substituting the R group from a proton to a 5-formylthien-2-yl on uridine created a strong 
inhibitor of GBT, N. meningitidis α-1,4-GalT, and B. taurus α-1,3-GalT. Although several 
substituents inhibited the three enzymes, 5-formylthien-2-yl was the most effective. They 
attribute this to interactions of the moiety with a flexible loop in the enzyme. They then 
attempted to combine this inhibitory effect with Vidal’s C-glycosidic mimic, figure 23. With 
these combined modifications, inhibitory action was maintained, but it was lower across all 
enzymes compared to the simpler 5-formylthien-2-yl. The authors do not speculate on the 
reason behind the reduction in activity. However, it could be that the introduction of the 
ethylene group changes the conformation of the uridine enough to reduce the strength of its 
hydrogen bond to Arg77 of the enzyme’s active site. 
Figure 23 – UDP-Gal analogues where R = H or 5-formylthien-2-yl, and X = ethylene or O 
Sujino et al. studied the effect of removing each hydroxyl on the galactose of UDP-Gal against 
three retaining GalTs: calf thymus 1,3-GalT, blood group B -1,3-GalT and Neisseria 
meningitidis -1,4-GalT (Sujino et al., 2000). From this, they observed that only hydroxyls at 
C3 and C4 are important for recognition since all three enzymes failed to process UDP-3-deoxy 
and 4-deoxy-galactose, figure 24. They also noted that removing the hydroxyl at C6 only 
slightly affected the activity of the substrate. Persson et al. published the crystal structure of 
a retaining GalT isolated from Neisseria meningitides with UDP-2-deoxy-2-fluoro-galactose. 
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They found that O4 of the donor sugar forms hydrogen bonds with an asparagine side chain 
of the protein (Persson et al., 2001). This interaction was also observed by Angulo et al. from 
NOE NMR studies of inverting blood group B GalT with UDP-Gal (Angulo et al., 2006). These 
studies can explain Sujino’s observations surrounding the importance of a hydroxyl at C4 as 
this hydrogen bond interaction may be crucial to the binding of the sugar to the enzyme’s 
active site. Combining all of these studies, we propose that the fluorination of UDP-Gal at 
position C4 would increase the strength of the hydrogen bond to the GalT and would thus 
produce an effective and stable affinity based probe. Since position 6 is not important for 
recognition, conjugating a linker here should not prevent binding. 
Figure 24 – Important moieties of UDP-Gal for recognition by GalTs 
There have been a number of other studies related to GalT inhibitors (Burkart et al., 2000; 
Schaefer et al., 2013; Jingqian Jiang et al., 2016). All these studies, along with those discussed 
above, target specific enzymes and none require their analogue to be immobilised. From this 
collection, we must design a general inhibitor that can be synthetically immobilised on a 
support. We know that the uridine moiety is important for recognition and modifying it can 
create powerful inhibitors; fluorinating C2 can inhibit -1,4-GalT, but not -1,3-GalT and the 
hydroxyl at C3 and C4 is important for retaining GalTs. Since the nature of the GalTs that we 
are searching for is unknown, a range of inhibitors will most likely be need. Fluorinating at C3 
or C4 of UDP-Gal could create an inhibitor of retaining GalTs due to the importance of this 
position in recognition. 
7.7.2 Resin bound sugars in solid support synthesis 
Immobilising the inhibitor on a resin requires a tailored synthesis of UDP-Gal or its analogues. 
We suggest the introduction of the linker at C6, since this position seems to be away from the 
sites of recognition. Most sugars in the literature are attached to supports or resins via C1, 
therefore they require a very different strategy (Osamu Kanie and Wong, 2000; de Souza et 
al., 2004; Jang et al., 2008; Ban et al., 2012). Those that couple at the C6 often do so purely as 
33 
 a synthetic aid and are removed from the resin before the end of the synthesis (Xu, 
Springfield and Koh, 2000; López-Prados et al., 2005). 
 
Lourenço et al. successfully synthesised a sugar bound to tentagel MB resin via a succinate 
linker at the C6 position as a synthetic aid (Lourenço and Ventura, 2011), figure 25. This linker 
can be easily attached to C6 from the ring opening of succinic anhydride, leaving a carboxylic 
acid moiety. This can be attached to the resin with amide bond formation. For Lourenço et al., 
the resin was used to avoid lengthy purification procedures that are often encountered in 
carbohydrate synthesis. 
Figure 25 – Sugar bound to tentagel resin via succinic anhydride adapted from Lourenço and 
Ventura, 2011 
Tethered sugars have been used on arrays with a PEG/ alkyl linker using either a thiol/ 
maleimide pairing or alkyne/ azide click chemistry (Ban et al., 2012; Jianbing Jiang et al., 2016). 
These sugars were used as acceptors in a glycosyltransferase array, therefore were tethered 
via the C1, figure 26. 
Figure 26 – Sugars linked to an array via thiol/ maleimide pairing or alkyne/ azide click chemistry, 
(Ban, 2012) 
7.7.3 Carbohydrate chemistry 
Carbohydrates are compounds consisting of carbon, hydrogen and oxygen. The simplest 
carbohydrates are monosaccharides, the building blocks of glycans. In 1902, Emil Fischer 
received the Nobel Prize for Chemistry for his outstanding work in purine and carbohydrate 
synthesis (Fischer, 1902). Since then, a further four Nobel prizes have been awarded for 
contribution to the field of carbohydrates; Walter Haworth in 1937, Carl and Gerty Cori and 
Bernardo Houssay in 1947 and Luis Leloir in 1970. In Fischer’s prize winning speech, he said 
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“the abundance of substances of which animals and plants are composed, the remarkable 
processes whereby they are formed and then broken down again have claimed the attention 
of mankind of old, and hence from the early days they also persistently captivated the interest 
of chemists.” It is the important roles that carbohydrates play in every aspect of life and their 
enormous abundance that has driven the work of many great scientists like Fischer. 
 
Fischer deduced the structures of most natural monosaccharides and established the Fischer 
projection – a way to represent these monosaccharides in their open chain form on paper 
(‘Rules of Carbohydrate Nomenclature’, 1963).  Monosaccharide backbones can be from 3 to 
7 carbons long with those of length 5 called pentoses and those of length 6 hexoses. In the 
open form, each monosaccharide has two enantiomers which are non-superimposable mirror 
images of each other (D or L). However, most exist in their cyclic form. In this form, there are 
two anomers:  and  which are epimers at the hemiacetal carbon. Between 
monosaccharides with the same length carbon backbone, the differences are subtle 
epimerisations of hydroxyl groups anywhere except at the hemiacetal carbon. Examples of all 
these isomers are shown in figure 27. 
Figure 27 – The different isomers of galactose and examples of hexoses and pentoses 
Monosaccharides are polar and highly soluble in water due to the high number of hydroxyl 
groups that can form hydrogen bonds. In nature, these monosaccharides can be bound 
enzymatically to produce di-, tri-, oligo- or polysaccharides. These complexes can be extracted 
and purified from their native organisms, but are rarely obtained in large quantities. Unnatural 
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 carbohydrates also present interesting biological properties, but cannot be extracted from 
natural sources. In order to obtain large quantities of natural or unnatural carbohydrates, they 
must be made synthetically (Stick, 2001). 
 
Synthesis of carbohydrates often involves extensive protection strategies in order to 
differentiate the near identical hydroxyl groups on the sugar. To avoid lengthy routes, some 
products can be obtained through chemoenzymatic methods (Hayashi et al., 1997; Burkart et 
al., 2000; Li et al., 2014). However, using enzymes leads to long reaction times, the use of 
water as a solvent, strict control on pH and temperature and they are often expensive. More 
crucially, enzymes are normally used only with their naturally occurring substrates since 
analogues are often inhibitors of the enzyme, thus limiting their utility (Akiyaffici et al., 1987). 
 
A number of GalT inhibitors have been synthesised, as discussed. Fluorinated analogues of 
UDP-Gal have been synthesised as inhibitors of UDP-galactose 4-epimerase (Chapeau and 
Frey, 1994), Galactopyranose mutase (Burton and Boons, 1997) and Human -1,4-
Galactosyltransferase (Takaya et al., 2005), along with other uses (Hayashi et al., 1997; Barlow 
and Blanchard, 2000; Burkart et al., 2000). All these studies targeted specific enzymes and did 
not require their analogue to be immobilised. Immobilisation on the resin will require a 
tailored synthesis of UDP-Gal and its analogues where the C6 position must be differentiated. 
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7.8 Aims 
 
This thesis aimed to use chemical methods to study glycosylation in Trypanosoma brucei and 
Plasmodium falciparum under four main aims: 
(i) to design a synthetic route to immobilised nucleotide sugars 
(ii) to develop a strategy to characterise unknown galactosyltransferases of 
Trypanosoma brucei 
(iii) to examine the effects and utility of the small molecule N-glycosylation inhibitor 
NGI-1 on Trypanosoma brucei 
(iv) to characterise the N-glycans of Plasmodium falciparum. 
 
To address aims (i) and (ii), activity based probes were synthesised and a protocol was 
developed to use these probes to enrich galactosyltransferases from a mixture of proteins. 
The protocol was then adapted to try and enrich galactosyltransferase from whole cell lysates 
of Trypanosoma brucei. 
 
To address aim (iii), Trypanosoma brucei was cultured in the presence of NGI-1. Its growth was 
monitored over a range of concentrations and western blots performed to view alterations to 
N-glycosylation. 
 
To address aim (iv), Plasmodium falciparum was cultured and a number of different lectin-
based purification techniques were evaluated to purify N-glycoproteins. Mass spectrometry 
was then used to characterise these proteins. 
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8 Chapter 1 
Synthesis of resin bound affinity-based 
galactosyltransferase probes 
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8. Chapter 1 
Synthesis of resin bound affinity-based galactosyltransferase probes 
8.1 Results and discussion 
This chapter has two main aims; (i) to synthesise activity based probes based on known 
inhibitors of galactosyltransferases (GalTs); (ii) to develop a method to use the activity based 
probes to enrich galactosyltransferases from a mixture of proteins. The probes were based 
upon known inhibitors of GalTs and their synthesis was designed by modifying routes to 
similar compounds using intricate protection strategies. The enrichment protocol was 
developed using commercially available bovine β-1,4-galactosyltransferases (GalT) in a range 
of systems. 
 
8.1.1 Author Contributions 
J. G. M. Bevan, E. C. Lourenço and M. R. Ventura designed the synthetic route to the resin 
bound probes. J. G. M. Bevan, M. Chaves-Ferreira and J. A. Rodrigues designed the 
experiments to enrich -1,4-GalT using the resin bound probes. J. G. M. Bevan performed all 
the reactions and experiments, data analysis and created all the figures and tables. M. R. 
Ventura and J. A. Rodrigues mentored and supervised the work.  
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 8.1.2 Synthesis of resin bound glycosyltransferase probes 
 
The synthesis of two activity based probes, UDP-galactose (UDP-Gal) and UDP-4-deoxy-4-
fluoro-galactose (UDP-(4F)-Gal), will be described as well as their conjugation to tentagel 
resin. Although the synthesis of free UDP-Gal and UDP-(4F)-Gal have been described (Burton 
and Boons, 1997; Wagstaff et al., 2015), this represents the first synthetic route to any 
nucleotide sugar attached to a solid support. 
 
The main challenges of these syntheses are: 1) selective addition of the linker at the C6 
position for subsequent coupling to the resin; 2) the sensitivity of the phosphate to acidic 
conditions; 3) selective fluorination at C4; 4) the low reaction rates of uridine morpholidate 
with galactose phosphate; 5) carrying out synthesis in water. 
 
The PEG resin tentagel was chosen as a solid support due to its ability to swell in a wide range 
of solvents – important for the crossover between chemistry and biology. Its reactive end 
contains an amine moiety, which can be coupled to the sugar via an appropriate linker. 
8.1.2.1 Resin bound UDP-Galactose as a glycosyltransferase probe 
Starting from galactose, the synthesis of resin bound UDP-Gal was designed to consider the 
following: 
- Hydroxyls at positions 1 and 6 must be differentiated from each other and from 2, 3 and 4 
so that UDP can be added to 1 and the linker to the resin attached at 6 (Figure 28): 
Figure 28 - Galactose 
- The phosphate must be added before the sugar is attached to the resin to avoid cross 
reactivities: 
- The UMP must be added last as it is sensitive and the reaction occurs in water. 
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The planned route to resin bound UDP-Gal is shown in figure 29. Orthogonal protection of C1 
and C6 would produce sugar A. From A, the phosphate and the linker could be introduced 
producing C. Finally, UMP can be conjugated, producing the final sugar D. 
Figure 29 - Proposed general route to resin bound UDP-Gal. R = a C1 protecting group, R’ = a linker. 
Initially, the efficacy of the allyl and TBDPS moieties to be orthogonal protecting groups of C1 
and C6 were investigated. The addition of the allyl chain is specific to C1 due to the hemiacetal 
nature of the anomeric hydroxyl. The bulky TBDPS is specific to C6 due to steric hindrance of 
the other hydroxyls (Takahashi and Nakata, 2002). Their addition leaves C2, C3 and C4 
available to be protected by benzyl groups. Selective removal of either the allyl or the TBDPS 
would then allow for the addition of the phosphate or the linker. 
Scheme 1 - Protection of galactose with an allyl chain and TBDPS 
 
Although the yields for reactions a to c are good to very good, this route from galactose (1) to 
sugar 5 (Scheme 1) proved to be inefficient. The deprotection of the allylic alcohol from the 
anomeric position of 4 to produce 5 formed two inseparable products. NMR evidence strongly 
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 suggests that these products were the alpha and beta anomers of TBDPS migration to C4 
without the allyl at C1. This is most likely due to the close proximity in space of the O4 to the 
O6 particular to galactose allowing for migration. The migration probably occurred during the 
addition of the benzyl protecting groups as these are strongly basic conditions. The mixture of 
anomers of the desired product could have hidden the extra product in the NMR spectra. 
However, once the allyl was removed, these products were then clearly visible on the TLC and 
the NMR showed four products. The migration of a silyl group under basic conditions is not 
unprecedented but this exact migration has not been reported (Stanciu and Bennett, 1974; 
Kira and Iwamoto, 2001). An alternative route to 5 is outlined in Scheme 2.  
Scheme 2- Alternative route to sugar 5 
This utilises the selectivity of the TBDPS protection of C6 over C1 as in Takahashi’s synthesis 
of Mucocin (Takahashi and Nakata, 2002). Methyl -glucoparanoside (6) was benzylated 
under strongly basic conditions with sodium hydride (added at 0 °C) in a quantitative yield 
(Scheme 2).  Then 1-OH and 6-OH were acetylated under strongly acidic conditions to afford 
sugar 2 in a 82% yield (Lourenço, Maycock and Rita Ventura, 2009). They were then efficiently 
deprotected in a very good yield of 82%, leaving C6 to be selectively protected in a very good 
yield of 89% (Takahashi and Nakata, 2002). This route is a great improvement upon the 
previous. 
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Scheme 3 - Addition of phosphate to C1 and linker to C6 
From sugar 5, a phosphorous needed to be introduced to C1, the TBDPS removed and a linker 
conjugated at C6 (sugar B in figure 29). Dibenzyl phosphate was added via the phosphityl in a 
quantitative yield (Priestley, 1996) and the TBDPS removed in a good yield of 76% (Takahashi 
and Nakata, 2002) producing sugar 11. The succinate linker was then conjugated to C6 in a 
near quantitative yield (scheme 5) forming sugar 12 (Lourenço and Ventura, 2011). This linker 
was chosen due to its previous success in the group and because it is able to form amide bonds 
with our chosen resin (Lourenço and Ventura, 2011). A disadvantage of this linker is that for 
selective conjugation to the C6 position, all other hydroxyls must be protected. 
 
Subsequently, the sugar either had to be linked to the resin and then deprotected or 
deprotected and then bound to the resin (Scheme 4). 
Scheme 4 - Two possible routes to theoretical sugar C 
Deprotecting the sugar of its benzyl groups before linking to the resin leaves many hydroxyls 
free to potentially react with the resin. However, deprotecting by catalytic hydrogenation on 
the resin is problematic since the common reagent used is Pd/C (a solid), which would be 
difficult to remove. Since neither route is perfect, both were explored. 
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 After optimisation, sugar 12 underwent hydrogenation to give 13 in a quantitative yield, 
Scheme 5. We saw that the solvent system of this reaction was crucial to its success and that 
a 50:50 mixture of EtOH:H2O has to be used (Liu, Shen and Ichikawa, 1992). This is likely due 
to the solubility of the intermediate products of the reaction and of the fully protected starting 
material – if they are not able to dissolve they cannot react with the palladium and remain 
partially deprotected. 
Scheme 5 - Deprotection of sugar 12 
We then tested a range of amide forming conditions to couple sugar 13 to tentagel-NH2 resin 
using the coupling reagent HOBt with EDC or DIC (Lourenço and Ventura, 2011; Tonn and 
Meier, 2011). In order to determine that the sugar was bound to the resin, High Resolution 
Magic Angle Spinning NMR was used (HRMAS). This analytical technique utilises the resin’s 
ability to swell in solvent to obtain a “semi-solid” NMR spectra. Standard NMR is unable to 
resolve spectra of semi-solids and solids due to dipolar coupling, quadropolar interactions and 
chemical shift anisotropy. The rapid movement of liquids averages out these interactions but 
in solids dipolar interactions and anisotropy broaden the NMR signal reducing resolution. 
Magic angle spinning reduces the effect of these interactions by physically spinning the sample 
at a mathematically defined “magic” angle thereby improving resolution (Power, 2003). In this 
case, HRMAS still suffers from some broadening due to the inflexible backbone of the PEG 
resin. In addition, the soluble arm of the resin is highly abundant in comparison to the 
conjugated sugars and can dominate the spectra, especially when dissolved in D2O where it is 
soluble. However, HRMAS remains a powerful tool allowing characterisation of compounds 
conjugated to a solid support. The alternative would be cleavage of the compound and 
standard NMR of the cleaved product – an often-impractical solution especially when the 
product needs to remain on the solid support. 
 
HRMAS of the coupling of 13 to tentagel resin showed several environments present in the 
31P spectra, suggesting that 13 attached via the phosphorous as well as the desired succinate 
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linker. This should have been predicted since phosphates are also able to react with amines in 
the presence of carbodiimides to produce phosphoramidates (Hermanson, 2008). This route 
was put to one side and the alternative route investigated (attaching sugar 12 to the resin 
followed by deprotection). 
Scheme 6 - Conjugation of sugar 12 to tentagel resin 
 
Sugar 12 underwent amide bond forming conditions with EDC, HOBt and tentagel (scheme 6) 
(Lourenço and Ventura, 2011). From 1H, 13C and 31P HRMAS NMR it was clear that the resin 
had bound to the correct location at C6. Figure 30 shows the spectra of sugar 12 free and 
conjugated to the resin. The line broadening in HRMAS spectra described above can be 
observed here, although there are clearly peaks from the sugar on the resin. As the spectra 
was conducted in CDCl3, the peaks associated to the soluble chain of the resin are minimised. 
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Figure 30 – 1H NMR of sugar 12 and 1H HRMAS of resin 14 
We showed that sugar 12 can be deprotected using Pd/C in H2O: EtOH (1:1). Therefore, these 
conditions were applied to the sugar on the resin. Unfortunately, there was no reaction and 
the palladium proved impossible to separate from the resin. Many other conditions were tried 
with no success (Jones, 1980; Tam, Heath and Meriifield, 1983; Bourne et al., 2001; Chéry et 
al., 2001). The main disadvantage of coupling to a solid support is that any solid phase reaction 
is much slower than one in liquid. With two solids (i.e. palladium on carbon and the resin) the 
rate is even slower since the surface area which can come together to react is very small and 
the chance of contact is low since their movement is more restricted than that of a liquid. 
Although the resin is swelled and is therefore not completely solid, the deprotection of benzyl 
groups must be performed before the sugar is coupled to the resin to avoid this solid-solid 
reaction. This route showed that the chemistry of the succinate linker and the phosphate are 
too similar to proceed and an alternative linker must be found. 
Aromatic Hs 
Succinate 
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8.1.2.2 Use of Succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) linker  
The linker SMCC contains two reactive groups; an N-hydroxysuccinimide (NHS) ester and a 
maleimide (Figure 31) and is an FDA approved linker commonly used in bioconjugation 
especially in antibody-drug conjugation (Koniev and Wagner, 2015; Luo et al., 2015; Yao et al., 
2015). These groups react towards amino and sulfhydryl groups respectively. 
Figure 31 – SMCC, with NHS ester and maleimide groups highlighted 
We chose this linker to replace the succinimide because its two reactive groups are orthogonal 
and should avoid overlapping reactivities with the phosphorous. A disadvantage of SMCC is 
that it is hydrophobic which can lead to problems with rapid clearance in antibody drug 
conjugation (R. Y. Zhao et al., 2011). In this case, the deprotected sugar is hydrophilic and 
should counteract the hydrophobicity of SMCC and dissolve in water for the biological assays. 
Tentagel should be compatible with this linker as the NHS ester end of SMCC will link to the 
amine end of the tentagel resin. If a thiol can be installed at the C6 of the sugar, then it can 
also be linked to SMCC via the maleimide. The sugar in figure 32 could theoretically be 
attached to SMCC via the thiol. 
Figure 32 - Example of a sugar that could be linked to SMCC, where R is a C1 protecting group 
Succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) was synthesised 
according to literature procedure (Scheme 7) (Paterson and Eggleston, 2008; Leonard and 
Brunckova, 2011). 
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 Scheme 7 - Synthesis of SMCC 
SMCC was linked to the resin in PBS buffer and DMF (Yoshitake et al., 1982; Harrison and 
Balasubramanian, 1998) with a loading of 76% (scheme 8). The SMCC had to be dissolved in 
DMF before adding it to the PBS otherwise it precipitated due to its hydrophobicity. The 
loading of the resin was calculated by calculating the mmol of SMCC added according to the 
weight increase of the resin as a percentage of the 0.3 mmolg-1 loading of NH2 on the 
unconjugated resin. 
Scheme 8 - Coupling of SMCC to tentagel resin  
If an alkyl chain terminating in a bromine was coupled to C6, this bromine could be converted 
to a thiol, which could then be conjugated to the maleimide of the SMCC resin. Conditions to 
add the alkyl chain to sugar 11 were tested as shown in Scheme 9 (Dohi et al., 2002). 
Scheme 9 - Conditions tested to add alkyl chain to sugar 11 
Unfortunately, under these highly basic conditions, the benzyls on the phosphorous were 
removed producing a range of products, including alkylation of the phosphate. The hydride is 
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a hard nucleophile which could attack the phosphate displacing a benzyl ester in an SN2 
manner, the same way that fluoride is known to (Blackburn, 2006). In turn, this hydrogen could 
be then displaced by the alkyl halide producing the products observed. 
 
We concluded that it would be better to alkylate the sugar before introducing the phosphate. 
The following route was evaluated (Scheme 10). This route uses the previous steps to produce 
sugar 8 from sugar 6. Then sugar 8 could be glycosylated with p-toluenesulphonic acid at C1. 
This would leave C6 differentiated for selective deprotection and available to couple to the 
alkyl chain linker before the phosphate is introduced to C1. 
Scheme 10 – Alternative route to resin bound UDP-Gal 
 
Donor formation with p-toluenethiol occurred in the very good yield of 86% (Scheme 11). The 
subsequent deprotection of C6 with sodium methoxide in methanol gave sugar 19 in the 
excellent yield of 94% (Scheme 11). 
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 Scheme 11 – Differentiation of C6 for subsequent selective addition of alkyl chain linker 
With sugar 19 in hand we were able to proceed to the addition of the alkyl chain terminating 
in bromine (scheme 12). Dibromohexane was conjugated to C6 with sodium hydride catalysed 
by TBAI (Tetrabutylammonium iodide) in a yield of 68%. This reaction also gave a side product 
where the second bromide of the dibromohexane also coupled to 19, but consistently in a 
yield lower than 8%, 20a. This side reaction is in a low yield and can be reduced by careful 
monitoring of the reaction so was not considered to be a problem. TBAB 
(Tetrabutylammonium bromide) is a common, and cheaper, catalyst used in alkylation 
reactions (Rong and Ruoho, 1999; Kanemaru, Yamamoto and Kadokawa, 2012), but when 
tested in place of TBAI there was no reaction. Both TBAI and TBAB are phase transfer catalysts 
but can also catalyse reactions by activating the alkyl halide (in this case alkyl bromide) by 
displacing the halide (Lu et al., 2014). TBAI can displace alkyl bromide with the more reactive 
iodide whereas TBAB obviously cannot. The alkyl iodide formed is a more susceptible to attack 
from a nucleophile like the oxygen anion. This explains why TBAB was unable to catalyse the 
reaction. 
Scheme 12 - Conjugation of alkyl chain linker and glycosylation 
Subsequent glycosylation with the acceptor dibenzyl phosphate and NIS/TMSOTf gave a very 
good yield of 85% with an : of 1:0.9  (Burton and Boons, 1997). The neighbouring benzyl 
group is electron rich and stabilises the oxonium ion intermediate. We found that sugar 20 
could not be stored (even at -20 °C) for longer than a week as the phosphate is cleaved by acid 
hydrolysis.  
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Hydrogenolysis must be performed before the thiol is introduced to avoid poisoning the 
palladium catalyst. After optimisation, sugar 20 was deprotected in 30 min, quantitatively. 
Sugar 20 also suffers from rapid decomposition as the phosphate is sensitive to acidic 
conditions and the solution from the hydrogenation is acidic (pH1-2).  The next step is to 
convert the bromine to a thiol, which can be achieved by first displacing the bromine with a 
thioacetate, then hydrolysing it to a thiol with a base. Once in these basic conditions, the sugar 
is much more stable as hydrolysis occurs in pH 1 to 4 (Foster and Overend, 1955). 
Scheme 13 - Deprotection of sugar 20 and conversion of the bromine moiety to thiol 
The reaction to add a thioacetate is quick and goes to complete conversion (Chen et al., 2005). 
A number of bases can be used to hydrolyse the thioacetate to a thiol (Singh et al., 2010). KOH 
gave the thiol but also the elimination side product 21b in a 14% yield. The elimination product 
was also produced (11%) when attempts were made to go via the thiourea (Ferrell, Garces 
and Desmyter, 1976; Galano et al., 2013). These were only separable by using a G-10 sephadex 
column, therefore the alternative softer base potassium carbonate was tested. This base 
produced the thiol in an 88% yield and no elimination product was seen. However, over time 
(a few days) the thiols formed disulphide bridges between themselves. These bridges are 
easily broken by a reducing agent such as TCEP or DTT. Both reagents are used in excess and 
are difficult to separate from sugar 21 due to their solubility in water. DTT is more reactive 
towards maleimides as it contains a thiol and would therefore act as a competitor on 
conjugation of 21 to the maleimide of SMCC. TCEP is stable in a wider range of pH compared 
to DTT, and is a more powerful reducing agent; within 5-10 min all disulphide bonds can be 
broken (Burns et al., 1991; Shafer, Inman and Lees, 2000). Therefore, TCEP was used to reduce 
disulphide bonds of 21. 
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 Scheme 14 - Conjugation of sugar 21 to the maleimide of SMCC on tentagel resin 
 
Sugar 21 was coupled to the maleimide of SMCC bound to tentagel resin in H2O/DMF (Scheme 
14). The solution was acidified with K2HPO4 to pH 7-7.5 to allow the formation of the thiolate 
and the reaction allowed to stir overnight where the resin changed from yellow to pink and 
22 was formed in a 71% loading (Harrison and Balasubramanian, 1998; Koniev and Wagner, 
2015). The loading of the resin was calculated from amount of sugar added according to the 
weight increase of the resin as a percentage of the loading of SMCC on the unconjugated resin. 
 
 Uridine was activated with morpholidine to form the morpholidate. Then UMP morpholidate 
was coupled to the phosphate on 22 using the catalyst tetrazole. It increases the rate of 
reaction by protonating the morpholine group making it a better leaving group (Wittmann and 
Wong, 1997). This reaction is very slow, taking days to complete. Reloading the resin after 6 
days with fresh UMP morpholidate and tetrazole improved the yield. Although much slower 
than the equivalent in-solution reaction, 23 was produced in a good loading of around 83% 
(Scheme 15). 
Scheme 15 - Coupling of UMP with resin bound sugar 22  
An exact loading was not always possible to calculate due to loss in mass of the resin after 
reaction. This loss in mass could be from transferring the resin, poor drying of the resin before 
the reaction or loss of substrate from the resin. However, by integrating the phosphate 
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environments of the diphosphate and the monophosphate, a ratio can be calculated and used 
to estimate how many have been converted to the diphosphate. This is not ideal as it assumes 
that no decomposition occurred. Carbohydrates can be quantified by reaction with sulphuric 
acid which dehydrates them to hydroxymethyl furfural. On reaction with phenol, the colour 
changes and this can be measured by a spectrophotometer and correlated to concentration 
(Nielson, 2009). Recently, a method was published that skips the phenol step and measures 
the concentration on a UV spectrophotometer after dehydration (Albalasmeh, Berhe and 
Ghezzehei, 2013). This method could be used to quantify the amount of sugar on the resin 
and then the ratios of the phosphate from the NMR spectra could quantify the amount of 
mono and diphosphate. 
8.1.2.3 Resin bound fluorinated UDP-Gal 
Starting from glucose, the synthesis of resin bound UDP-(4F)-Gal was designed to consider the 
following: 
- Hydroxyls at positions 1, 4 and 6 must be differentiated from each other and from 2 and 3 
so that UDP can be added to 1, fluorine at 4 and the linker to the resin attached at 6 (Figure 
33).  The starting sugar must be glucose due to inversion of the stereochemistry on 
fluorination; 
- The phosphate must be added before the sugar is attached to the resin to avoid cross 
reactivity with the resin; 
- The UMP must be added last as it is sensitive and the reaction occurs in water. 
Figure 33 – Glucose 
Initially, DAST was used to fluorinate position 4. DAST generates free HF in solution, which is 
highly corrosive and volatile but this fluorinating reagent requires the least extensive 
protection strategy (Card and Reddy, 1983). C1 was protected with an allyl moiety in a very 
good yield of 80%.  
 
The next step was to introduce a protecting group at C6. In literature, either trityl or pivolate 
are chosen to protect the C6 during fluorinations (Card and Reddy, 1983; Chapeau and Frey, 
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 1994; Hayashi et al., 1997; Burkart et al., 2000; Hartman and Coward, 2002; Giuffredi et al., 
2011; Giuffredi, Gouverneur and Bernet, 2013). When C4 of galactose is fluorinated, trityl 
appears to be the protecting group of choice most likely due to its robustness. The trityl moity 
was added to sugar 23 in a yield of 58% (scheme 16). 
Scheme 16 – Protection of C1 and C6 of 24 (glucose) 
 
Sugar 25 was then fluorinated with DAST in DCM over 3 days (Card and Reddy, 1983). This 
reaction was low yielding and produced two products. The desired product 26 was produced 
in a very low yield of 16%. Sugar 27 was isolated (fluorinated at C3) in a 37% yield (scheme 
17). The two different products arise from the fact that  and -glucose promote two different 
reactions. Somawardhana and Brunngraber studied the effect of the anomeric conformation 
on the selectivity of DAST and concluded that steric hindrance of substituted -glucose 
prevented fluorination of C3 since the attack of the fluoride ion would have to approach from 
below on the same plane as the axial anomeric group (Somawardhana and Brunngraber, 
1983). However, -glycosides possess no such hindrance and C3 is preferentially fluorinated. 
Fluorination at C3 is unwanted since it produces an unnatural sugar, not galactose. Reduction 
of the reaction time to 1 day lead to a drastic reduction in yield to 2% for the desired product 
26. 
Scheme 17 - DAST as a fluorinating agent 
 
When anomerically pure methyl -D-glucopyranoside protected at C6 with trityl, 29, was 
fluorinated sugar 30 was formed in a yield of 29% (Scheme 18). Although this yield is 
comparable to literature, it is still low, the reaction time is very long and no starting material 
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can be recovered. The low yield can be explained by formation of the elimination product and 
decomposition of the starting material. 
 
Scheme 18 – Protection of 28 and subsequent fluorination with DAST 
 
To avoid the use of DAST as the fluorinating agent, we investigated an alternate route (Koketsu 
et al., 2011). By installing a triflate at C4, fluorine can be introduced with TBAF through 
displacement of the triflate with a fluoride ion. Burton et al. used TBAF to fluorinate the C4 
position of glucose in a good yield of 74% (Burton and Boons, 1997). Since this method is not 
selective, the sugar must be fully protected leaving only position 4 free, requiring multiple 
protection steps. In literature, all steps give good to excellent yields so it was theorised that 
this method could improve the overall yield of the synthetic route compared to using DAST. 
Burton’s route must be altered to suit our needs, the C6 hydroxyl must be differentiated for 
later coupling to dibromohexane. We proposed to introduce the TBDPS protecting group and 
to protect C1 with a thioester (Scheme 19). This avoids using an acetyl at C1 which was 
previously found to be difficult to remove. The thioester is also convenient for the 
glycosylation with dibenzylphosphate later. 
Scheme 19 - Proposed route to protected sugar for fluorination 
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Glucose was acetylated in a quantitative yield by stirring overnight in acetic anhydride and 
pyridine catalysed by DMAP. Acetylated glucose was then protected in a yield of 80% (Scheme 
20). This reaction is slow, taking up to 3 days to complete. However, starting material is easily 
recovered for re-use. Removal of the acetyls proceeded with the excellent yield of 94% with 
the standard conditions of sodium methoxide in methanol. 
Scheme 20 - Synthesis of sugar 31 (glucose protected at C1) 
C4 and C6 were protected with an acetal in a good yield of 70% by reacting sugar 31 with 
PhCH(OMe)2 and a catalytic amount of CSA in DMF. The C2 and C3 of this sugar were then 
protected in a quantitative yield with benzyl moieties by reaction with benzylbromide in DMF 
with sodium hydride. The acetal could then be removed using p-toluene sulfonic acid in 
DCM/MeOH in an excellent yield of 94%, forming sugar 32 and leaving C6 open for selective 
protection and C4 open for fluorination. 
Scheme 21 – Synthesis of sugar 32  
Silyl groups are bulky and are therefore frequently used to protect the C6 of sugars that are 
less sterically hindered. Attempts to protect 32 with TBDPS in a range of conditions were not 
successful.  
Scheme 22 - Protection of C6 with TBDPS 
When TBDPSCl was replaced with the smaller, less sterically hindered, TBDMSCl, the reaction 
proceeded with a quantitative yield (Scheme 23). This left C4 deprotected and free for 
fluorination. Using conditions adapted from Burton et al. the C4 was first activated with a 
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triflate before its displacement with a fluorine anion provided by TBAF (Burton and Boons, 
1997). The addition of TBAF also simultaneously deprotects C6. After optimisation, the 
fluorination and deprotection of C6 afforded 34 in a 48% yield (Scheme 23). During the 
fluorination step, the alpha anomer was predominant. Sugar 32 is re-formed as a side product 
from the deprotection of C6 without fluorination of C4 or the hydrolysis of the triflate before 
fluorination. The C3 hydroxyl is in the same environment in the beta and the alpha anomer, 
therefore  it is unlikely to be a case of the beta anomer forming 32 faster than the alpha 
(Miljkovic, 2009). 
Scheme 23 – Synthesis of sugar 34 
 
From sugar 34 we could follow a similar route to that of resin bound UDP-Gal. Under the 
conditions that were applied to 19, sugar 34 was coupled to the dibromohexane linker in a 
good yield of 80%. It was then glycosylated in a yield of 61% to produce sugar 35. 
Scheme 24 – Synthesis of sugar 35 
 
Burton’s synthesis of UDP-(4F)-Gal is similar to this newly developed route. However, their 
use of the vinyl glycoside to obtain only alpha phosphate reduces their yield of glycosylation 
and introduces an extra step in the route. Since this selectivity wasn’t necessary, our route 
obtained a higher overall yield: 15% over 10 steps compared to 5% over 11 steps. This is 
despite the higher yield Burton obtained in the fluorination step (74% compared to 48%). The 
smaller yield is likely due to the competing reactions of the hydrolysis of TBDMS and the 
fluorination of C4.  
 
59 
 Sugar 35 was then subjected to hydrogenolysis under the conditions that were applied to the 
UDP-Gal derivative. The optimal reaction time was found to be 1 hour, which produced 36 in 
a near quantitative yield. Although bromine has the potential to poison palladium, the fact 
that it is a primary alkyl halide makes it difficult to hydrogenate. However, if longer reaction 
times are used, sugar 37 is produced where the terminal CH2Br has been reduced to a methyl 
group (Scheme 25). 
Scheme 25 – Synthesis of sugar 36 and side product 37 
The bromine of sugar 36 was then converted to a thiol via the thioacetate in quantitative yield 
as previously described for sugar 20. Resin 17 was coupled to the thiol with a loading of 78%. 
Subsequent coupling to uridine morpholidate catalysed by tetrazole gave 37 in an 
approximate yield of 38%. This was calculated as described above as an estimate of the 
phosphate environments. 
Scheme 26 – Synthesis of resin bound sugar 37. 
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8.1.3 Assessment of resin bound UDP-Gal and UDP-(4F)-Gal as glycosyltransferase probes 
8.1.3.1 Enrichment of 1,4-galactosyltransferase with UDP-Gal based affinity probes. 
Before testing if the resins are able to enrich GalTs from whole proteome extracts, we first 
developed a simpler system. First, the affinity of the resins to -1,4-galactosyltransferase (-
1,4-GalT, a common, commercially available, galactosyltransferase) was tested. Then we 
looked at their ability to enrich -1,4-GalT from two other proteins: variant surface 
glycoprotein (VSG) and BSA. VSG was chosen because in future experiments we propose to 
try the resin in T. brucei extracts and it is a highly abundant protein in T. brucei (Taylor and 
Drickamer, 2011). 
 
A system was designed whereby the resin was placed on a column capped with a 40 m filter, 
closed with parafilm and incubated with proteins. The 40 m filter allowed the resin to be 
washed whilst the parafilm kept the buffer in place whilst the resin was incubated. The resin 
was washed and any bound proteins were eluted by boiling in laemmli buffer. The washed 
and eluted proteins were then run on a gel to visualise if any enrichment had occurred, figure 
34. 
Figure 34 - Method to enrich for GalTs with an affinity resin 
Initially, the amount of protein used was not sufficient to see on a gel in the washes nor the 
elution. Therefore, to determine the amount of protein to use, a gel was run with varying 
amounts of -1,4-GalT and BSA. From this, it was clear that above 2 g of -1,4-GalT and above 
1 g of BSA was enough to see on a gel, see annex figure 67. 
 
When the UDP-Gal resin or the UDP-(4F)-Gal resin is incubated with only -1,4-GalT in a buffer 
containing MnCl2 (to help GalT bind to the resin) it is eluted after the resin is boiled, as can be 
seen in lanes 5 and 10 of the gel in fig. 35. The washing lanes (2 to 4 and 7 to 9) in the gel show 
little protein in comparison. The control lane 6 contained half the amount of protein compared 
x 3 
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 to the amount incubated with the resins. Unfortunately, this does not seem to be enough to 
visualise well and more needs to be used. The multiple bands seen are most likely glycosylated 
forms of the GalT and aggregates of the enzyme. As a monomer, it has a molecular weight of 
44 kDa and is the lowest band seen. The identity of all the bands is not known and some could 
be due to the resin itself. 
              1      2       3      4      5      6       7     8       9    10 
Figure 35 – Binding of -1,4-GalT to the UDP-Gal and UDP-(4F)-Gal resins. Lane 1 = ladder, UDP-Gal 
resin lanes 2 to 5: 2 = wash 1, 3 = wash 2, 4 = wash 3, 5 = elution, lane 6 = control, UDP-(4F)-Gal 
resin lanes 7 to 10: 7 = wash 1, 8 = wash 2, 9 = wash 3, 10 = elution. 
Since it was evident -1,4-GalT was able to bind to the resin, the next experiment moved to a 
more complicated system to assess if it preferentially bound to -1,4-GalT over VSG and BSA. 
The resins were incubated with -1,4-GalT, VSG and BSA, washed three times and bound 
proteins eluted with laemmli buffer. In order to check that the resins themselves were not 
leaching material that caused the bands seen in previous gels, they were also boiled in laemmli 
without exposure to any proteins. The washes, elution and the supernatant from the boiled 
unexposed resins were loaded on to a gel along with a control lane of the three proteins 
together, figure 36. 
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                 1    2    3    4    5    6    7    8    9   10  11 12  13  14  15 
Figure 36 – Gel showing enrichment of -1,4-GalT by UDP-Gal and UDP-(4F)-Gal. Lanes 1 = ladder, 
UDP-Gal resin lanes 2 to 5: 2 = wash 1, 3 = wash 2, 4 = wash 3, 5 = elution, lane 6 = blank, lane 7 = 
control, lane 8 = blank, UDP-(4F)-Gal resin lanes 9 to 11: 9 = wash 1, 10 = wash 2, 11 = wash 3, 12 = 
elution, 13 = blank, 14 = UDP-Gal resin, 15 = UDP-(4F)-Gal. 
The elution lane of the UDP-(4F)-Gal resin, 12, contains the same bands that were seen in the 
experiment where only -1,4-GalT was present, suggesting that the enzyme has selectively 
bound to the resin. The elution lane of the UDP-Gal resin, 5, does not contain any protein – 
perhaps the resin was blocked with non-specific proteins binding that washed off and the 
affinity was not high enough to bind -1,4-GalT in the presence of other proteins. The strong 
band seen in W1 of both resins (2 and 9) and the control lane is VSG, which does not seem to 
bind strongly to the resin. Boiling the resins that were not exposed to proteins proved that 
they alone do not cause bands to appear (lanes 14 and 15). 
 
This experiment was repeated omitting the controls of resin that hadn’t been exposed to 
protein, figure 38. In parallel, the resins were also incubated with only VSG and BSA in order 
to assess the binding of these proteins in the absence of -1,4-GalT, figure 37. The washes, 
elution and control samples of protein were run on an SDS gel and each band was extracted 
and tryptic digested for subsequent mass spectrometry analysis and compared against a 
database of proteins (figure 37 and 38). 
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 The extracted bands for the condition without -1,4-GalT are labelled in figure 37. In the 
control lane, 8, VSG is not very visible due to the poor de-staining. The two visible bands are 
from BSA. The proteins eluted from the UDP-Gal resin are in lane 6 (bands A3 and A4). In lane 
14 are the proteins eluted from the UDP-(4F)-Gal resin (bands A9 and A10). The bands in lane 
6 and 14 look remarkably similar to those eluted in the previous experiment where -1,4-GalT 
was present figure 36, but by mass spectrometry only keratin was detected in these bands. 
They are likely to be BSA binding non-specifically to the resin. Perhaps the extraction was not 
sufficient to extract enough protein to detect as they were low in abundance, although their 
intensity is similar to or higher than bands A1, A2, A5, A6, A7 and A8 and VSG and BSA were 
detected in these lanes. 
                    1   2    3   4   5   6   7   8    9  10 11 12 13 14  15 
Figure 37 - Gel of UDP-Gal and UDP-(4F)-Gal incubated with VSG and BSA. Lanes 1 = ladder, UDP-Gal 
resin lanes 2 to 6: 2 = wash 1, 3 = wash 2, 4 = wash 3, 5 = blank, 6 = elution, lane 7 = blank, lane 8 = 
control, lane 9 = blank, UDP-(4F)-Gal resin lanes 10 to 14: 10 = wash 1, 11 = wash 2, 12 = wash 3, 13 
= blank, 14 = elution, 15 = blank. 
For the condition where -1,4-GalT was present and for both UDP-Gal and UDP-(4F)-Gal 
resins, -1,4-GalT was the major protein eluted from UDP-(4F)-Gal, figure 38. The only other 
protein present in the elution was keratin. For the UDP-Gal resin, -1,4-GalT was present 
without a significant peptide count indicating less was bound to the UDP-Gal resin than in the 
UDP-(4F)-Gal experiment where it had a significant count. VSG was not present in any band 
and was most likely left on the gel as the de-staining was not good enough to see it and 
therefore could have been present in the elution. The resins were both present in excess of 
the 0.2 nmol of -1,4-GalT used as they were of the order of 0.6 µmol. Therefore, the presence 
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of -1,4-GalT in the first wash of each resin, lanes 2 and 10, could be due to the low affinity of 
the probe to the enzyme or the resin could be blocked by non-specific interactions. Some 
contaminants in the elution were detected in both experiments. However, since these 
proteins were not present in the assay, nor had high counts, we do not believe them to be 
true binders; they are contaminants added during sample preparation. 
                 1   2   3   4   5    6    7    8    9  10  11 12 13 14  15 
Figure 38 - Gel of UDP-Gal and UDP-(4F)-Gal incubated with -1,4-GalT, VSG and BSA. Lanes 1 = 
ladder, UDP-Gal resin lanes 2 to 6: 2 = wash 1, 3 = wash 2, 4 = wash 3, 5 = blank, 6 = elution, lane 7 = 
blank, lane 8 = control, lane 9 = blank, UDP-(4F)-Gal resin lanes 10 to 14: 10 = wash 1, 11 = wash 2, 
12 = wash 3, 13 = blank, 14 = elution, 15 = blank. 
This experiment showed that the resin was able to bind to -1,4-GalT and suggests that it is 
selective in binding to the enzyme over VSG and BSA. However, it isn’t conclusive since VSG 
was not present in any extracted band – not even washes or the control. In order to improve 
this protocol, a protein should be added to each lane so that it can be used as a control for 
extraction. Furthermore, two gels should be run: one to visualise the proteins and one for 
extraction. The gel run for extraction should only be run enough so that the proteins only just 
enter the gel so they can all be extracted together as one band. This would avoid missing 
proteins from the extraction and differences between the extractions of individual bands. 
Non-specific protein binding to the resin is inevitable, but with careful experiment design 
these non-specific interactions can be mitigated, see 8.3.2 for description. 
8.1.3.2 Limit of detection of -1,4-galactosyltransferase 
The UDP-(4F)-Gal resin performed better in the previous enrichment experiment and was 
therefore taken forward to decipher the limit at which it could no longer enrich for GalTs from 
250 
75 
50 
37 
25 
65 
 a mixture of proteins. It was subjected to the same enrichment conditions with -1,4-
galactosyltransferase (-1,4-GalT) with a mixture of proteins. However, three more proteins 
were added to the mix to increase the complexity and six concentrations of -1,4-GalT were 
trialled, table 1. 
Table 2 – Amount of (-1,4-GalT) added per condition 
 Amount of 1,4-GalT (ng) 
Condition 1 2 3 4 5 6 
-1,4-GalT 5500 550 55 5.5 0.55 0.055 
 
The same mixtures of proteins plus -1,4-GalT were incubated to be used as a control, without 
resin. The resins were then washed and the bound proteins were eluted by boiling the resin 
in laemmli buffer. The washes and elution were run on a gel just enough so that they entered 
it but did not separate. The samples were then sent to mass spectrometry. Comparing the 
ratio of the control proteins that were not subjected to the resin (‘before”) to the proteins 
eluted from the resin (“after”), it is possible to determine if -1,4-GalT is enriched. 
Unfortunately, the mass spectrometer was unable to detect -1,4-GalT in the control and 
eluted samples of conditions 4, 5 and 6 as they were too low in abundance. The mass 
spectrometer (4800 Plus MALDI-TOF/ TOF Analyzer, AB SCIEX, Framingham, MA, USA) is able 
to detect proteins in the 10-20 fmol range therefore it might have been too ambitious to try 
to detect below 5.5 ng of -1,4-GalT (0.125 pmol) especially since some protein will be lost 
during the extraction process. 
 
Normalised spectral abundance factor (NSAF) takes into account the length of the protein and 
the number of MS/MS spectra found in the mass spectrometer run. The length of the protein 
is taken into consideration because the longer the protein the more peptides will be produced 
therefore the more MS/MS spectra are found. In doing so, it can estimate the amount of 
protein in the sample compared to others present. Some bias has been observed for long 
proteins where the formula over compensates for their length and underestimates their 
abundance (Deng et al., 2015). Most of the proteins used in this assay are around 450 amino 
acids in length, see table 2 for protein lengths. Ribonuclease B and Bovine Serum Albumin are 
of two extremes in length and their abundance should be evaluated with care. A table 
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summarising the NSAF counts of the proteins in each condition before and after enrichment 
is annex table 9. 
Table 3 - Protein length of each protein used 
Protein Protein length 
Bovine serum albumin 583 
Variant surface glycoprotein 450 
Ribonuclease B pancreatic 124 
Fetuin 359 
Green fluorescent protein 238 
-1,4-galactosyltransferase 402 
 
For condition 1, 5.5 g of -1,4-GalT was used in a mixture of proteins where this represented 
48% of the total g of proteins, or 9% of the NSAF. After enrichment, -1,4-GalT is clearly 
enriched to 23% NSAF of the proteins present in the elution, figure 39. Fetuin and BSA also 
seem to be enriched, although not to the same extent as -1,4-GalT. Their binding can be 
attributed to these non-specific hydrophobic interactions with the backbone of the resin. 
Ribonuclease B is not present in the elution and the % presence of VSG and GFP are reduced 
in the enriched mixture. As Ribonuclease B is the shortest protein, the hydrophobic 
interactions it would form with the resin would be the weakest since its sequence contains 
less regions of hydrophobicity than the longer proteins. It is possible that the other proteins 
had a higher affinity for the resin than Ribonuclease B, blocking it from interacting. 
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   Before enrichment            Elution 
Figure 39 - Comparison of ratio of proteins present before and after enrichment of 5.5 g of GalT 
For condition 2, 0.5 g of -1,4-GalT was used in a mixture of proteins where this represented 
8.5% of the total g of proteins, or 13% of the NSAF. After enrichment, -1,4-GalT is slightly 
less in proportion to the remaining proteins at 11% NSAF, figure 40. However, like in the 
previous experiment, no Ribonuclease B is present in the elution. This means that although 
the % -1,4-GalT has reduced, in reality it has been enriched since there are less proteins in 
the elution. Fetuin and VSG are present in the elution at a higher % and BSA and GFP are 
reduced. It is hard to say which have been enriched since we were unable to directly quantify. 
Before enrichment            Elution  
Figure 40 - Comparison of ratio of proteins present before and after enrichment of 0.55 g of GalT 
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For condition 3, 55 ng of -1,4-GalT was used in a mixture of proteins where this represented 
0.9% of the total g of proteins, or 2% of the NSAF. After enrichment, -1,4-GalT is enriched 
to 5% NSAF, figure 41. Fetuin and GFP are also enriched but Ribonuclease B, VSG and BSA are 
reduced or remain the same. This time Ribonuclease B was not washed away. This could be 
because there was less -1,4-GalT present so there was more space available for non-specific 
binding to the resin. 
Before enrichment    After enrichment  
Figure 41 - Comparison of ratio of proteins present before and after enrichment of 55 ng of GalT 
Although the resin clearly has an affinity for GalTs, it becomes more difficult to enrich with 
lower quantities of the -1,4-GalT present compared to the other proteins. It is still enriched 
when representing 0.9% of total protein, but along with many other proteins that form non-
specific interactions with the resin. The PEG resin will always attract non-specific binders as it 
has hydrophobic and hydrophilic regions. A better way to perform this experiment would be 
to use an internal standard that would be added to the mixture when loaded on to a gel so 
that the proteins could be quantified and the % recovery of -1,4-GalT (and the other proteins) 
could be calculated. This standard would also account for loss of proteins during the extraction 
process and allow direct comparisons between lanes. The experiment also cannot distinguish 
between proteins that bind to the resin by interacting specifically with the UDP-(4F)-Gal or via 
non-specific interactions. Repeating the experiment in the same way but with an internal 
standard could help in discerning the proteins the bind non-specifically from those that are 
specific but the best way would be to have a system that discourages non-specific interactions. 
Fetuin
6%
GFP
43%
BSA
9%
VSG
17%
RNase B
23%
b-1,4-GalT
2% Fetuin
14%
GFP
45%
BSA
9%
VSG
14%
RNase B
13%
b-1,4-GalT
5%
69 
 This could be done by adding a protein that blocks the resin (to remove non-specific 
interactions) or by adding a small molecule that inhibits the target protein (a reduction in 
binding would indicate that it had been binding specifically). 
 
8.2 Chapter summary 
In this chapter, UDP-galactosyltransferase affinity based probes were synthesised based upon 
inhibitors of GalTs, with the aim of using these probes to enrich for galactosyltransferases 
which could enable their characterisation. These probes, UDP-Gal and UDP-(4F)-Gal, were 
attached to tentagel resin via an SMCC linker. This synthesis of resin bound nucleotide sugars 
is the first of its kind, as most sugars are bound to resins via the C1 and none are coupled to a 
nucleotide. Preliminary studies using a commercially available GalT indicated that the probes 
were potential affinity probes and that UDP-(4F)-Gal had a higher affinity. 
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8.3 Materials and methods 
8.3.1 Synthesis 
8.3.1.1 General information 
Reactions were carried out under an inert atmosphere (argon), using standard techniques 
with oven-dried glassware. Anhydrous solvents were obtained by distillation and drying (DMF, 
DCM, Pyridine). All non-aqueous reactions were run using anhydrous solvents. Commercial 
reagents were used as supplied or purified by standard techniques where necessary. Na2SO4 
was used as the organic phase drying reagent. 
Flash column chromatography was performed using 230-400 mesh silica with the indicated 
solvent system according to standard techniques. Analytical thin-layer chromatography (TLC) 
was performed on precoated, foil-backed gel plates. Visualisation of the developed 
chromatogram was performed by UV absorbance (254nm). Staining of the developed 
chromatogram was carried out using a 5% phosphomolybdic acid in ethanol stain. 
 
Standard nuclear magnetic resonance spectra were recorded on a Bruker AV II 400 (400 MHz) 
spectrometer. NMR spectra of resins were recorded on a Bruker AV II 500 (500 MHz) 
spectrometer equipped with a 4mm HRMAS Triple H/P/C probe-head. Chemical shifts for 1H 
NMR spectra were recorded in CDCl3 in parts per million from tetramethylsilane, the internal 
standard (δ = 0 ppm). For samples in DMSO-d6, MeOH-d4 and D2O the solvent peak was the 
internal standard. Data were reported as follows: chemical shift [multiplicity (s = singlet, d = 
doublet, t = triplet, m = multiplet and br = broad), coupling constant in Hz, integration and 
assignment]. 13C NMR and 31P spectra were recorded with complete proton decoupling. 
Chemical shifts are reported in parts per million with the solvent resonance as the internal 
standard (13CDCl3: 77.0 ppm, MeOD: 49.2 ppm, DMSO: 39.5 ppm). NMR experiments used for 
the assignments of NMRs: APT, COSY and HMQC or HSQC. 
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 8.3.1.2 6-deoxy-2,3,4-tri-O-(phenylmethyl)-1-thio-α/β-D-Glucopyranoside (3) 
 
Methyl galactosylpyranoside (5.0 g, 25.8 mmol) and BnBr (15.8 mL, 128.8 mmol) were 
dissolved in DMF (50 mL) and stirred at 0 °C. NaH (3.7 g, 154.5 mmol) was added portion-wise, 
the reaction allowed to warm to room temperature and stirred for 17 h. The reaction was 
quenched with MeOH, water added, extracted with Et2O (3 x 50 mL), dried and concentrated 
in vacuo. Purification by flash chromatography (100% Hex to 7:3 Hex:EtOAc) afforded the 
product as an oil (14.7 g, 100%) (Lourenço, Maycock and Rita Ventura, 2009). To this sugar, 
(4.7 g, 8.5 mmol), acetic acid (20.5 mL) and acetic anhydride (20.5 mL) were added and the 
reaction stirred at room temperature. Concentrated sulphuric acid (0.83 mL) was added drop 
wise and the reaction stirred for 26 h. The reaction was quenched with NaHCO3 (60 mL) and 
water added until pH 7. It was extracted with EtOAc (3 x 50 mL), dried and concentrated in 
vacuo. Purification by flash column (Hex:EtOAc, 8:2) afforded the product as an oil (3.7 g, 81%) 
(Lourenço, Maycock and Rita Ventura, 2009). This sugar, (19.3 g, 36 mmol) was dissolved in 
DCM and cooled to 0 °C. BF3OEt2 (10 mL, 54 mmol) and p-toluenethiol (9 g, 72 mmol) were 
added and the reaction stirred at 0 °C for 1 h. The reaction was quenched with NaHCO3 (500 
mL), extracted with DCM (3 x 900 mL), dried and concentrated in vacuo. Purification with flash 
chromatography afforded the product as an oil (18.6 g, 86%).  (18.6 g, 31 mmol) and NaOMe 
(1 g, 18.5 mmol) were stirred in MeOH (40 mL) for 1 h. The reaction was quenched with 
NaHCO3 (100 mL), extracted with EtOAc (3 x 300 mL), dried and conc in vacuo. Purification by 
flash chromatography (100% Hex to 50:50 Hex:EtOAc) afforded product 3 as an oil (16.2 g, 
94%); := 1:8.3; δH(400 MHz; CDCl3, Me4Si) 7.46-7.31 (18 H, m, Ar-H), 7.04 (2 H, d, J = 8.2 
Hz, Ar-H), 4.97 (1 H, d, J = 11.7 Hz), 4.84 (1 H, d, J = 10.2 Hz, 1 x PhCH2), 4.77-4.71 (4 H, m, 4 x 
PhCH2), 4.64 (1 H, d, J = 11.7 Hz, 1 x PhCH2), 4.59 (1 H, d, J = 9.7 Hz, C(1)H), 3.93 (1 H, t, J = 9.4 
Hz, C(2)H), 3.86-3.81 (2 H, m, C(4)H + C(6)H), 3.60 (1 H, dd, J = 9.2, 2.7 Hz, C(3)H), 3.53-3.49 (1 
H, m, C(6)H), 3.44-3.41 (1 H, m, C(5)H), 2.30 (3 H, s, Me); δC(101 MHz; CDCl3, Me4Si) 138.3 (Ar-
Cq), 138.3 (Ar-Cq), 138.1 (Ar-Cq), 137.4 (Ar-Cq), 132.2 (Ar-C), 130.0 (Ar-Cq), 129.6 (Ar-C), 
128.49 (Ar-C), 128.39 (Ar-C), 128.34 (Ar-C), 128.31 (Ar-C), 128.22 (Ar-C), 127.83 (Ar-C), 127.79 
(Ar-C), 127.75 (Ar-C), 127.63 (Ar-C), 88.1 (C1), 84.3 (C3), 78.7 (C5), 77.6 (C2), 75.7 (PhCH2), 74.1 
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(PhCH2), 73.3 (C4), 73.1 (PhCH2), 62.3 (C6), 21.1 (CH3); HR-MS: calcd for C34H36O5SNa+ [M+Na]+: 
579.2176 ; found: 579.2164; νmax/cm-1  3445.6 (br, OH). 
 
8.3.1.3 p-Tolyl 4,6-O-benzylidene-1-thio-α/β-D-Glucopyranoside (6) 
 
Glucose (11.28 g, 62.6 mmol) was dissolved in pyridine (76.7 mL) and cooled to 0 °C. Ac2O (60 
mL) and DMAP (cat. amount) were added and the reaction stirred overnight. The reaction was 
quenched with NaHCO3 (100 mL) and extracted with EtOAc (3 x 150 mL). The organic phase 
was dried and concentrated in vacuo afforded the product as a white powder (24.4 g, 100%) 
(Ermolenko and Sasaki, 2006). The sugar (490 mg, 1.25 mmol) was dissolved in DCM (10 mL) 
with p-toluenethiol (311 mg, 2.5 mmol). BF3.OEt2 (771 ul, 6.25 mmol) was added at 0°C and 
the reaction allowed to warm to rt before stirring for 2 d. The reaction was washed with 
NaHCO3 (20 mL) and the aqueous phase extracted with DCM (3 x 10 mL) and the combined 
organic phases were dried and concentrated in vacuo. Purification by flash chromatography 
(8:2, Hexane: Ethyl acetate) gave the product as a yellow solid (445 mg, 78%) (Bruneau et al., 
2015; Chatterjee et al., 2015). The sugar (135 mg, 0.30 mmol) and NaOMe (10 mg, 0.18 mmol) 
were stirred in MeOH (3 mL) for 1.5 h. The reaction was quenched with dowex, filtered and 
concentrated in vacuo to yield the product as a yellow solid (80 mg, 94%) (Bruneau et al., 
2015). The sugar (492 mg, 1.71 mmol), PhCH(OMe)2 (520 mL, 3.44 mmol) and CSA (cat. 
amount) were dissolved in DMF (15 mL), the reaction mixture heated to 85 °C and stirred for 
30 h. The reaction was then quenched with NaHCO3 (200 mL) and the aqueous phase 
extracted with EtOAc (3 x 100 mL) before the combined organic layers were dried and 
concentrated in vacuo. Purification by flash chromatography (8:2, Hex:EtOAc to 100% EtOAc) 
afforded the product 6 as a white solid (450 mg, 70%); := 1:0.5; δH(400 MHz; CDCl3, Me4Si) 
7.55-7.37 (m, 11 H, Ar-H), 7.16 (dd, J = 7.5, 5.5 Hz, 3 H, Ar-H), 5.53 (t, J = 9.2 Hz, 2 H,H1 + 
CHPh), 4.57 (d, J = 9.7 Hz, 1 H, H1), 4.40-4.26 (m, 2 H, H5 + H6), 4.01-3.89 (m, 1 H, H2), 
3.88-3.74 (m, 3 H, H3 + H4 + H6), 3.58-3.39 (m, 4 H, H4 + H4 + H2 + H5), 3.21-3.07 
(m, 1 H, OH), 2.89 (s, 2 H, OH), 2.37 (m, 5 H, CH3 + CH3); δC(101 MHz; CDCl3, Me4Si) 138.8 
(Ar-Cq), 138.1 (Ar-Cq), 137.0 (Ar-Cq), 136.9 (Ar-Cq), 133.6 (Ar-C), 133.4 (Ar-C), 132.7 (Ar-C), 
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 123.0 (Ar-C), 129.9 (Ar-C), 129.7 (Ar-Cq), 129.3 (Ar-C), 129.0 (Ar-C), 128.4 (Ar-C), 127.4 (Ar-
Cq), 127.0 (Ar-C), 126.4 (Ar-C), 126.3 (Ar-C), 102.0 (CHPh), 101.9 (CHPh), 91.1 (C1), 88.7 
(C1), 81.0, 80.2, 77.4, 77.0, 76.7, 74.5, 72.51 (C2), 72.47, 72.1, 70.5, 68.7 (C6), 68.6 (C6), 
63.8 (C), 60.4, 21.2 (CH3), 21.1 (CH3); HR-MS: calcd for C20H22O5SNa+ [M+Na]+: 397.1080; 
found: 397.1073; νmax/cm-1  3417.8 (br, OH). 
 
8.3.1.4 p-tolyl 2,3-di-O-benzyl-1-thio-α/β-D-Glucopyranoside (7) 
 
Sugar 6 (450 mg, 1.19 mmol) and BnBr (360 uL 2.99 mmol) were dissolved in DMF (10 mL) 
and stirred at 0 °C. NaH (85 mg, 3.57 mmol) was added portion-wise, the reaction allowed to 
warm to room temperature and stirred for 18 h. The reaction was quenched with MeOH (5 
mL), water added (5 mL), extracted with EtOAc (3 x 15 mL), dried and concentrated in vacuo. 
Purification by preparative TLC (8:2 Hex:EtOAc) afforded the product as an oil (660 mg, 100%). 
The sugar (660 mg, 1.19 mmol) and p-TsOH (cat. amount) were dissolved in DCM:MeOH (3 
mL: 15 mL) and the reaction stirred for 16 h. Another portion of p-TsOH was added and the 
reaction stirred for a further 5 h. The reaction was quenched with NaHCO3 (10 mL), extracted 
with EtOAc (3 x 20 mL), dried and concentrated in vacuo. Purification by flash chromatography 
yielded product 7 as a white solid (520 mg, 94%); δH(400 MHz; CDCl3, Me4Si) 7.45 (4 H, d, J = 
8.0 Hz, 4 x Ar-H), 7.37 (8 H, m, 8 x Ar-H), 7.15 (2 H, d, J = 7.8 Hz, 2 x Ar-H), 5.58 (1 H, d, J = 5.5 
Hz, C(1)H), 5.06 (d, J = 11.4 Hz), 4.99 (2 H, dd, J = 10.9, 5.3 Hz, 2 x CH2Ph), 4.76 (2 H, t, J = 10.4 
Hz, 2 x CH2Ph), 4.69 (1 H, d, J = 9.4 Hz, C(1)H), 4.26-4.22 (m, H), 4.18-4.13 (m, H), 3.89 (2 
H, dd, J = 11.9, 3.2 Hz, 1 x C(6)H + C(2)H), 3.77 (1 H, dd, J = 11.7, 5.1 Hz, 1 x C(6)H), 3.64-
3.45 (3 H, m, C(2)H + C(3)H + C(4)H), 3.35 (1 H, dt, J = 8.9, 4.4 Hz, C(5)H), 2.93 (d, J = 24.5 
Hz), 2.37 (3 H, s, Me); δC(101 MHz; CDCl3, Me4Si) 138.3 (Ar-Cq), 138.0 (Ar-Cq), 137.9 (Ar-
Cq), 132.8 (Ar-C), 132.5 (Ar-C), 129.9 (Ar-C), 129.8 (Ar-C), 129.6 (Ar-Cq), 128.7 (Ar-C), 
128.6 (Ar-C), 128.5 (Ar-C), 128.5 (Ar-C), 128.3 (Ar-C), 128.1 (Ar-C), 128.1 (Ar-C), 128.0 
(Ar-C), 128.0 (Ar-C), 127.9 (Ar-C), 127.9 (Ar-C), 88.0 (C1), 87.4 (C1), 86.1 (C3), 81.6 
(C), 80.9 (C2), 79.6 (C2), 79.1 (C5), 75.4 (CH2Ph), 75.4 (CH2Ph), 72.3 (CH2Ph), 71.7 
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(C), 70.4 (C4), 70.1 (C), 62.7 (C6), 62.3 (C6), 21.1 (CH3); HR-MS: calcd for C27H30O5SNa+ 
[M+Na]+: 489.1706; found: 489.1697; νmax/cm-1  3405.1 (br, OH). 
 
8.3.1.5 p-Tolyl 2,3-di-O-benzyl-4-deoxy-4-fluoro-1-thio-α-D-Glucopyranoside (8) 
 
Sugar 7 (520 mg, 1.1 mmol), imidazole (230 mg, 3.3 mmol), and TBDMSCl (500 mg, 3.3 mmol) 
were dissolved in DMF (5 mL). The reaction was stirred at rt for 16 h. The reaction was 
quenched with water (2 mL), extracted with Et2O (3 x 5 mL), dried and concentrated in vacuo. 
Purification by flash chromatography (100% hexane to Hex:EtOAc, 7:3) afforded the product 
as an oil (582 mg, 90%). This sugar (73 mg, 0.13 mmol) was dissolved in DCM (1 mL) and 
pyridine (0.4 mL) and cooled to -78 °C. Tf2O (60 mL, 0.19 mmol) was added, the reaction was 
allowed to warm to room temperature and stirred for 1.5 h. The solvent was evaporated, DCM 
added (5 mL) and the organic phase washed with NaHCO3 (5 mL) and brine (5 mL). The organic 
phase was the dried and concentrated in vacuo. The crude product was dissolved in THF (1 
mL), TBAF was added (0.25 mL, 0.25 mmol) and the reaction was stirred for 2 h. THF was 
evaporated, DCM (5 mL) added and the organic phase washed with brine (5 mL). The organic 
phase was dried and concentrated in vacuo and the crude purified by preparative TLC (60:40, 
EtOAc:Hex). This afforded the product 8 as a yellow solid (30 mg, 48%); δH(400 MHz; CDCl3, 
Me4Si) 7.45 (4 H, t, J = 8.0 Hz, 4 x Ar-H), 7.39-7.31 (8 H, m, 8 x Ar-H), 7.13 (2 H, d, J = 8.1 Hz, 2 
x Ar-H), 4.86-4.72 (5 H, m, 4 x CH2Ph), 4.63-4.61 (1 H, m, C(1)H), 3.99-3.94 (1 H, m, 1 x C(6)H), 
3.82-3.72 (2 H, m, C(2)H + 1 x C(6)H), 3.65-3.62 (1 H, m, C(3)H), 3.58-3.55 (1 H, m, C(4)H), 3.52-
3.48 (1 H, m, C(5)H), 2.35 (3 H, s, Me); δC(101 MHz; CDCl3, Me4Si) 138.1 (Ar-Cq), 138.0 (Ar-Cq), 
132.7 (Ar-C), 129.8 (Ar-C), 128.5 (Ar-C), 128.4 (Ar-C), 128.3 (Ar-C), 128.0 (Ar-C), 127.9 (Ar-C), 
87.8, 87.0, 85.1, 81.1, 81.0 (C5), 80.9, 77.3 (C5), 77.2 (C2), 75.8 (CH2Ph), 72.3, 61.48 (C6), 61.43, 
21.1 (Ph-CH3); δF (376 MHz; CDCl3): -215.9 (dt, J = 51.58, 26.39); HR-MS: calcd for C27H29FO4SNa+ 
[M+Na]+: 491.1663; found: 491.1659; νmax/cm-1 3445.8 (br, OH). 
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 8.3.1.6 1-O-Dibenzylphosphate-2,3,4-tri-O-benzyl-6-O-hexyl-6-bromide-α/β-D-
galactopyranoside (9) 
 
Sugar 3 (8.86 g, 16 mmol) and NaH (0.77 g, 32 mmol) was stirred in DMF (5 mL) for 1 h. 1,6-di-
Bromohexane (6.6 mL, 43 mmol) and TBAI (cat. amount) were added and the reaction stirred 
for 4 h. Another portion of NaH (0.38 g, 16 mmol) was added and the reaction stirred for a 
further 16 h. Water was added to the reaction, it was washed with NaHCO3 (400 mL) and then 
extracted with EtOAc (3 x 300 mL). The organic phase was dried and concentrated in vacuo 
before purification by flash chromatography afforded the product as an oil, (7.84 g, 68%). This 
sugar (86 mg, 0.12 mmol) and dibenzyl hydrogen phosphate (37 mg, 0.13 mmol) were stirred 
in DCM (2 mL) with powdered molecular sieves for 30 min. The reaction was cooled and 
maintained at 0 °C. NIS (32 mg, 0.14 mmol) and TMSOTf (10 l, 0.06 mmol) were added and 
the reaction stirred for 15 min before being quenched with Na2S2O3 (10% soln, 1 mL). NaHCO3 
(2 mL) was added and extracted with DCM (3 x 2 mL). Purification by flash chromatography 
(EtOAc:Hex) afforded the product 9 as an oil (89 mg, 85%); : = 1:0.9; δH(400 MHz; CDCl3. 
Me4Si) 7.38-7.25 (25 H, m), 5.99 (1 H, dd, J = 6.6, 3.4 Hz, C(1)H), 5.25 (1 H, t, J = 7.3 Hz, 
C(1)H), 5.12-4.97 (10 H, m, CH2Ph), 4.85-4.73 (9 H, m, CH2Ph), 4.69-4.62 (3 H, m), 4.18-4.06 
(3 H, m, C(2)H), 3.99-3.89 (5 H, m, C(3)H + C(4)H + C(6)H2 + C(2)H), 3.69-3.59 (2 H, m, 
C(5)H + C(3)H), 3.56-3.45 (4 H, m), 3.44-3.25 (10 H, m, 2 x CH2Br), 1.87-1.79 (4 H, m, 2 x 
CH2CH2Br), 1.50-1.29 (15 H, m, 2 x OCH2CH2R + O(CH2)3CH2R + 2 x O(CH2)2CH2R); δC(101 MHz; 
CDCl3, Me4Si) 138.54 (ArCq), 138.49 (ArCq), 138.47 (ArCq), 138.3 (ArCq), 138.1 (ArCq), 138.0 
(ArCq), 135.98 (ArCq), 135.93 (ArCq), 135.91 (ArCq), 135.90 (ArCq), 135.86 (ArCq), 135.72 (ArCq), 
135.6 (ArCq), 128.5 (Ar-C), 128.41 (Ar-C), 128.40 (Ar-C), 128.38 (Ar-C), 128.33 (Ar-C), 128.29 
(Ar-C), 128.28 (Ar-C), 128.26 (Ar-C), 128.23 (Ar-C), 128.11 (Ar-C), 128.05 (Ar-C) 128.0 (Ar-C), 
127.8 (Ar-C), 127.8 (Ar-C), 127.74 (Ar-C), 127.70 (Ar-C), 127.66 (Ar-C), 127.58 (Ar-C), 127.57 
(Ar-C), 127.51 (Ar-C), 127.49 (Ar-C), 127.4 (Ar-C), 99.3 (d, J = 6.4 Hz, C1), 96.6 (d, J = 8.1 Hz, 
C1), 82.0 (C5), 82.0 (d, J = 2.1 Hz, C3), 79.2, 79.1, 78.7, 78.1, 75.82, 75.75, 75.2, 74.9, 74.70, 
74.67, 74.61, 74.1, 73.6, 73.3, 73.04, 72.95, 72.90, 71.4, 71.3, 69.5, 69.23, 69.20, 69.18, 69.15, 
 76 
69.00, 68.95, 68.87, 68.6, 33.8 (CH2Br), 32.6 (CH2CH2Br), 29.4 (OCH2CH2R), 27.9 (O(CH2)3CH2R), 
25.3 (O(CH2)2CH2R); δP(162 MHz; CDCl3) -2.14 (), -2.23 (; HR-MS: calcd for C47H54BrO9PNa+ 
[M+Na]+: 895.2581; found: 895.2580; νmax/cm-1  946.1 (s, P-OBn) and 1167.7 (s, P=O). 
 
8.3.1.7 1-O-Dibenzylphosphate-2,3-di-O-benzyl-4-deoxy-4-fluoro-6-O-(hexyl-6-bromide)-α-D-
Glucopyranoside (10) 
 
 
Sugar 8 (107 mg, 0.23 mmol) and NaH (11 mg, 0.46 mmol) were stirred in DMF (2 mL) for 30 
min. 1,6-dibromohexane (240 l, 0.62 mmol) and TBAI (cat. amount) were added and the 
reaction stirred for 3 h. Further NaH was added (5 mg, 023 mmol) and the reaction stirred for 
a further 3 h. Water was added to the reaction, it was washed with NaHCO3 (5 mL) and then 
extracted with EtOAc (3 x 5 mL). The organic phase was dried and concentrated in vacuo 
before purification by flash chromatography afforded the product as a white solid (115 mg, 
80%). This sugar (98 mg, 0.16 mmol) with dibenzyl phosphate (48 mg, 0.17 mmol) was stirred 
in DCM (2 mL) with molecular sieves for 30 min. The reaction was cooled to 0 °C, NIS (42 mg, 
0.19 mmol) and TMSOTf (13 L, 0.08 mmol) were added and it was stirred for 30 min before 
being quenched with Na2S2O3 (10% soln, 1 mL). NaHCO3 was added (2 mL) and extracted with 
DCM (3 x 3 mL). Purification by flash chromatography (EtOAc:Hex) afforded product 10 as a 
white solid (116 mg, 95%); δH(400 MHz; CDCl3, Me4Si) 7.43-7.23 (6 H, m, Ar(H)), 5.95 (1 H, td, 
J = 3.4, 2.9 Hz, C(1)H), 5.08 (dd, J = 7.6, 4.1 Hz), 5.03 (1 H, d, J = 7.4 Hz), 4.93-4.80 (1 H, m, 
C(4)H), 4.78 (1 H, d, J = 4.7 Hz, C(1)H), 4.11-4.07 (m), 4.03-3.97 (1 H, m, C(2)H), 3.89-3.79 (1 H, 
m, C(3)H), 3.60-3.56 (m), 3.46-3.44 (m), 3.43-3.37 (2 H, m, CH2Br), 1.83 (2 H, quintet, J = 7.2 
Hz, CH2CH2Br), 1.55-1.48 (1 H, m), 1.45-1.38 (2 H, m, CH2(CH2)2Br), 1.35-1.28 (2 H, m, 
CH2(CH2)3Br); δC(101 MHz; CDCl3, Me4Si) 137.8, 137.7, 135.8, 135.7, 128.5, 128.44, 128.38, 
128.36, 128.1, 127.84, 127.77, 127.75, 96.1 (d, J = 184.1 Hz, C1), 86.8 (d, J = 6.2 Hz, C4), 
75.1 (C2), 75.08, 75.04, 75.01, 74.97, 74.94, 73.6, 72.5, 71.5, 70.05, 69.86, 69.3 (d, J = 4.5 Hz, 
POCH2Ph), 69.1 (d, J = 4.2 Hz, POCH2Ph), 67.8 (d, J = 5.4 Hz, C6), 33.8 (CH2Br), 32.6 (CH2CH2Br), 
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 29.3, 27.9, 25.2 CH2(CH2)3Br; δP (162 MHz; CDCl3) -2.17; δF (376 MHz; CDCl3) 42.0 (dt, J = 
52.8, 24.5); HR-MS: calcd for C40H47BrFO8PNa+ [M+H]+: 785.2249; found: 785.2252. 
 
8.3.1.8 1-O-Diphosphate-2,3,4-trihydroxy-6-O-hexyl-6-thiol-α/β-D-galactopyranoside (11) 
 
Sugar 9 (914 mg, 1.046 mmol) was dissolved in EtOH (5 mL) and added to a reactor containing 
Pd/C (550 mg, 0.52 mmol). The reactor was shaken under a pressure of 50 psi and an 
atmosphere of H2 for 30 min. The reaction mixture was filtered through celite and washed 
with H2O, MeOH and DCM. The solvents were evaporated and the residue dissolved in water 
(10 mL). The aqueous phase was washed with Et2O three times (20 mL) and evaporated leaving 
the product as a solid (400 mg, 88%). This sugar (347 mg, 0.81 mmol) was dissolved in DMF (5 
mL) and potassium thioacetate (75 mg, 0.98 mmol) added. The reaction was stirred overnight 
before evaporating the DMF, adding water (5 mL) and washing with EtOAc (3 x 5 mL). The 
aqueous phase was dried and re-dissolved in water (3 mL) and K2CO3 added (329 mg, 2.37 
mmol). The reaction was stirred overnight, the water was evaporated and the product purified 
by sephadex column (water) affording the product 11 as a solid (303 mg, quant.); := 1:0.2; 
δH (400 MHz; D2O):  5.41 (1 H, dd, J = 7.8, 3.6 Hz, C(1)H), 4.20-4.17 (1 H, m, C(5)H), 3.92-3.90 
(1 H, m, C(4)H), 3.84 (1 H, dd, J = 10.3, 3.3 Hz, C(3)H), 3.70-3.67 (1 H, m, C(2)H), 3.59 (2 H, m, 
C(6)H), 3.52-3.47 (2 H, m, OCH2CH2), 2.47 (2 H, t, J = 7.2 Hz, CH2SH), 1.54-1.49 (4 H, m, alkyl 
CH2), 1.35-1.22 (4 H, m, alkyl CH2); δC (101 MHz; D2O): 99.0 (d, J = 5.2 Hz, C1), 93.8 (d, J = 5.2 
Hz, C1), 71.6 (OCH2), 69.8 (OCH2), 69.6 (C5), 69.5 (C6), 69.4 (C4), 69.0 (C3), 69.0 (d, J = 5.6 Hz, 
C2), 33.2 (CH2), 28.2 (CH2), 27.3 (CH2), 24.6 (CH2), 23.8 (CH2SH); 31P NMR (162 MHz; ): δ 2.70 
(), 2.66 (); νmax/cm-1  3176.9 (br, OH), 952.7 (s, P-OH) and 1167.7 (s, P=O). 
 
 78 
8.3.1.9 1-O-Di-phosphate-4-deoxy-4-fluoro-6-O-(hexyl-6-thiol)-α/β-D-galactopyranoside (12) 
 
Sugar 10 (168 mg, 0.21 mg) was dissolved in EtOH (5 mL) and added to a reactor with Pd/C (70 
mg, 0.07 mmol). The reactor was shaken at 50 psi under a H2 atmosphere for 1 h before 
filtering through celite. The celite was washed with H2O, MeOH and DCM. The solvents were 
evaporated and the residue dissolved in water (20 mL). The aqueous phase was washed with 
Et2O (3 x 10 mL) and evaporated leaving the product as a solid (79 mg, 98%). This sugar (110 
mg, 0.29 mmol) was dissolved in DMF and potassium thioacetate (80 mg, 0.56 mmol) added. 
The reaction was stirred for 40 min before evaporating the DMF, adding water and washing 
with DCM. The aqueous phase was evaporated, re-dissolved in water (1 mL) and K2CO3 added 
(120 mg, 0.87 mmol). The reaction was stirred for 5 h, the water was evaporated and the 
product purified by sephadex column affording the product 12 as a solid (106 mg, quant.);  
:= 1:0.9; δH(400 MHz; D2O) 5.45 (1 H, dd, J = 7.7, 3.4 Hz, C(1)H), 4.84 (1 H, dd, J = 31.0, 
2.8 Hz, C(4)H), 4.87-4.75 (1 H, m, C(1)H + C(4)H), 4.27 (1 H, dt, J = 31.5, 6.3 Hz, C(4)H), 
4.01-3.89 (2 H, m, C(3)H), 3.89-3.85 (1 H, m), 3.79 (1 H, dd, J = 10.1, 2.7 Hz), 3.75-3.74 (1 H, 
m), 3.72 (1 H, d, J = 2.7 Hz, C(2)H), 3.70-3.63 (5 H, m), 3.52 (1 H, m, C(2)H), 3.50 (5 H, m),  
2.48 (2 H, t, J = 7.2 Hz, 2 x CH2SH), 2.41-2.29 (4 H, m), 2.18-2.11 (3 H, m), 1.54-1.51 (9 H, m, 
CH2), 1.29 (10 H, m, CH2); δC(101 MHz; D2O) 97.2 (d, J = 4.5 Hz, C1), 93.8 (d, J = 5.1 Hz, C1), 
91.7, 90.7, 89.9, 88.9, 72.2, 71.99, 71.94, 71.62, 71.58, 71.3, 71.1, 69.08, 69.02, 68.99, 68.95, 
68.55, 68.4, 68.35, 68.32, 68.29, 68.1 (d, J = 3.0 Hz, C4), 32.9 (CH2), 29.80 (CH2), 29.77 (CH2), 
28.2 (CH2), 27.17 (CH2), 27.16 (CH2), 26.3 (CH2), 25.8 (CH2), 24.5 (CH2), 23.7 (CH2SH); δF(376 
MHz; D2O) -216.5 (), -219.2 (); δP(162 MHz; D2O) 2.46(), 2.38 (); νmax/cm-1 3250.5 (br, 
OH), 1099.1 (str, br, P=O), 975.5 (str, P-OH). 
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 8.3.1.10 Resin bound SMCC derivative (15) 
 
SMCC was synthesised according to a literature procedure. Observed data  (1H NMR and 13C 
NMR) is consistent with that reported (Leonard and Brunckova, 2011). SMCC (175 mg, 0.55 
mmol) was dissolved in DMF (2 mL) and tentagel resin (813.8 mg, 0.24 mmol) was stirred in 
DMF (10 mL). The two were combined, PBS (2 mL of stock solution: 8 g NaCl, 0.2 g KCl, 1.44 g 
Na2HPO4, 0.24 g KH2PO4 in 1 L H2O) added, and the mixture stirred for 16 h. The resin was 
washed with DMF, water, MeOH then DCM and dried leaving a white resin 15 (872.8 mg, 76% 
loading); δH(500 MHz; CDCl3) 11.62-11.58 (1 H, m, NH), 6.66 (br, CHCONR), 3.76-3.73 (br), 
3.38-3.31 (br), 3.16-3.14 (br), 2.86-2.74 (br), 2.05-2.01 (br), 1.89-1.77 (br), 1.80-1.66 (br), 1.46-
1.36 (br), 0.98-0.94 (br); δC(126 MHz; CDCl3) 134.0, 128.1, 70.5, 70.1, 69.9, 45.6, 44.9, 43.7, 
43.6, 43.5, 39.5, 39.0, 38.9, 36.9, 36.9, 36.8, 36.4, 36.3, 29.84, 29.76, 29.7, 29.6, 29.5, 28.8, 
28.73, 28.68, 28.67, 28.6. 
8.3.1.11 Resin bound 1-O-Diphosphate-2,3,4-trihydroxy-6-O-hexyl-6-thiol-α/β-D-
galactopyranoside (16) 
 
 
 
 
 
 
Sugar 11 (297 mg, 0.79 mmol) was dissolved in water (10 mL) and added to resin 15 (766.5 
mg, 0.16 mmol) already swelled in DMF (5 mL). The pH was adjusted to pH 8 using K2HPO4 
10% soln. and the reaction was stirred for 16 h. The resin was washed with DMF, water, MeOH 
and DCM then dried leaving a pink resin 16 (809.8 mg, 71%); δH(500 MHz; MeOD) 7.13-6.93 
(br), 5.63 (br, sugar), 4.27-4.24 (br, sugar), 3.95-3.84 (br, sugar), 3.79-3.77 (br, sugar), 3.64 (s), 
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3.54-3.51 (m), 3.36-3.33 (m), 2.90-2.87 (m), 2.76-2.74 (m), 2.50 (br, sugar), 2.46 (br, sugar), 
2.17-2.17 (br, sugar), 1.86-1.84 (m), 1.78-1.76 (m), 1.73-1.63 (m), 1.60-1.59 (m), 1.46-1.42 (m), 
1.26 (s), 1.06-1.04 (m); δC (126 MHz; MeOD) 177.5, 166.6, 136.5 (SMCC), 128.6 (SMCC), 102.07 
(sugar), 102.05 (sugar), 78.5 (SMCC), 78.3 (SMCC), 78.0 (SMCC), 70.0 (SMCC), 69.4 (sugar), 
48.33, 48.15, 47.99, 47.82, 47.66, 47.65, 47.49, 47.32, 45.35, 45.27, 44.82 (SMCC), 44.70, 38.9 
(SMCC), 37.08, 36.91, 29.76 (SMCC), 29.63 (SMCC), 28.96 (SMCC), 28.76 (SMCC); δP(202 MHz; 
MeOD) 1.5 (br). 
8.3.1.12 Resin bound 1-O-Di-phosphate-4-deoxy-4-fluoro-6-O-(hexyl-6-thiol)-α/β-D-
galactopyranoside (17)  
 
Sugar 12 (151 mg, 0.40 mmol) was dissolved in water (1 mL) and added to resin 15 (798.9 mg, 
0.17 mmol) already swelled in DMF (5 mL). The pH was adjusted to pH 8 using KH2PO4 10% 
soln. and the reaction was stirred for 17 h. The resin was washed with DMF, water, MeOH and 
DCM then dried leaving an orange resin 17 (850.4 mg, loading 78%); δH(500 MHz; MeOD) 
7.13-6.99 (br), 6.65-6.41 (br), 5.67-5.65 (br), 5.01-4.99 (br), 4.84 (br), 4.63-4.56 (br), 4.38-4.31 
(br), 3.82-3.77 (br), 3.70 (br), 3.63-3.55 (br), 3.54-3.54 (br), 3.37-3.33 (br), 2.92-2.89 (br), 2.78-
2.75 (br), 2.54-2.48 (br), 2.24-2.14 (br), 1.89-1.58 (br), 1.47-1.43 (br), 1.08-1.03 (br); δC(126 
MHz; MeOD): δ 102.1, 69.9, 69.9, 69.3, 69.3, 67.9, 48.3, 48.3, 48.3, 48.1, 48.1, 47.9, 47.9, 47.7, 
47.7, 47.6, 47.6, 47.6, 47.5, 47.4, 47.3, 47.2, 46.5, 44.6, 44.6, 38.9, 38.9, 38.9, 35.9, 29.7, 28.7, 
25.4; δ δP(202 MHz; MeOD) 1.2. 
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 8.3.1.13 Resin bound UDP-Galactose (18) 
 
Trioctylamine (157 uL, 0.361 mmol) was added to resin 16 (478.7 mg, 0.072 mmol) in pyridine 
(2 mL) and the pyridine evaporated. It was re-dissolved in dry pyridine (2 mL) and again the 
pyridine evaporated twice more. UMP morpholidate  was synthesised according to literature 
procedures and observed data  (1H NMR and 13C NMR) is consistent with that reported 
(Moffatt and Khorana, 1961). UMP morpholidate (114 mg, 0.289 mmol) and tetrazole (20 mg, 
0.289 mmol) were co-evaporated with dry pyridine three times before being added to the 
resin mixture in pyridine (5 mL). The mixture was shaken for 6 d. The resin was then washed 
with DMF, H2O, pyr., MeOH and DCM and dried. The process was repeated exactly and the 
mixture shaken for a further 6 d before the resin was washed with DMF, H2O, pyr., MeOH and 
DCM affording a yellow resin 18 (577.4 mg); δH (500 MHz; MeOD) 8.10-8.08 (br), 7.83-7.80 
(br), 7.07-7.02 (br), 6.55-6.44 (br), 6.32-6.29 (br), 6.00-5.96 (br), 5.94-5.89 (br), 5.76-5.72 (br),  
5.61-5.58 (br), 5.18 (br), 4.84 (br), 4.64-4.43 (br), 4.44-4.35 (br), 4.35-4.20 (br),  4.16-4.13 (br), 
4.11-4.07 (br), 3.96-3.96 (br), 3.93-3.89 (br), 3.85-3.84 (br), 3.82-3.76 (br), 3.64 (br), 3.57-3.47 
(br), 3.36-3.33 (br), 3.24 (br),  3.17-3.15 (br), 3.12-3.01 (br), 2.91-2.87 (br), 2.79-2.75 (br), 2.52-
2.47 (br), 2.22-2.15 (br), 1.98-1.94 (br), 1.90-1.80 (br), 1.80-1.68 (br), 1.62-1.58 (br), 1.40-1.34 
(br), 1.25-1.22 (br), 1.06-1.03 (br), 0.93-0.92 (br); δC(126 MHz; MeOD) 102.2, 102.0, 101.9, 
69.3, 65.8, 54.6, 47.7, 44.5, 38.8, 33.1, 31.5, 30.9, 29.6, 28.7, 24.8; δP(202 MHz; MeOD) -0.5 
(monophosphate), -11.2 (diphosphate), -13.2 (diphosphate). 
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8.3.1.14 Resin bound 4-deoxy-4-fluoro-UDP galactose (19) 
 
Trioctylamine (0.2 mL, 0.45 mmol) was added to resin 17 (562.0 mg, 0.09 mmol) in pyridine (5 
mL) and the pyridine evaporated. It was re-dissolved in dry pyridine (5 mL) and again the 
pyridine evaporated twice more. UMP morpholidate (141 mg, 0.36 mmol) and tetrazole (25 
mg, 0.36 mmol) were co-evaporated with dry pyridine three times before being added to the 
resin mixture in pyridine (5 mL). The mixture was shaken for 7 d. The resin was then washed 
with DMF, H2O, pyr., MeOH and DCM and dried. The process was repeated exactly and the 
mixture shaken for a further 6 d before the resin was washed with DMF, H2O, pyr., MeOH and 
DCM affording a brown resin 19 (537.3 mg);  δH (500 MHz; MeOD):  7.13-6.99 (br), 6.65-6.41 
(br), 5.67-5.65 (br), 5.01-4.99 (br), 4.84 (br), 4.63-4.56 (br), 4.38-4.31 (br), 3.82-3.77 (br), 3.70 
(br),3.63-3.55 (br), 3.54-3.54 (br), 3.37-3.33 (br), 2.92-2.89 (br), 2.78-2.75 (br), 2.54-2.48 (br), 
2.24-2.14 (br), 1.89-1.58 (br), 1.47-1.43 (br), 1.08-1.03 (br); δP NMR (202 MHz; MeOD): -11.2, 
-13.4. 
8.3.1.15 Enrichment of -1,4-galactosyltransferase with UDP-Gal based affinity probes. 
UDP-Gal resin or UDP-(4F)Gal resin were incubated at 37 C for 3 h with 30 ul of solution A (4 
ul of VSG2 (1.5 ug/ul), 2 ul of BSA (2.5 ul/ug), 4.8 ul of MnCl2 (100 mM), 36 ul of buffer (50 
mM HEPES, 125 mM NaCl, 10 mM CaCl2, 5% NP-40) and 43.2 ul of water) or solution B (9.6 uL 
of (1,4)GalT (0.85 ug/ul), 4 ul of VSG2* (1.5 ug/ul), 2 ul of BSA (2.5 ul/ug), 4.8 ul of MnCl2 
(100 mM), 36 ul of buffer (50 mM HEPES, 125 mM NaCl, 10 mM CaCl2, 5% NP-40) and 33.6 ul 
of water) As a control, 30 ul of solution A and B were also incubated alone at 37 C for 3 hours. 
Then the resins were spun for 1 min at 13.4 rpm and the filtrate kept (W1). The collection 
Eppendorf was replaced with a new one and water (30 ul) was added to each resin, and the 
samples were spun again for 1 min at 13.4 rpm and the filtrate kept (W2). The collection 
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 Eppendorf was replaced with a new one and water (500 ul) was added to each resin, and the 
samples were spun again for 1 min at 13.4 rpm and the filtrate kept (W3). W3 was spun on 
the speed vac until dry, then 30 ul of water and 30 ul of 2 x laemmli buffer was added. To W1, 
W2 and the resins, 30 ul of water and 30 ul of 2 x laemmli buffer was added. The elution 
corresponds to the proteins eluted when the resin is boiled in laemmli. All samples were boiled 
for 8 mins at 90 C then loaded onto 15 ul well SDS page gels and run in TGS buffer. They were 
stained in coomassie, the bands were cut, in-gel trypsin digestion was performed and the 
samples sent to mass spectrometry. 
 
 
 
 
Table 4 - Table to show mg of each resin used in each condition. *VSG2 purified from T. brucei 
 
8.3.2 Protocol for MALDI-TOF/TOF and Protein Identification 
Samples were centrifuged and the supernatant removed to a new eppendorf for each sample. 
Each peptide samples were concentrated in a speedvac (Eppendorf) and resuspended in 
trifuoroacetic acid 0.1% (v/v). Samples were concentrated and cleaned according to the 
manufacturer’s instructions on micro C18 column (ZipTip, Millipore, Bedford, MA, USA). The 
proteins were eluted in 1.5 μL directly onto the MALDI plate using the matrix α-cyano-4-
hydroxycinnamic acid (α-CHCA) at 7 mg/mL prepared in ACN (50/50% v/v), trifuoroacetic acid 
(0.1%) and ammonium phosphate (6 mM). 
Peptide mass spectrometry analyses were performed using a MALDI-TOF/TOF (4800 Plus 
MALDI-TOF/ TOF Analyzer, AB SCIEX, Framingham, MA, USA) in reflector positive mode (700–
5000 Da). The experimental mass spectra were searched against the Uniprot protein sequence 
database with the MASCOT (Matrix Science, London, UK) algorithm, integrated in the GPS 
Explorer software (AB SCIEX, Framingham, MA, USA). The search parameters used were up to 
two maximum trypsin missed cleavages, mass tolerance of 50 ppm, cysteine 
  Resin used (mg) 
 µmol/ mg Condition A Condition B 
UDP-Gal 0.205 2.4 2.3/ 0.5 µmol 
UDP-(4F) Gal 0.167 2.2 2.1 /0.36 µmol 
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carbamidomethylation (fixed modification), methionine oxidation (as variable modification) 
and a charge state of +1. 
8.3.3 Limit of detection assay 
24 µL of buffer (50 mM HEPES, 125 mM NaCl, 10 mM CaCl2, 5 mM NP-40) was added to 12.3 
µL water, 3.2 µL of 100 mM MnCl2, 1.7 µL Ribonuclease B (1 µg/ µL), 0.7 µL of GFP (2.5 µg/ 
µL), 2 µL of fetuin (1 µg/ µL), 1.3 µL BSA (2.5 µg/ µL) and 2 µL of VSG (1.5 µg/ µL) to make the 
reaction buffer. 1,4-GalT (0.85 µg/ µL) in water was added according to the below table 4 
by serial dilutions so that the total volume equalled 12.8 µL and 6.4 µL of each dilution was 
added to the UDP-(4F)-Gal resin (0.167 mmol/g) to form conditions 1 to 6. 23.6 µL of reaction 
buffer was added to each UDP-(4F)-Gal resin and 23.6 µL was added to 6.4 µL of the 
corresponding 1,4-GalT dilution for a control. All solutions (1-6 with resin and 1-6 control) 
were then incubated at 37 C for 3 h. 
 
Table 5 - Table of conditions 
 mg of resin / µL of 1,4-GalT 
Condition 1 2 3 4 5 6 
UDP(4F)Gal 3.68 3.84 3.39 3.94 4.11 4.03 
-1,4-GalT 12.8 1.28 0.128 0.0128 0.00128 0.000128 
% -1,4-GalT of 
total protein 
48.19 8.46 0.85 0.1 0.00 0.00 
 
After 3 h, the parafilm was removed from the samples (excluding controls) and they were spun 
for 1 min at 13.4 rpm and the filtrate kept – this is W1. The collection Eppendorf was replaced 
with a new one. Water (30 µL) was added to each resin, and the samples were spun again (1 
min at 13.4 rpm) – W2. The collection Eppendorf was replaced with a new one. Water (500 
µL) was added to the resins and the samples were spun again (1 min at 13.4 rpm) – W3. The 
collection Eppendorf was replaced with a new one. W3 was spun on the speed vac for a few 
hours until dry, then 30 µL of water was added. To the resins, parafilm was added to the 
column and 15 µL of water and 15 µL laemmli buffer. To W1, W2, W3 and the controls: 20 µL 
of laemmli was added. All samples were boiled for 8 mins then loaded onto two 15 x 15 µL 
well gels (7 µL ladder used). The gels were run for 20 mins at 50 V and for 15 min at 110 V – 
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 just enough so that the proteins entered the gel but did not separate. The bands were cut 
and digested according to the Boisvert lab protocol and sent for mass spectrometry. 
 
8.3.4 LC–MS/MS 
All samples were loaded onto a nanoAcquity UPLC system (Waters) equipped with a 
nanoAcquity Symmetry C18, 5 μm trap (180 μm × 20 mm Waters) and a nanoAcquity HSS T3 
1.8 μm C18 capillary column (75 μm × 250 mm, Waters). The trap wash solvent was 0.1% (v/v) 
aqueous formic acid, and the trapping flow rate was 10 μL/min. The trap was washed for 5 
min before switching flow to the capillary column. The separation used a gradient elution of 
two solvents (solvent A: 0.1% (v/v) formic acid; solvent B: acetonitrile containing 0.1% (v/v) 
formic acid). The flow rate for the capillary column was 300 nL/min. Column temperature was 
60 °C with the following gradient profile: Linear 2-30%B over 50 min and then linear 30-50% 
B over 5 min. All runs then proceeded to wash with 95% B for 5 min. The column was returned 
to initial conditions and re-equilibrated before subsequent injections. 
 
The nanoLC system was interfaced to a maXis HD LC–MS/MS System (Bruker Daltonics) with 
a CaptiveSpray ionization source (Bruker Daltonics). Positive ESI–MS and MS/MS spectra were 
acquired using AutoMSMS mode. Instrument control, data acquisition, and processing were 
performed using Compass 1.7 software (microTOF control, Hystar, and DataAnalysis, Bruker 
Daltonics). Instrument settings were: ion spray voltage: 1450 V, dry gas: 3 L/min, dry gas 
temperature 150 °C, ion acquisition range: m/z 150–2000. AutoMS/MS settings were: Cycle 
time 3s, MS spectra rate 2 Hz, MS/MS spectra rate 2 Hz at 2500 cts and 12 Hz at 250000 cts, 
Quadrupole low mass 300 m/z, collision RF 1400 Vpp, Transfer time 120 ms and Collision 
Energy 100. The collision energy and isolation width settings were automatically calculated 
using the AutoMSMS fragmentation table, absolute threshold 200 counts, preferred charge 
states: 2–4, singly charged ions excluded. A single MS/MS spectrum was acquired for each 
precursor and former target ions were excluded for 0.8 min unless the precursor intensity 
increased 4-fold. The data was processed using MaxQuant15 version 1.3.0.5 which 
incorporates the Andromeda search engine. Proteins were identified by comparing against a 
protein sequence database from combined from UniProt and frequently observed 
contaminants. A MS tolerance of 6 ppm, an MS/MS tolerance at 0.5 Da and full trypsin 
specificity, allowing for up to two missed cleavages were specified. Fixed modifications were 
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set to carbamidomethylation of cysteine and oxidation of methionines. Variable modifications 
were set to N-terminal protein acetylation and N-pyroglutamate. Peptides were required to 
be at least 7 amino acids in length and a MaxQuant score >5, with false discovery rates (FDRs) 
of 0.01 calculated at the levels of peptides, proteins and modification sites based on the 
number of hits against the reversed sequence database. Protein inference and spectral counts 
were attained using the open source software PeptideShaker searched against a compiled 
database from UniProt and validated at a 1% false discovery rate. 
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Affinity probe enrichment of galactosyltransferases 
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9. Chapter 2 
Affinity probe enrichment of galactosyltransferases from 
Trypanosoma brucei. 
9.1 Results and Discussion 
This section will describe how resin bound UDP-galactose (UDP-Gal) and resin bound UDP-
(4F)-Galactose (UDP-(4F)-Gal) probes were used in an attempt to enrich candidate GalTs in T. 
brucei. First, the use of Stable isotope labelling by amino acids in culture (SILAC) to distinguish 
between affinity binders and contaminants will be explained.  Then this will be put into the 
context of our affinity probe protocol before the results of mass spectrometry analysis are 
explored. This chapter has two main aims: 
(i) to use the activity based probes and the developed method from the previous 
chapter to search for GalTs in T. brucei 
(ii) to characterise any GalTs found using RNAi 
Using a combination of the developed enrichment protocol and Stable Isotope Labelling of 
Amino acids in Cell culture, the probes were used to enrich GalTs from lysates of T. brucei. Any 
enriched proteins were evaluated to determine if they were potential GalTs. 
9.1.1 Author contributions 
J. G. M. Bevan, M. Chaves-Ferreira, J. A. Rodrigues, S. Duncan and M. A. Ferguson designed 
the experiments. J. G. M. Bevan and S. Duncan performed the experiments. J. G. M. Bevan and 
the FingerPrints Proteomic Facility at the University of Dundee performed the data analysis. 
J. G. M. Bevan created all the figures and tables. J. A. Rodrigues mentored and supervised the 
work. 
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 9.1.2 Stable isotope labelling by amino acids in cell culture (SILAC) 
Immobilising the proposed ABPP probe on a resin will allow for characterisation of captured 
proteins. However, the resin itself will trap non-specific proteins and the true binders to the 
probe must be differentiated from these. This can be done in a couple of ways: 
1) Comparing probe-bound resin (a) to resin without the probe 
2) Comparing probe-bound resin plus free UDP-Gal (a) with probe-bound resin (b)  
Option 1 would differentiate between those proteins that bind to the PEG resin versus those 
that bind to the probe specifically. In this way, we would look for proteins whose binding 
increases in (a) compared to (b). Option 2 is similar but the addition of free UDP-Gal would 
reduce the binding of proteins that are specific to UDP-Gal by competitive inhibition. For this 
condition, we would look for the proteins whose binding is reduced in (a) compared to (b). In 
order to compare the two different conditions using mass spectrometry, they must be 
labelled. There are a number of methods used to enable comparison between two samples 
and these can be split in to three categories; label free, chemical labelling and metabolic 
labelling. 
 
Label free comparisons use either the abundance or volume of ion counts or spectral counts. 
There is no limit to the number of experiments that can be compared as there are no labels, 
which also reduces the cost. However, there are no formalised internal standards meaning 
that errors in each dataset have to be averaged with replicates and certain biases are 
introduced by the algorithms used to calculate abundance based on the length of the peptide 
(Patel et al., 2000; Deng et al., 2015). 
 
Chemical labelling is often used to follow multiple time points or many experiments or for 
cultures that cannot be labelled metabolically. It is more accurate than label free although it 
is more expensive (Megger et al., 2014). The number of experiments that can be compared 
depends on the label chosen. Isotope coded affinity tagging (ICAT) can label only three 
different conditions, but tandem mass tags (TMT) and Isobaric Tags for Relative and Absolute 
Quantitation (iTRAQ) can label 6 and 8 respectively (Wiese et al., 2007; Mertins et al., 2012). 
Each chemical modification has its own advantages and disadvantages. ICAT labels cysteines 
and therefore suffers from errors caused by proteins who do not contain a cysteine or only 
have one in their sequence and cannot be reliably quantified (Hsu et al., 2003).  Dimethyl 
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labelling is a cheaper alternative that labels globally and can be used in triplex (Hsu et al., 
2003). 
 
All chemical labels are added at a late stage and therefore are subject to errors introduced by 
the reaction itself. Metabolic labelling is the most sensitive method to compare samples 
because the labels are incorporated early on in sample preparation. Stable Isotope Labelling 
by Amino Acids in Cell culture (SILAC) involves labelling cells with heavy atoms through 
metabolic incorporation of heavy amino acids. When it was first reported, deuterated leucine 
was the only heavy amino acid used and it still outperformed ICAT as leucine is 20 x more 
abundant than cysteine (Ong et al., 2002). Now, the most commonly used amino acids are 
heavy arginine and lysine (Lau et al., 2014; Xiao, Tang and Wu, 2016). These experiments can 
be performed in triplex by using commercially available light, medium (2H4-lysine (Lys4) 
and 13C6-arginine (Arg6)) and heavy (15N213C6-lysine (Lys8) and 15N413C6-arginine (Arg10)) 
amino acids. 
 
Not all organisms can incorporate these amino acids, or they metabolise them which can 
complicate the spectra. For example, heavy isoleucine (13C615N1) is the only amino acid that 
can be used to metabolically label Plasmodium falciparum as it is the only amino acid that the 
parasite cannot produce itself, nor does it uptake it from red blood cells or metabolise it to 
another amino acid (Nirmalan, Sims and Hyde, 2004). Of course, this means that any peptide 
without an isoleucine would not be labelled and cannot be quantified. In order to follow the 
metabolism of glucose in T. brucei, Creek et al used heavy glucose (13C1) and in doing so were 
able to follow its distribution (Creek et al., 2015). Although SILAC has proven to be a useful 
tool in proteomics, not every cell line grows efficiently in the dialysed medium required and 
some take too long to incorporate. 
 
We propose to use SILAC to determine specific from non-specific binders. Trypanosomes 
readily and quickly incorporate heavy arginine and lysine into their proteins. This technique is 
well established in T. brucei and has been used to differentiate the glycosome proteome from 
the mitochondrial in order to establish T. brucei glycosome proteome (Guther et al., 2014). It 
has also been used to identify phosphorylation sites in two life stages of T. brucei and to 
quantify the differences between the two stages (Urbaniak, Martin and Ferguson, 2013).  
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 Anything that has bound in both experiments will be a non-specific binder but if there is a 
large increase in intensity for a specific protein in the heavy experiment compared to light 
then it has specifically bound to the probe, figure 42. 
 
Figure 42 - Application of SILAC to affinity probes – Option 2 
9.1.3 Design of affinity probe protocol 
T. brucei procyclics are able to grow at a higher density compared to T. brucei blood stream 
forms therefore the SILAC experiment will be performed with procyclics to increase the 
amount of protein available per mL of medium. Another advantage of using procyclics is that 
the only characterised galactosyltransferase in T. brucei is present, TbGT3 – responsible for 
linkage 33, figure 13. This GalT forms two glycosidic linkages on the glycan of the GPI anchor 
of procyclin and is a good positive control. The GalTs responsible for linkages 28,29, 32 and 36 
(figure 13) will also be present. GTs can be identified using characteristics described in the 
section 7.1.4 Glycosyltransferases. If the protein sequence contains a DXD motif, a 
transmembrane domain and/or is listed as a putative GT of T. brucei then it will be considered 
as a candidate worth pursuing (Izquierdo, Nakanishi, Mehlert, Machray, Geoffrey J Barton, et 
al., 2009; Rini, Esko and Varki, 2009). 
 
Due to the specificity of each GT, they are inherently low in abundance (Taylor and Drickamer, 
2011). In order to capture GalTs and reduce the amount of non-specific background, the 
 94 
amount of probe used must be of a similar order to GalT abundance. If the protein is known, 
then this could be calculated (Milo, 2013) but we will have to estimate. To get an idea of scale, 
two highly abundant proteins in the proliferative stages, procyclin and VSG, have around 106 
and 107 copies per cell, respectively. However, the transferrin receptor TfR, only expressed in 
blood stream forms, only has around 2.3 x 103 copies per cell (Magez and Radwanska, 2013). 
Assuming GalTs are of a similar low abundance of around 1 x 103 to 1 x 104 we can estimate 
the following: 
200 mL of procyclics at 2 x 107
cells
mL
= 2 x 109 cells 
2 x 109 cells x 1 x 103 to 1 x 104 GTs =  2 x 1012 to 2 x 1013 GT molecules  
50% yield =  1 x 1012 to 1 x 1013 GT molecules  
𝐺𝑇 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒𝑠
6.022 x 1023
=  1.7 x 10−12 to 1.7 x 10−11 mol of GT = 1.7 𝑝𝑚𝑜𝑙 𝑡𝑜 17 𝑝𝑚𝑜𝑙 𝐺𝑇 
  
There are around 10 GalTs – assuming 5 “known” (28, 29, 32, 33, 36, figure 13) plus 5 
unknown: 
𝑚𝑎𝑥. 𝑚𝑜𝑙 𝑜𝑓 𝐺𝑎𝑙𝑇 𝑖𝑛 200 𝑚𝑙 𝑐𝑢𝑙𝑡𝑢𝑟𝑒 = 10 𝑥 17 𝑝𝑚𝑜𝑙 = 170 𝑝𝑚𝑜𝑙 
 
To allow a 10 fold excess of probe to GalT: 
𝑚𝑎𝑥. 𝑚𝑜𝑙 𝑜𝑓 𝑝𝑟𝑜𝑏𝑒 = 10 𝑥 170 𝑝𝑚𝑜𝑙 = 1.7 𝑛𝑚𝑜𝑙 
 
For a 200 mL culture, considering that the density of UDP-Gal on the resin is 0.205 mmolg-1 
and UDP-(4F)-Gal on the resin is 0.167 mmolg-1: 
1.7 nmol = 8 µg UDP-Gal resin 
1.7 nmol = 10 µg UDP-(4F)-Gal resin 
Once a protocol is optimised, 3 biological replicates should be completed and the data pooled 
in order to reduce errors introduced by sample handling. 
 
9.1.1 Resin bound UDP-Galactose has a low affinity to galactosyltransferases 
9.1.1.1 Trial 1 
First the ability of the UDP-Gal resin to pull out GalTs from pcf lysates was tested. Pcfs were 
cultured until 200 mL of culture at 2x107 cells/mL in light and heavy medium were obtained. 
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 The cells were washed, lysed and ultracentrifuged (see method) so that a clarified 
supernatant without cell debris was obtained with a concentration of 4x108 cells/mL (10 mL). 
0.1 mM of free UDP-Gal was added to the light lysates in order to block the interactions of 
GalTs with the resin. 
 
The heavy and light supernatants were passed through 4 mm PVDF membranes on which 10 
L of swelled UDP-Gal resin sat. The PVDF was used to act as a support for the resin to allow 
it to be incubated with proteins. The small diameter was chosen in order for all the lysates to 
pass through the bed of resin without having to use a large quantity of resin. As discussed 
above, the more resin used the more chance there is of encouraging non-specific interactions. 
Unfortunately, after 3 mL of lysates (approx. 1.2x109 cells) were passed through the 
membrane before it blocked. As these are small membranes, 10 mL of concentrated protein 
was too much. In order to continue, the resin was back-washed through the PVDF membrane 
and washed in an Eppendorf. The proteins were eluted in an Eppendorf with 2% SDS, figure 
43. 
Figure 43 - Method used with UDP-Gal resin to pull out GalTs from pcf lysates 
These light and heavy samples were then joined and prepared for mass spectrometry. There 
were 265 proteins listed as enriched in this experiment (see annex table 10 for the top 12). 
However, only one protein was significantly enriched (more than 5 times). This protein has an 
assigned function and is a catalytic subunit of the vacuolar transporter chaperone 4, with no 
characteristics of a GalT. There were no putative GalTs present in the captured protein list of 
the light nor the heavy as discerned by the lack of a DXD motif. Perhaps repeated experiments 
are required to reduce the background of non-specific binding and reveal those that have an 
affinity for the probe not the resin. However, since no GalT was present in the light or the 
heavy experiment is more likely due to the low volume of lysates able to pass through the 
resin, the low abundance of GalTs and low affinity of the GalTs to the probe. If it a matter of 
abundance, repeats could increase the chances of seeing a GalT but with a low affinity probe 
the probability this might not be feasible. The amount of free UDP-Gal used in the light 
Lysates 
Discard Wash 
Discard Elute 
KEEP 
x 3 x 2 
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experiment would influence the resolution between heavy and light but as no GalTs were seen 
in the light, the amount of free UDP-Gal is not likely to be the problem. If more resin was used, 
this would increase the chances of capturing a GalT. It would also increase the amount of non-
specific binding; therefore, many repeats would be needed to reduce the background noise. 
To summarise, from this experiment it is unclear if the probe has a low affinity or if the volume 
of lysates passed was insufficient to capture enough GalT to be seen by mass spectrometry. 
9.1.1.2 Trial 2 
Two 200 mL cultures of heavy pcfs and two of light were grown. To improve upon the previous 
experiment, this time each time a membrane blocked the resin was moved to a new 
membrane. In this way, all the lysates could be passed through the resin. A second method 
was also trialled where the resin was rolled in a falcon with the lysates for 3 hours at 4 C. 
Since there were two biological replicates, these were spilt in two to be used in each method 
giving a total of four experiments, figure 44. To ensure that all GalTs are blocked in the light 
experiment, the amount of free UDP-Gal was increased to 1 mM.  
Figure 44 – Illustration of how biological replicates were split in to the two methods: passing 
through a membrane or rolled in a falcon. 
The light and heavy eluted proteins for each of the four experiments were joined to their 
respective partner and sent to mass spectrometry. During initial mass spectrometry runs, the 
sample intensities observed were too low, so methods 1 and 2 for each culture were combined 
so that the biological replicates still stood true. There were over 500 proteins listed as 
enriched in both biological replicates, double that of the previous experiment. The increase in 
amount of enriched proteins can be explained by the improved technique – the full 10 mL of 
lysates were passed through the resin. Of these 500 enriched proteins, 10 were more than 5 
x enriched (see annex table 11 for the top 20), but none of the 500 were putative GalTs. 
 
Included in the list of enriched proteins were UDP-galactose 4-epimerase (GALE, 2.7 fold in 
culture 1 and 1.7 fold in culture 2) and a UDP-Gal transporter (Tb927.10.13900, 9 fold in 
Culture 1
5 x 109 cells
Method 1
2.5 x 109 cells
Method 2
2.5 x 109 cells
Culture 2
5 x 109 cells
Method 1
2.5 x 109 cells
Method 2
2.5 x 109
cells
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 culture 1 and 1.5 fold in culture 2). Although they are not the focus of this study, these are 
both UDP-Gal processing enzymes and their presence is a promising indication that the probe 
is available to bind to enzymes with affinity to UDP-Gal. These two enzymes could have a 
higher abundance than GalTs or they could simply have a higher affinity to the probe. They 
each are unique enzymes (unlike the approximate 10 GalTs) therefore it is plausible that their 
abundance is higher increasing their chances of binding. 
 
The affinity of the UDP-Gal probe to GalTs is clearly not high enough to enrich them when they 
are in such low abundance. However, the change in method from the PVDF membrane to 
rolling did improve the binding of the resin to UDP-Gal processing enzymes. This is probably 
because more lysates were exposed to the resin and for a longer time giving an increased 
opportunity for these enzymes to interact. Furthermore, in the PVDF method, the transfer of 
the resin from membrane to membrane lead to loss of resin and therefore sample. If the 
affinity of the resin could be improved, the “rolling” method could potentially enrich GalTs. 
 
9.1.2 Resin bound UDP-(4F)-Galactose has an improved affinity to galactosyltransferases 
UDP-(4F)-Gal was designed to have a higher affinity to GalTs than UDP-Gal since the 
introduction of the fluorine increases the strength of the 4-OH hydrogen bond to the enzyme, 
as discussed in 7.3.1. Since the UDP-Gal resin has a low affinity it can replace the use of free 
UDP-Gal and can act as the control for the non-specific binders compared to the UDP-(4F)-Gal 
resin, figure 45. 
Figure 45 – Use of UDP-Gal resin compared to UDP-(4F)-Gal resin 
Using the rolling method as validated previously, the light lysates were incubated with the 
UDP-Gal resin and the heavy with the UDP-(4F)-Gal resin and the eluted proteins combined 
for mass spectrometry, see methods. Nearly 700 proteins were enriched with the UDP-(4F)-
Gal resin, of which 80 were significantly enriched and these enrichments were greater than 
before (see annex table 12 for the top 20 proteins). This great increase in enrichment could 
UDP-Gal 
Non-specific binders Non-specific and Specific 
UDP-(4F)-Gal 
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be because the addition of the fluorine has increased affinity of many proteins to the resin, 
but almost all the proteins that were enriched were not UDP-Gal processing; it therefore 
seems unlikely that the fluorine caused the increase in number. The increase in number of 
proteins enriched could be due to the improvement in technique that increased the number 
of proteins detected in general. In Trial 1 only 453 proteins were detected. This increased to 
761 for Trial 2 and even further for this experiment to 1408. The technique was improved 
partly by practise and partly by utilising the rolling method which lead to less loss of resin. By 
using only one method, less resin per culture was used which reduces the amount of non-
specific interactions. Of course, this increase could be anomalous and repeated experiments 
would be needed to confirm. 
 
Within the 700 proteins UDP-galactose 4-epimerase was again enriched 2.5 times. None of 
the MaxQuant assigned enriched proteins were putative GalTs. However, GT3 (the only 
characterised GalT in T. brucei) was present in the 700. It was not assigned a H/L ratio because 
it and 54 other proteins were completely absent in the light experiment, according to 
MaxQuant. There were 4 unique peptides in the heavy experiment assigned to GT3. In order 
to confirm total absence of GT3 from the light experiment, extracted ion chromatographs (XIC) 
were performed for each of the 4 peptides. This checks the presence of the ions and ensures 
that the mass spectrometer did not overlook them for analysis by extracting the m/z values 
of the peptide across the entire chromatograph. The result is a plot that gives the intensity of 
the ion across the whole run. Of the four heavy peptides present, one peptide’s light 
counterpart was absent but three clearly had light equivalents. From these three, one peptide 
was not overlapping any other peptide and could be quantified. The resulting ratio is 1: 3.57, 
L: H meaning that it is not a case of presence and absence, but GT3 was truly enriched in this 
experiment. The remaining two peptides overlapped others making quantification with these 
inaccurate. As an example, the XIC of the peptide chosen for quantification is shown in figure 
46. 
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Figure 46 - XIC plot of peptide LVNTPYSESNIEDFR – Heavy m/z 895.4395, Light m/z 892.4271, RT 
79.60 
  
The top 50 enriched proteins and the 55 proteins that were present in the heavy but absent 
in the light experiment were checked for GalT properties. If the protein did not have an 
assigned function and had at least one transmembrane domain, the sequence was checked 
for a DXD motif. Unfortunately, no candidate GalTs were found as the few that were 
transmembrane proteins had no DXD motif present. There was a high number of ribosomal 
proteins present in the enriched list, these proteins should bind non-specifically and would 
reduce in number over repeated experiments. 
 
Although the only GalT that was enriched was the already characterised GT3, this experiment 
showed that the probes have the potential for enriching (and allowing the identification of) 
GalTs from lysates. Repeating the experiment with the fluorinated probe would increase the 
probability of other GalTs binding and the background binding of the ribosomal proteins 
would be reduced. The reaction conditions could be optimised to give time for binding by 
increasing the time that the resin was incubated with the lysates from 3 hours to overnight. 
 
Tentagel is an ampiphilic resin and has a reduced non-specific binding compared to purely 
hydrophobic solid supports who bind many proteins non-specifically. However, it can still bind 
non-specifically to proteins. Kim et al. designed a new PEG-based resin that reduced non-
specific interactions by efficiently displaying small molecules on its surface. They attributed 
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tentagel’s non-specific binding to its uneven surface and proved their smooth surfaced resin 
minimised non-specific interactions by reducing the sterics and allowing proteins to gain 
access to the affinity tag (Kim et al., 2006). 
 
Similarly, Chen et al. discuss the high ligand concentration of beads such as tentagel which 
leads to multiple interactions of one protein with many ligands. Even if this protein only has a 
low avidity, the multiple interactions combined would produce a high affinity that could be 
higher than a specific interaction. Furthermore, even if the original interaction was specific, 
further non-specific interactions of one protein with the hydrophobic surface of the resin 
would bias a study towards those proteins over the ones that could only form the original 
specific interaction (Chen et al., 2009). 
 
Based on these observations, the hydropathy plots of GALE and the UDP-Gal transporter were 
compared to that of GT3, figure 47 (Aslett et al., 2010). Although there are no striking 
differences between the three, GT3 appears to have a region of almost neutral hydrophobicity 
where GALE and UDP-Gal transporter have peaks and troughs of hydrophobicity. These subtle 
differences could encourage binding via a combination of specific and non-specific 
interactions as suggested by Chen et al who propose reducing ligand loading and increasing 
spacing between ligands to overcome this problem (Chen et al., 2009). 
 Figure 47 – Hydrophobicity plots adapted from the TriTryp database 
An alternative to reducing ligand loading or spacing between ligands would be to block the 
resin prior to using it. Tentagel resin is often blocked by hydrophobic BSA or milk overnight 
which reduces non-specific binding (Nafffin et al., 2003; Göksel et al., 2011). This technique 
could be incorporated in to the protocol prior to incubation with the lysates and could reduce 
background binding, revealing GalTs. Finally, the affinity of the probes must be increased since 
GT3 
 
 
GALE 
 
 
UDP-Gal 
transporter 
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 the GalTs are of very low abundance. This could be achieved by modifying the probe as 
discussed in 7.4. 
 
9.2 Chapter summary 
In this chapter, we saw that, when applied to whole lysates of T. brucei procyclic forms, the 
UDP-Gal probe did not have a high enough affinity to enrich any GalTs. UDP-(4F)-Gal was able 
to enrich GT3, a known and characterised GalT of procylic forms. However, no other predicted 
GalTs were enriched. Although these results suggest good selectivity for UDP-(4F)-Gal resin, 
these assays would benefit from additional experiments and optimization steps to increase 
enrichment capacity and enable the identification of novel UDP-galactosyltransferases from 
the parasite. In the future, a new probe could be synthesised with an increased affinity by 
modifying either the sugar, the nucleotide or both, so that the low in abundance GalTs could 
be enriched and characterised. This work paves the way towards the synthesis other similar 
probes using the same synthetic approach. GlcNAc transferase are also of great importance in 
T. brucei therefore a probe based on GlcNAc could be designed to characterise the putative 
GlcNAc transferases as yet uncharacterised. 
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9.3 Materials and methods 
9.3.1 Culture of procyclic form T. brucei 
One litre of SDM-79 without L-Arg or L-Lys was made from powder with the following recipe: 
800 ml MilliQ water, 1 pot of powder SILAC SDM-79 (it comes minus L-Arg and L-Lys, from 
Tryp Community), 2 g NaHCO3 (Merck cat n. 1.06329.1000), 0.75 ml of 10 mg/ml haemin in 50 
mM NaOH (haemin is Sigma cat. H5533), 10 ml Glutamax I ( Invitrogen cat. 35050-38), pen-
strep (Gibco 15140, diluted 1:1,000) and 150 ml Dialised and Heat inactivated FBS (PAA lot 
1488). This 1L media (minus L-Arg and L-Lys) is then is divided in 2 x 500 ml, one for R0K0 and 
the other for R6K4. L-Arg and L-Lys were then added at R0 HCl (ordinary 12C isotope, Sigma 
A-5131) or R6 (heavy, 13C6-arginine) HCl (13C isotope, Cambridge Isotope Labs cat CLM-2265-
H-05) 248 mg/L and K0 2HCl (ordinary 12C isotope, Sigma L-5751) or K4 (heavy, 2H4-lysine) 
2HCl (13C isotope Cambridge Isotope Labs cat DLM-2640-05) 91 mg/L. Procyclic form 
Trypanosoma brucei, monomorphic strain 427, were grown at 28 C without CO2 in fully 
capped culture flasks in light R0K0 SDM-79. These cells, in log phase, were suspended in either 
SDM-79 supplemented with light lysine and arginine or SDM-79 supplemented with 2H4-lysine 
(Lys4) and 13C6-arginine (Arg6) at 2x106 cells/mL and passed every 2 days (enlarging the culture 
each time) until 6-7 cell divisions had occurred in the heavy medium and the cultures were 
200 mL at 2x107 cells/mL. The cells were harvested by centrifugation and washed with ice-
cold PBS three times. The cell pellet was resuspended in lysis buffer (2%nOG, 50 mM Tris-HCl 
pH 7.4, 0.1 mM TLCK, 1 μg/mL, complete protease inhibitor cocktail without EDTA and 2 mM 
manganese chloride) at 5x108 cells/mL and incubated on ice-water for 30 mins. The 
suspension was clarified by ultra-centrifugations (50,000 g, 1 hr, 4 C) and the supernatant 
taken for affinity purification. 
9.3.2 Affinity purification on PVDF membranes with UDP-Gal resin 
The affinity UDP-Gal resin was swelled in an eppendorf in lysis buffer then the excess buffer 
was removed. 10 L of swelled resin (with 10 L reach tips cut for a wider bore) was loaded 
on to two a 4 mm hydrophilic PVDF syringe filter membranes with a 0.45 m pore size. The 
resin was washed on the membrane with 1 mL 2% SDS, 20 mM Tris-HCl pH 7.4 then 0.5 mL of 
lysis buffer. To the light cell lysates 1 mM of free UDP-Gal was added and to the heavy cell 
lysates the equivalent volume of water was added. The light lysates were then passed slowly 
through the PVDF membrane loaded with resin (less than 1 drop/sec). The heavy cell lysates 
were passed slowly through the remaining PVDF membrane loaded with resin. If the 
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 membrane blocked, the resin was back washed into an eppendorf and loaded on to a new 
membrane. After all the lysates passed both membranes, the light lysate resin was back-
washed into a new low bind eppendorf. This resin was washed 3 x with 0.5 mL lysis buffer with 
protease inhibitors and the supernatant discarded. The heavy resin was added to the light 
resin and washed a further 5 x with 0.5 mL lysis buffer, discarding the supernatant. Elution 
buffer, 100 L 2% SDS, 20 mM Tris-HCl pH7.4 was added to the resins and they were incubated 
for 30 min at 50 C in an incubator with shaking. They were cooled, centrifuged and the SDS-
eluate from the top of the resin was transferred into a low protein bind Eppendorf. The elution 
was repeated and the eluate added to the same eppendorf. The resin was washed once more 
with elution buffer, centrifuged and the SDS-eluate was added to the same Eppendorf. This 
elution was taken for FASP. 
9.3.3 In-falcon affinity purification with UDP-Gal resin 
The affinity resin UDP-Gal was swelled in an eppendorf in lysis buffer and the excess buffer 
was removed. 10 L of the swelled resin (with 10 L reach tips cut for a wider bore) was added 
to two 15 mL falcons. The resins were washed with 1 mL 2% SDS, 20 mM Tris-HCl pH 7.4 then 
0.5 mL of lysis buffer. To the light cell lysates 1 mM of free UDP-Gal was added and to the 
heavy cell lysates the equivalent volume of water was added. The lysates were added to the 
falcons containing UDP-Gal resin and were incubated rotating at 4 C for 3 h. The resins were 
washed separately with 3 x with 0.5 mL lysis buffer with protease inhibitors and transferred 
to an Eppendorf together. 100 L 2% SDS, 20 mM Tris-HCl pH7.4 (elution buffer) was added 
and the resins incubated for 30 min at 50 C in an incubator with shaking. They were cooled, 
centrifuged and the SDS-eluate collected from the top of the resin into a low protein bind 
Eppendorf. The elution was added to the same eppendorf. The resin was washed with 100 L 
of 2% SDS, 20 mM Tris-HCl, centrifuged and added to the same eppendorf. The elution was 
taken for FASP. 
 
9.3.4 In-falcon affinity purification with UDP-(4F)-Gal resin 
The affinity resins UDP-Gal and UDP-(4F)-Gal were swelled in an eppendorf in lysis buffer and 
the excess buffer was removed. 10 l of each swelled resin (with 10 ul reach tips cut for a 
wider bore) was added to two 15 mL falcons. The resins were washed with 1 mL 2% SDS, 20 
mM Tris-HCl pH 7.4 then 0.5 mL of lysis buffer. The light lysates were added to the falcon 
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containing UDP-Gal resin. The heavy cell lysates were added to the falcon containing UDP-
(4F)-Gal resin. The falcons were incubated rotating at 4 C for 3 h. The resins were washed 3 
x with 0.5 mL lysis buffer with protease inhibitors and transferred to an eppendorf. The resins 
were combined, 100 L 2% SDS, 20 mM Tris-HCl pH7.4 (elution buffer) added and incubated 
for 30 min at 50 C in an incubator with shaking. They were cooled, centrifuged and the SDS-
eluate collected from the top of the resin into a low protein bind Eppendorf. The elution was 
added to the same eppendorf. The resin was washed with 100 L of 2% SDS, 20 mM Tris-HCl, 
centrifuged and added to the same eppendorf. The elution was taken for FASP. 
9.3.5 Filter aided sample preparation (FASP) 
Samples were prepared using a modified version of a published FASP procedure (Wiśniewski 
et al., 2009). An Amicon 30kda column was pre-washed with 400 L of ddH2O. The sample 
was loaded on to the column 50 L at a time with 200 L of UA (8M urea in 0.1 M Tris HCl pH 
8.5) and centrifuged at 14,000 g for 15 min. Another 200 L of UA was added and centrifuged 
at 14,000 g for 15 min. The flow through was discarded and 100 L of 0.05 M iodoacetamide 
in UA was added to the column. It was incubated in the dark for 20 min then centrifuged at 
14,000 g for 10 min. The filter unit was washed twice with 100 L of UA, each time centrifuging 
at 14,000 g for 15 min and discarding the flow through. It was then washed 4 x 100 L 40 mM 
NH4HCO3, each time centrifuging at 14,000 g for 10 min and discarding the flow through. The 
filter unit was transferred to a new collection tube, trypsin-Lys-C added (promega, use 25:1 
protein: protease, w: w) in 40 mM NH4HCO3 (0.4 g trypsin/L) and incubated overnight at 37 
C. The filter unit was centrifuged at 14,000 g for 10 min. The filter was washed twice with 40 
L of BB (40 mM Tris/HCl pH 7.6, 2mM MnCl2, 2mM CaCl2, 1 M NaCl) and centrifuged at 14,000 
g for 10 mins. The filtrate was collected for C18 purification. 
 
9.3.6 C18 purification 
All solvents used in this purification were of mass spectrometry grade. The solutions used 
were as follows:  
Conditioning solution: 90/10 MeOH/H2O with 0.1% TFA (v/v/v) (10 ul TFA per 10 mL) 
Equilibration solution: 0.1% TFA in H2O (v/v) 
Desalting solution: 5% MeOH/ H2O with 0.1% TFA (v/v/v) 
Elution solution: 50/50 AcCN/ H2O with 0.1% TFA (v/v/v) 
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 The C18 SPE cartridge was conditioned by passing 3 mL conditioning solution through the 
packing bed. It was then equilibrated by passing 2 mL equilibration solution through the 
packing bed. The sample was reconstituted in up to 1 mL of 0.1-0.5% TFA. The pH was adjusted 
to <3 with formic acid if needed. The sample was loaded by passing slowly (1 drop/ sec) into 
the cartridge. Loading was completed by passing 1 mL of equilibration solution into the 
cartridge. The sample was desalted by passing 1 mL desalting solution through cartridge. A 
new was placed below the cartridge for collection of the sample. The sample was eluted by 
slowly (1 drop/ sec) passing 1 mL of elution solution through cartridge. The sample was dried 
on a speed vac overnight. 
9.3.7 Mass spectrometry 
Liquid chromatography tandem mass spectrometry was performed by the FingerPrints 
Proteomic Facility at the University of Dundee on an LTQ Orbitrap Velos Pro mass 
spectrometer. Trypsin-digested peptides were separated using an UltiMate 3000 RSLC 
(Thermo Scientific) nanoflow LC system. Around 0.5 µg of protein was loaded with a constant 
flow of 5 µl/min onto an Acclaim PepMap100 nanoViper C18 trap column (100 µm inner-
diameter, 2cm; Thermo Scientific). After trap enrichment, peptides were eluted onto an EASY-
Spray PepMap RSLC nanoViper, C18, 2 µm, 100 Å column (75 µm, 50 cm; Thermo Scientific) 
with a linear gradient of 2–35% solvent B (80% acetonitrile with 0.08% formic acid, Solvent A 
– 0.1% formic acid) over 70 min with a constant flow of 300 nl/min and column temperature 
of 50 °C. The HPLC system was coupled to a linear ion trap Orbitrap hybrid mass spectrometer 
(LTQ-Orbitrap Velos, Thermo Scientific) via an easyspray ion source (Thermo Scientific). The 
spray voltage was routinely set to 1.8 kV, and the temperature of the heated capillary was set 
to 250 °C. Full-scan MS survey spectra (m/z 335–1800) in profile mode were acquired in the 
Orbitrap with a resolution of 60,000 after accumulation of 1,000,000 ions. The fifteen most 
intense peptide ions from the preview scan in the Orbitrap were fragmented by collision-
induced dissociation (normalized collision energy, 35%; activation Q, 0.250; and activation 
time, 10 ms) in the LTQ after the accumulation of 5,000 ions. Maximal filling times were 1,000 
ms for the full scans and 150 ms for the MS/MS scans. Precursor ion charge state screening 
was enabled, and all unassigned charge states as well as singly charged species were rejected. 
The lock mass option was enabled for survey scans to improve mass accuracy (Olsen, J.V. et 
al., 2005). Data were acquired using the Xcalibur software. 
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9.3.8 Quantification and bioinformatics analysis 
The raw mass spectrometric data was loaded into MaxQuant (version 1.5.2.8) (Cox, J., and 
Mann, M., (2008). Nat Biotechnol 26, 1367-72.) using the Andromeda search engine software 
(Cox, J., et al, (2011) J. Prot. Research 10 (4), 1794-1805). Enzyme specificity was set to that of 
trypsin, allowing for cleavage N-terminal to proline residues and between aspartic acid and 
proline residues. Other parameters used were: 
(i) variable modifications- methionine oxidation, protein N-acetylation, gln  pyro-
glu, deamidation (NQ) 
(ii) fixed modifications, cysteine carbamidomethylation 
(iii) database: TriTrypDB-33_TbruceiTREU927_AnnotatedProteins (170626) 
(iv) labels: R0K0, R6K4 
(v) MS/MS tolerance: FTMS- 10ppm , ITMS- 0.6 Da 
(vi) maximum peptide length, 6 
(vii) maximum missed cleavages, 2 
(viii) maximum of labelled amino acids, 3 
(ix) false discovery rate, 1% 
Peptide ratios were calculated for each arginine- and/or lysine-containing peptide as the peak 
area of labelled arginine/lysine divided by the peak area of non-labelled arginine/lysine for 
each single-scan mass spectrum. Peptide ratios for all arginine- and lysine-containing peptides 
sequenced for each protein were averaged. 
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N-glycosylation inhibitor NGI-1 and its uses with T. brucei 
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10. N-glycosylation inhibitor NGI-1 and its uses with T. brucei 
10.1 Results and Discussion 
 
This chapter had three main aims; (i) to study the effect that NGI-1 has on T. brucei growth; 
(ii) to examine the effect that NGI-1 has on T. brucei N-glycosylation; (iii) to investigate the 
utility of NGI-1 as a tool to study N-glycosylation. The parasites were grown in culture medium 
supplemented with NGI-1 at various concentrations and their growth monitored. Lectin blots 
of lysates and mass spectrometer analysis of VSG were performed to profile N-glycosylation. 
 
10.1.1 Author Contributions 
 
J. G. M. Bevan, M. Chaves-Ferreira and J. A. Rodrigues designed the experiments. J. G. M. 
Bevan and M. Chaves-Ferreira performed the experiments. J. G. M. Bevan performed the data 
analysis and created all the figures and tables. J. A. Rodrigues mentored and supervised the 
work. 
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 10.1.2 Predicted utility of NGI-1  
The small molecule inhibitor of mammalian Stt3B, NGI-1, was described in chapter 1 and is 
shown in figure 48. This reversible inhibitor also reduced the capabilities of mammalian Stt3A 
to glycosylate but did not fully inhibit it. Due to this incomplete inhibition, the cells remained 
viable but under-glycosylated allowing for the study of glycosylation defects within a number 
of mammalian cell lines (Lopez-Sambrooks et al., 2016). 
Figure 48 - NGI-1 
Published knock downs of TbSTT3A and TbSTT3B showed the substrate specificities of these 
oligosaccharide transferases were for Man5GlcNAc2 and Man9GlcNAc2 respectively and that 
the parasite in blood stream forms need both OSTs for survival in vivo. In vitro, they could be 
knocked down individually without effecting the culture’s growth  (Izquierdo, Schulz, et al., 
2009). Although these knock downs provided a wealth of information about OSTs in T. brucei, 
small molecule inhibition provides unique benefits, figure 49. RNAi can be easier to monitor 
than small molecule inhibition since the absence of a protein is easier to visualise (western or 
qPCR) than the effect of its inhibition. However, small molecules are much easier to use and 
they can be used in conjunction with other probes including RNAi. They can also be used in 
varying quantities allowing observation of their effects across a range and can be developed 
as therapeutics if their activity is specific. Furthermore, small molecules are much faster in 
their inhibition than RNAi, which enables time specific experiments to be performed. 
Moreover, scaling up with siRNA is not efficient, but scale up with small molecules is very easy 
to achieve (Weiss, Taylor and Shokat, 2007). 
 112 
Figure 49 – siRNA (a) vs Small molecule inhibition (b), adapted from (Weiss, Taylor and Shokat, 
2007) 
A BLAST protein alignment showed that Stt3B of T. brucei has a 68.36 % similarity to the 
mammalian Stt3b, see annex figure 71. Unless NGI-1’s target is allosteric, there is a high 
probability that it inhibits TbStt3B in the same way that it does for the mammalian. Lopez-
Sambrooks et al. concluded that due to its specificity for Stt3B over Stt3A and from results of 
a cellular thermal shift assay that NGI-1 targets the active site of Stt3B (Lopez-Sambrooks et 
al., 2016). Complete inhibition of TbStt3B will inhibit the transfer of oligomannose structures 
and lead to an increase in complex and paucimannose structures like those seen in the 
TbSTT3B knock down (Izquierdo, Schulz, et al., 2009). 
 
The variant surface glycoprotein (VSG) of monomophic Trypanosoma brucei 427 has two N-
glycosylation sites and is called VSG221. Ans263 is glycosylated with paucimannose and 
complex structures which are derived from the transfer of Man5GlcNAc2 by Stt3A. Asn428 is 
glycosylated with oligomannose structures which are derived from the transfer of 
Man9GlcNAc2 by Stt3B (Manthri et al., 2008). This highly abundant protein is therefore a 
convenient control to monitor the inhibition of Stt3A and Stt3B that has already been used in 
numerous studies of glycosylation in T. brucei (Urbaniak, Turnock and Ferguson, 2006; 
Manthri et al., 2008; Izquierdo, Schulz, et al., 2009; Izquierdo, Mehlert and Ferguson, 2012; 
Castillo-Acosta et al., 2013). To get an overview of the effect of NGI-1 on T. brucei and its N-
glycosylation a number of studies were performed.  
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 10.1.3 NGI-1 inhibits the growth of T. brucei 
NGI-1 is soluble in DMSO up to 5 mg/mL so stock solutions were made at 10 mM (equivalent 
to 4 mg/mL). This lead to some limitations in terms of the concentration of NGI-1 that the cells 
could be grown in due to the toxicity of DMSO. DMSO only affected growth at 1%, below this 
the cultures grew at the same rate as a culture without DMSO, figure 50. Trypanosomes grown 
in 100 µM NGI-1 (1% DMSO + NGI-1) were not viable after 12 h, figure 50. This could be a 
combination of DMSO toxicity and the toxicity of NGI-1 on or off target. To know if it has off-
target effects, a mutant resistant to NGI-1 would have to be indentified. However, this is off 
the scope of this project was not studied. When T. brucei was grown in 50 µM NGI-1 for 3 days 
and then transferred to medium without NGI-1, the culture reverted to normal growth 
showing that the inhibition if reversible, figure 50. Although the difference in trajectory 
between the growth and trend line from day 1 to 3 looks small from day 3 to day 4, the scale 
is logarithmic and this represents a rapid increase in growth. 
Figure 50 – A: Growth curve of T. brucei grown in 1% DMSO, 0.1% DMSO or 100 µM NGI-1, n = 1. B: 
T. brucei growth with 0.5% DMSO or 50 µM NGI-1 which is removed at day 3, n = 1. 
 
T. brucei blood stream forms were grown in varying concentrations of NGI-1 dissolved in 
DMSO or the same concentrations of DMSO without the inhibitor, figure 52 graph A. The 
controls grown in the equivalent amounts of DMSO showed no reduction in growth. Increasing 
the concentration of NGI-1 from 10 µM to 50 µM slowed the growth of T. brucei with this 
effect being most visible after 3 days. Cultures grown with 50 µM NGI-1 often displayed the 
big-eye phenotype indicating the culture was stressed, figure 51 (Young and Smith, 2010). 
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Figure 51 - Big eye phenotype observed in cultures grown in above 20 µM NGI-1 
 
Figure 52 – A: T. brucei growth curves at different concentrations of DMSO and NGI-1 dissolved in 
DMSO. Error bars are calculated using standard error, n = 2 or 3, own data. B: Growth of the following 
T. brucei cells at 37 °C: wild type (closed circles), TbSTT3A,B,C+/- - STT3BRNAi minus Tet (open 
squares) and TbSTT3A,B,C +/- - STT3BRNAi plus Tet (closed triangles) adapted from (Izquierdo, 
Schulz, et al., 2009). 
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 Izquierdo et al. described a minimal growth phenotype for their Stt3B knock-down, figure 52 
graph B. However, NGI-1 caused a drastic growth phenotype in RTK dependant non-small lung 
cancer cells even at 10 µM (Lopez-Sambrooks et al., 2016). At 10 µM of NGI-1 there was little 
effect on the growth of T. brucei until day 5 where a slight decrease could be seen. The growth 
phenotype at higher concentrations could be due to the effect of NGI-1 on alternative 
pathways that cannot be predicted.  It could also be that the speed of inhibition is faster with 
NGI-1 than that of RNAi therefore causing a more severe phenotype as the cells struggle to 
adapt as expected from figure 52. 
 
The IC50 of NGI-1 on T. brucei was calculated from 6 concentrations to be 75.73 µM, figure 53. 
Compared to other trypanocidal like suramin (IC50 of 20 nM, (Boda et al., 2005)), this value is 
high meaning that NGI-1 has a low potency for affecting growth. The IC50 often gives an 
indication of the efficacy of the drug. However, in the case of NGI-1, it could be significantly 
lower in vivo because the removal of N-glycosylation is lethal for STT3B knock downs in vivo 
but not in vitro. 
Figure 53 - IC50 plot of NGI-1 after 24 h of incubation with T. brucei. Results are an average of n = 
3, error bars represent standard error. 
10.1.4 NGI-1 appears to effect N-glycosylation 
Lectin blots of cultures grown for 3 or 5 days in 50 µM NGI-1 (0.5% DMSO + NGI-1) or 0.5% 
DMSO were performed with both Concanavalin A (ConA) and ricin in order to visualise the 
effect on both types of glycosylation. ConA is a legume lectin extracted from jack beans that 
binds to -D-Mannosyl and -D-glucosyl groups and is therefore used to visualise high 
mannose glycans transferred by Stt3B. Ricin is also a legume lectin but is extracted from caster 
beans and binds to terminal galactose residues formed after the addition of Man5GlcNAc2 by 
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Stt3A (Liener, Sharon and Goldstein, 1986). These time points were chosen as the growth 
curves showed the greatest difference between the cultures from day 3, figure 53. 
 
NGI-1 is dissolved in DMSO before being added to the medium, to improve its solubility. In 
blot A, figure 54, cells grown without DMSO or NGI-1 are shown in lane 1 as a negative control. 
From pounceau staining of the membrane, lanes 2 to 5 have a similar amount of protein 
present but lane 1 has less. ConA staining in lane 1 is comparable to lane 2 therefore there is 
no affect. Lanes 2 and 3 are from cells grown with or without NGI-1, respectively, for three 
days. There appears to be an increase in high mannose glycosylated proteins in the culture 
treated with NGI-1, the opposite of what was expected. It could be that proteins from lane 4 
that are very strong in signal overflowed into lane 3, enhancing its signal and masking the 
effect of the drug. When looking at lanes 4 and 5 there is an obvious decrease in signal of 
ConA in the cells grown with NGI-1 indicating that NGI-1 successfully inhibited the Stt3B. 
Considering B, figure 54, ricin was used to assess if the reduction in high mannose glycans lead 
to an increase in complex glycans terminal in galactose. When Stt3B was knocked down, some 
previously high mannoses structures were replaced with complex (Izquierdo, Schulz, et al., 
2009). Again, lane 1 contained less protein than 2 and 3 but this time lanes 4 and 5 also had 
less protein compared to 2 and 3 (but similar between themselves). This makes comparisons 
between day 3 and day 5 difficult. Considering each day individually, there is little difference 
between cells grown with or without the drug. The signal on day 5 from ricin is very weak for 
both the control and the cells grown in NGI-1 and is difficult to interpret. 
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 A             B        C           D 
        1     2     3     4      5  1     2     3     4      5        1     2    1     2  
Figure 54- Cell lysate blots stained with lectin (upper panel) or pounceau red (lower panel). A: lane 
1 = day 0 control, lane 2 = cultured for 3 days in 0.5 % DMSO, lane 3 = cultured for 3 days in 50 µM 
NGI-1, lane 4 = cultured for 5 days in 0.5 % DMSO, lane 5 = cultured for 3 days in 50 µM NGI-1 were 
incubated with ConA. B: lane 1 = day 0 control, lane 2 = cultured for 3 days in 0.5 % DMSO, lane 3 = 
cultured for 3 days in 50 µM NGI-1, lane 4 = cultured for 5 days in 0.5 % DMSO, lane 5 = cultured for 
3 days in 50 µM NGI-1 were incubated with Ricin. C: lane 1 = cultured for 5 days in 0.5 % DMSO, lane 
2 = cultured for 5 days in 50 µM NGI-1 were incubated with ConA. D: lane 1 = cultured for 5 days in 
0.5 % DMSO, lane 2 = cultured for 5 days in 50 µM NGI-1 were incubated with ricin. 
 
Blots C and D from figure 54 show whole lysates from cultures grown in 50 µM NGI-1 or 0.5% 
DMSO for five days. These conditions were repeated because of the different effects seen 
with the staining on ConA in A and the poor staining with Ricin in B. In C, there is no clear 
difference between lanes 1 and 2. In D, there is a drastic increase in signal in lane 2 compared 
to lane 1, suggesting a large increase in the amount of complex glycans present. This data is 
almost the opposite of the data from A and B. 
 
To improve this assay, a positive control should be used. Tunicamycin is the most common 
positive control for the reduction of N-glycosylation and was used to compared to NGI-1 
inhibition of RTK dependent cancer cell lines (Lopez-Sambrooks et al., 2016). However, since 
this inhibitor is toxic and doesn’t target high-mannose structures it isn’t ideal. There are a 
number of other small molecule inhibitors that reduce complex and hybrid glycan formation 
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but non except NGI-1 reduce high mannose. Therefore, the best control would be to use a 
knock down of Stt3B. This control might not be the most suited since small molecular 
inhibition is not always equivalent to RNAi. A major difference between RNAi and small 
molecule inhibition is that RNAi removes the actual protein and therefore also removes any 
protein-protein interactions that were taking place. Therefore, by comparing the Stt3B knock 
down to NGI-1 the effects of protein-protein interactions, if any, could even be elucidated. 
 
10.1.5 NGI-1’s effect on variant surface glycoprotein 221 
A more conclusive way to assess the effect of NGI-1 on N-glycosylation is to extract the most 
abundant glycoprotein, VSG. As described before, VSG221 of monomorphic T. brucei 427 
strain contains two glycosylation sites: one high mannose and one complex. T. brucei blood 
stream forms were cultured in 50 µM NGI-1 for 3 or 5 days and their VSG was extracted and 
prepared for mass spectrometry analysis. The VSG is expected to lose the high mannose N-
glycosylation site on exposure to NGI-1. This would lead to two potential VSGs: one with a 
single complex N-glycan and one with two complex N-glycans where the “empty” high 
mannose site has been glycosylated by Stt3A as was observed for the RNAi of Stt3B knock 
down (Izquierdo, Schulz, et al., 2009). 
 
VSG extracted from 3 days growth in in 50 µM NGI-1 was run on an SDS page gel. This was to 
visualise if the VSG extraction had been successful, to know the volume of elution of the VSG 
from the DE52 column and to see if any change in mass had occurred from the loss of an N-
glycan, figure 55. Lanes 1 to 3 and 5 to 7 were loaded with extracted VSG from the DMSO 
control and NGI-1 respectively. The bands clearly show purified VSG and an elution volume of 
1.5 mL was established (each lane contained 0.5 mL of eluted protein). The resolution of the 
gel is not sufficient to differentiate between the glycosylated forms. 
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      Control       + NGI-1 
   1      2      3     4      5     6      7     8     9   10 
Figure 55 – Lanes 1 to 3: VSG extracted from control cells cultured for 3 days in 0.5% DMSO. Lane 4: 
blank. Lanes 5 to 7: VSG extracted from cells cultured for 3 days in 50 µM NGI-1. Lanes 8 and 9: blank. 
Lane 10: ladder. 
The identity of the N-glycans present can be determined using Endo-H or PNGaseF as Endo-H 
cleaves high mannose N-glycans but PNGaseF cleaves complex N-glycans (Tarentino, Trimble 
and Plummer, 1989). By subjecting the VSG to these enzymes in turn and visualising if there 
is a change in mass by SDS-page the nature of the N-glycans present can be elucidated. 
Alternatively, these VSGs can be analysed by mass spectrometry and the exact structures of 
the N-glycans can be determined. This data is still in progress. 
 
10.2 Chapter summary 
The small molecule inhibitor of STT3B, NGI-1, proved to be an interesting tool to study the 
reduction of high mannose N-glycans in T. brucei through the inhibition of oligosaccharide 
transferase Stt3B. Although knock-downs of TbSTT3B are well characterised, small molecule 
inhibition is advantageous as it can be used in conjunction with RNAi or other small molecules 
and it is fast acting. NGI-1 effected the growth of the parasite when in concentrations of above 
25 μM and was toxic in high concentrations with an IC50 of 75.73 μM. Lectin blots indicated 
that NGI-1 inhibits STT3B, but mass spectrometry analysis of the VSG will be able to confirm 
this. To develop NGI-1 as a therapeutic, structure activity relationship and docking studies 
could be performed with TbSTT3B. In this way, the specificity of the drug to T. brucei’s STT3B 
could be increased and the toxic activity towards mammalian STT3B could be reduced.  
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10.3 Methods and materials 
10.3.1 Cell culture 
Blood stream form Trypanosoma brucei monomorphic strain 427 were grown at 37 C in HMI-
11 medium (For 1L: IMDM, 880 mL, FBS 100 mL (Gibco), hypoxanthine (stock at 13.6 mg/mL) 
10 mL, bathocuproinedisulfonic acid (stock at 28.2 mg/mL) 1 mL, L-cysteine (stock at 18.2 
mg/mL) 10 mL, pyruvic acid 69.2 µL and 2-mercaptoethanol (stock at 100 mM) 2 mL) and 
passed every day (enlarging the culture each time) until 3 or 5 days had passed and the 
cultures were 100 ml at 1x106 cells/ml. Cultures grown in NGI-1 (AKOS) were passed into 
medium with fresh NGI-1 and those grown with DMSO were passed into medium with fresh 
DMSO. The cells were harvested by centrifugation (10 M for western blotting and 50 M for 
mass spectrometry). 
 
10.3.2 IC50 
Blood stream form Trypanosoma brucei, single marker monomorphic strain 427, were seeded 
at 1x105 cells/ml in 6-well plates with NGI-1 at 0 µM, 10 µM, 25 µM, 40 µM, 55 µM, 70 µM or 
85 µM. Each concentration was grown at 37 C in triplicate and the cells were counted 24 h 
after the addition of NGI-1. 
 
10.3.3 Western blots 
The cell pellet was hypotonically lysed in 100 L of 10 mM sodium phosphate buffer at pH 8 
with 0.1 mM TLCK (Sigma, Missouri), 1 μg/mL leupeptin (Sigma, Missouri), and 1 μg/mL 
apronitin (Biochemica, Darmstadt) and incubated for 5 mins at 37 C. Laemmli (Sigma, 
Missouri, 100 L, 2 x conc.) was added and the solution incubated for 10 min at 99 C. 30 L 
was loaded on to a pre-cast SDS gel which was run at 60 V for 15 min then 100 V for 
approximately 100 min in TGS. The proteins were transferred to a nitrocellulose membrane 
via wet transfer for 1 h at 100V with 20% MeOH in TGS. The membrane was blocked for 1 h 
at 4 C in 3% BSA in blocking buffer (1 L blocking buffer = 50ml TrisHCl 1M, 150ml NaCl 1M, 1 
mL EDTA 1M, 500 L NP40 and 798.5 mL H2O). The membrane was then labelled either with 
ricin (1 L in 5 mL 3% BSA in blocking buffer, stock at 1 g/L) or ConA (1 L in 5 mL 3% BSA 
in blocking buffer, stock at 1 g/L) at 4 C for 1 h. The membrane was washed with 3 x 5 mL 
blocking buffer for 10 min each wash. It was then labelled with ExtrAvidin-peroxidase (1 L in 
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 5 mL 3% BSA in blocking buffer, stock at 2 g/L, Sigma Missouri) at 4 C for 1 h and then 
washed with 3 x 5 mL blocking buffer for 10 min each wash. The membrane was revealed with 
1 ml of Immobilon western chemiluminescent HRP substrate (Millipore, Billerica) and images 
recorded on a chemidoc XRS+ (50 images over 300 sec). 
10.3.4 VSG preparation 
The cell pellet was washed twice with 50 mL TDB at 0 C. It was transferred to an Eppendorf 
and washed a further three times (3 x 1 mL TDB).  As much TDB as possible was removed and 
the pellet was re-suspended in 0.5 mL of pre-warmed 10 mM sodium phosphate buffer at pH 
8 with 0.1 mM TLCK, 1 g/mL leupeptin and 1 g/mL appronectin and incubated for 5 mins at 
37 C.  The Eppendorf was then spun for 5 min at max speed and the supernatant transferred 
to a fresh falcon on ice. This supernatant was applied to a mini column loaded with 300 L of 
DE52 pre-equilibrated with 10 mM sodium phosphate buffer (pH 8). Once the sample was 
loaded on to the column, 1 mL of 10 mM sodium phosphate buffer (pH 8) was added. Another 
1.5 mL of 10 m sodium phosphate buffer (pH 8) was added and the eluate was collected in an 
eppendorf (total 1.5 mL). This elute was loaded in 250 L batches to an Amicon Ultra 10 kDa 
column and concentrated. Once loaded, the sodium phosphate buffer was removed with 
washes with mass spectrometry grade water (approx. 1 mL). The remaining eluate on top of 
the column was transferred to a low bind Eppendorf, dried and stored at -20 °C for mass 
spectrometry. 
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11. Hunting for the elusive N-glycoproteins of Plasmodium 
falciparum 
11.1 Results and Discussion 
This chapter has three main aims; (i) to develop a method to enrich glycoproteins from whole 
cell lysates of P. falciparum; (ii) to characterise the N-glycans present in P. falciparum; (iii) to 
identify the proteins that are N-glycosylated. Lectin affinity enrichment techniques were used 
to enrich glycoproteins from P. falciparum lysates. N-Glycans present and their associated 
proteins were characterised by mass spectrometry. 
 
11.1.1 Author Contributions 
 
J. G. M. Bevan, N. Cornillie, E. Aquilini and J. A. Rodrigues designed the experiments. J. G. M. 
Bevan performed all of the experiments. N. Cornillie and C. W. Lin submitted the samples of 
the Velos and galactose modified samples to mass spectrometry. J. G. M. Bevan, N. Cornillie 
and C. W. Lin performed the mass spectrometry data analysis. J. G. M. Bevan created all the 
figures and tables. J. A. Rodrigues mentored and supervised the work. 
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 11.1.2 P. falciparum glycopeptide enrichment using the FASP FACE protocol 
P. falciparum was cultured in O+ RBCs until a high parasitemia (at least 20%) in the trophozoite 
form. This form contains the most proteins in the blood stage and is where there is a peak of 
Stt3 transcription (Roos, 2001). The red blood cells were lysed and the remaining parasites 
washed. The parasites were then lysed and subjected to the Filter Aided Sample Preparation 
(FASP) and Filter Aided Capture and Elution (FACE) protocols, figure 56. 
Figure 56 – Diagram of FASP and FACE protocol 
This protocol enriches glycopeptides using an ultrafilter. Lectins bind to the glycopeptides, 
keeping them on top of the filter whilst the peptides with no affinity are washed away. The 
glycopeptides are then unbound by the addition of substrate with high affinity to the lectin 
(often a monosaccharide) and washed through the filter (Wiśniewski et al., 2009; Pan et al., 
2011). 
 
The lectins Griffonia (Bandeiraea) Simplicifolia Lectin II (GSLII) and Wheat Germ Agglutinin 
(WGA) were selected to enrich for P. falciparum glycopeptides because both lectins bind to 
GlcNAc residues. WGA also binds to sialic acid, both have affinity to blood groups A and B and 
WGA will also bind to blood group O. Both GSL II and WGA also have a lower affinity to GlcNAc 
compared to GlcNAc2 therefore proteins conjugated to a single GlcNAc may not be enriched 
(Liener, Sharon and Goldstein, 1986). WGA is able to recognise GlcNAc but GSL II only 
recognises terminal GlcNAc, therefore together they should cover any type of GlcNAc in P. 
falciparum. Although these lectins have off-target specificities, washing steps will remove the 
majority of red blood cell proteins and the remaining can be distinguished from P. falciparum 
by using proteome databases. Alternative lectins are Datura Stramonium, Lycopersicon 
esculentum or Solanum tuberosum lectins. However, these lectins have a high affinity for 
oligomers of GlcNAc, over the mono or dimer, which are not expected to be present in P. 
falciparum (Liener, Sharon and Goldstein, 1986). 
 
 126 
P. falciparum glycopeptides were eluted from WGA and GSLII with GlcNAc. These peptides 
were then desalted and analysed by mass spectrometry. Three fragmentation methods were 
used: Higher-energy collisional dissociation (HCD), Electron-transfer dissociation (ETD) and 
HCD with ETD triggered by oxonium ion 204 from GlcNAc. This ion is caused by the cleavage 
of one GlcNAc and would signal the presence of a glycopeptide. 
 
Standard fragmentation is caused by collision induced dissociation (CID) which cleaves glycans 
from their peptides. HCD is fragmentation technique that keeps the glycan intact and 
improves the detection of low m/z ions enabling the detection of monosaccharides with a 
higher accuracy and lower background noise. It also produces what is named a Y1 ion which 
are from the peptide + GlcNAc making glycopeptide characterisation easier. However, it often 
cannot fully fragment the peptide backbone. ETD also keeps the glycan attached to the 
peptide. It is a complementary method that is more efficient in peptide fragmentation often 
elucidating different glycopeptides to HCD. A combination of the two techniques has proven 
to be effective and has lead to the identification of many N-glycopeptides (P. Zhao et al., 2011; 
Singh et al., 2012; Cao et al., 2017). 
 
The mass spectrometry facility performed a MASCOT search based on proteins from the 
PlasmoDB database using a peptide mass tolerance of 0.5 Da, searching for the HexNAc 
oxonium ion 204.0866 and the HexNAc2 oxonium ion 407.1670. These results are summarised 
in table 6 and the hits are found in annex tables 14 to 17. There were a number of proteins 
identified as having either a HexNAc or HexNAc2 from the data generated by either ETD or 
HCD fragmentation. However, the sequon required for N-glycosylation (NXT(S)) was absent 
indicating that this hit is not a true N-glycan. The HCD/ETD data gave no glycopeptides. 
 
Performing searches using the MaxQuant software and the UniProt P. falciparum database on 
the HCD data gave a huge number of matches for O-glycosylated peptides but few for N- 
glycosylation. An advantage of the MaxQuant analysis is that it predicts where in the peptide 
the glycan is attached. This allowed for a rapid scan of those that contained sequons but for 
many it was not present. Those that had sequons present were manually analysed to confirm 
the presence of the HexNAc oxonium ion 204.0866 and the HexNAc2 oxonium ion 407.1670 
but to no avail. 
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 Table 6 - Summary of results from a number of database searches against the different ionisation methods. 
More detailed results are in annex tables 14 to 17. 
 
 
 
 
 
 
 
 
 
There was also almost no overlap between all six searches: one protein in MaxQuant search 
of O- and N- was also present in MaxQuant N- search. This protein is ARP1, actin-related 
protein and the peptide that was identified has the sequence NGHLFNTSSEMEVVK. This 
peptide does contain the sequon in the middle but MaxQuant labels the first N in the sequence 
as the position for the modification. When the MS/MS spectra were manually analysed for the 
presence of the GlcNAc containing ion, no amino acids were resolved. 
 
The fragment ions in this experiment were measured by an ion trap which is a lower accuracy 
and lower resolution mass analyser but it is more sensitive. The lower accuracy could be the 
reason behind the large number of false positives.  The HexNAc ion is very low mass therefore 
any deviations in mass caused by the low accuracy have a large impact on their detection. 
11.1.3 The orbitrap mass analyser for improved detection of P. falciparum glycopeptides 
Samples of P. falciparum glycopeptides were prepared using the FACE FASP procotol 
described above. They were sent for analysis by mass spectrometry on an orbitrap mass 
analyser that has a higher accuracy and is commonly used in the identification of glycans. The 
resulting peptides were compared to a customised combined database of the proteomes of 
all genus of Plasmodium as well as the human proteome to exclude red blood cell 
contaminents on MASCOT. According to this search, all the proteins found were not 
glycosylated. ARP1 was again present but this time without a modification. 
 
Search Database Raw file Type Hits Sequon 
MASCOT PlasmoDb ETD HexNAc (N) and HexNAc2 (N) 25 6 
MASCOT PlasmoDb HCD/ETD None 0 0 
MASCOT PlasmoDb HCD HexNAc (N) and HexNAc2 (N) 2 1 
MaxQuant Uniprot HCD HexNAc (ST) 254 N/A 
MaxQuant Uniprot HCD HexNAc (N) and HexNAc2 (N) 11 2 
MaxQuant Uniprot HCD HexNAc (N) and (ST) 22 7 
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A Total Ion Chromatogram (TIC) shows all the ions found during the mass spectrometer scan. 
Analysis of this plot can provide information on the type of sample. Glycopeptides elute later 
in the scan therefore the profile of the TIC should have a peak at the end for an enriched 
sample. This is clearly the case with the sample that was run on the orbitrap, top - figure 57. 
In contrast, the TIC profile of the peptides that were not bound to the lectins had no such 
profile (bottom, figure 57), further validating the enrichment. 
Figure 57 - Total Ion Chromatogram of enriched glycopeptides. Top: TIC of enriched glycopeptides 
with a search for HexNAc ion. Bottom: TIC of unbound peptides. 
Manual searches with Xcalibur showed that there were a large number of glycopeptides with 
either a GlcNAc or GlcNAc2 ion clearly present. MASCOT had not been able to identify the 
peptide, and therefore the protein, associated with these glycans. Interestingly, the mass 
difference associated with loss of a FucGlcNAc2 (552) was observed in couple of peptides but 
the full sequence of the peptides could not be elucidated. This is particularly interesting as 
homologues of the GDP-Fucose de novo pathway, PfGMD and PfFS, and the fucosyltransferase 
PoFUT2 are found in P. falciparum’s genome (Sanz et al., 2013). The surface of the parasite 
can be labelled with fucose binding lectin UEA which is reduced in the null mutant of PfGMD, 
but no fucosylated glycan has been identified so far (Sanz et al., 2016). 
 
Attempts were made to manually assign the peptides that contained a clear GlcNAc or GlcNAc2 
ion. To start interpretation the y1 ion (residue K at 147 or R at 175) was found. From there, 
mass differences were calculated between y1 ion and peaks to its right until the mass matched 
a peptide residue. Unfortunately, the full peptide sequence was never determined for all 
attempted GlcNAc or GlcNAc2 peptides. The problems in identifying the peptide fragments 
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 could be because it was not fragmented well enough, or the intensity of the fragments was 
not high enough to see. An example of a GlcNAc peptide is in figure 58. In this example, the 
oxonium ion for GlcNAc and the y1 ion for lysine are present. Attempts to work from lysine 
onwards gave some rare peptides that are unlikely and/or a dead end. The sequence AEE is 
potentially present as the mass differences match, but it was not possible to elucidate further. 
Figure 58 - Example of manual analysis of MS/MS spectra containing the 204.09 GlcNAc ion 
To improve the signal from the glycopeptides, a larger culture was grown to a higher 
parasitemia (25%) increasing the amount of P. falciparum protein used in the FASP FACE 
protocol from 500 µg to 3.6 mg. Again GlcNAc and GlcNAc2 ions were present but the increase 
in protein did not improve the quality of the spectra obtained. Haserick et al. had similar 
problems with the algorithm inbuilt in their peak assigning software not assigning 
glycopeptides in C. parvum. However, they were able to label their spectra manually (Haserick, 
Klein, et al., 2017; Haserick, Leon, et al., 2017). 
11.1.4 Magnetic bead-bound lectins for the enrichment of P. falciparum glycoproteins 
The FASP FACE method was proven to effectively enrich glycopeptides as observed by the TIC 
profile, figure 57. However, since the method uses ultra-centrifugal filters there is the 
possibility that some glycopeptides are lost in the washed in the step to remove non 
glycopeptides, that some remain bound to the lectin or that some are bound to the filter itself 
during both the FASP and the FACE stage. Amicon state that their 30 kDa ultra centrifugal filter 
has a 95% recovery of BSA when 4 mL is concentrated to 0.2 mL. However, the numerous 
washes involved in FASP FACE means that this ideal 95% would be lower. There are also 
proteins of lower Mw present in the sample which are more likely to be lost after many 
centrifguations. 
 
A 
E 
E 
K Pyroglutamic acid? 
GlcNAc 
Homoserine lactone? 
F? 
 130 
In an effort to reduce the loss of glycopeptides, thereby improving the quality of the sample 
and subsequent mass spectrometry, magnetic beads bound to streptavidin were investigated. 
In theory, these beads can be bound to any lectin conjugated to biotin and be used in a pull 
downs of glycopeptides. The can be boiled to more efficiently release the bound peptides 
from the lectin and the number of washing steps is drastically reduced, figure 59. 
Figure 59 – Use of lectin bound to beads for enrichment of glycoproteins 
Since the presence of P. falciparum N-glycoproteins is not yet proven, initial attempts at using 
magnetic beads were with T. brucei lysates and the lectin ricin due to the high abundance of 
Gal terminal N-glycans. T. brucei lysates were incubated with biotinylated ricin before MACs 
streptavidin beads were added. The beads were washed and bound proteins eluted by adding 
boiling laemmli buffer and loaded on to an SDS gel, gel A figure 60. The amount of protein 
loaded into lane 2 was a quarter of that used in the enrichment experiment. The enrichment 
seems to have been successful as a number of proteins appear higher in abundance in the 
enriched compared to the non. The same assay was therefore applied to P. falciparum lsyates. 
 A            B 
  1      2     3                  1       2      3     4      5     6     
Figure 60 – A: Magnetic bead-bound ricin enrichment of T. brucei. Lane 1 = ladder, lane 2 = T. brucei 
lysates and lane 3 = T. brucei proteins eluted from the magnetic bead-bound ricin. B: Magnetic bead-
bound GSLII and WGA enrichment of P. falciparum. Lane 1 = ladder, lane 2 = P. falciparum lysates, 
lane 3 = blank, lane 4 = P. falciparum proteins eluted from the magnetic bead-bound GSL II and WGA, 
lane 5 = P. falciparum proteins eluted from the magnetic bead-bound GSL II and lane 6 = P. 
falciparum proteins eluted from the magnetic bead-bound WGA. 
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 This time GSL II (lane 5), WGA (lane 6) or both lectins (lane 4) were used to enrich the 
potential short GlcNAcs-proteins, gel B figure 60. Unfortunately, no proteins were seen in any 
elution lane (4 to 6) and the lane containing around a quarter of the proteins compared to 
that used in the enrichement assay only showed a poor smear with barely any protein present. 
There was also a need for a positive control – a protein that contains a GlcNAc for certain. 
BSA-GlcNAc is a commercially available protein that has been chemically labelled with a 
GlcNAc and is sold as a control in agarose-lectin binding assays of WGA or GSL II. It is can 
therefore be used as a positive control in our magnetic bead-lectin assay to determine if the 
lectins are not binding to P. falciparum lysates due to the absence of GlcNAc or if there is a 
problem with the lectin. Furthermore, binding the lectin to the proteins and then to the beads 
could lead to lectin that is not bound to any protein binding to the bead and diluting the result. 
Therefore, binding the lectins to the beads first was tested with the BSA-GlcNAc control. The 
beads were washed before the addition of the protein so that any excess lectin was removed. 
Both lectins were again tested together and separately, gel A figure 61. Only some high 
molecular weight oligomers of BSA-GlcNAc are seen in elution lanes 4 to 6. Four times more 
BSA-GlcNAc was used in the enrichment experiment compared to the control lane 2, therefore 
the small amount of high molecular weight proteins is nothing in comparison. From this 
experiment, it is also not possible to tell if the binding of the oligomers is due to the GlcNAc 
or non-specific interactions. A negative control should have been used where the lectin is not 
present. The band of protein at the bottom of the gel in lanes 4 to 6 is from streptavidin. It is 
possible that more lectin is needed than was used. The beads have a high enough loading of 
streptavidin to conjugated around 20 x more lectin than was used in this assay. Using more 
lectin could improve the binding of BSA-GlcNAc as steric blocking of the few lectins conjugated 
could have prevented more proteins from binding, especially as it seems like the predominant 
form of the protein is as oligomers. 
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Figure 61 - A: Magnetic bead-bound GSLII and WGA enrichment of BSA-GlcNAc. Lane 1 = ladder, lane 
2 = BSA-GlcNAc, lane 3 = blank, lane 4 BSA-GlcNAc eluted from magnetic bead-bound GSL II and 
WGA, lane 5 = BSA-GlcNAc proteins eluted from magnetic bead-bound GSL II and lane 6 = BSA-
GlcNAc proteins eluted from magnetic bead-bound WGA. - B: Magnetic bead-bound GSLII and WGA 
enrichment of BSA-GlcNAc and P. falciparum. Lane 1 = ladder, lane 2 = BSA-GlcNAc, lane 3 = P. 
falciparum lysates, lane 4 BSA-GlcNAc eluted from magnetic bead-bound GSL II and WGA, lane 5 = 
BSA-GlcNAc proteins eluted from magnetic beads without lectin, lane 6 = P. falciparum proteins 
eluted from the magnetic bead-bound GSL II and WGA and lane 7 = P. falciparum proteins eluted 
from magnetic beads without lectin. 
The assay was repeated with 10 x more lectin with both the positive control BSA-GlcNAc and 
fresh P. falciparum lysates and the negative control of beads that were not conjugated to 
lectins and freshly purchased Dynaeads. There was only a slight increase in BSA-GlcNAc in lane 
4 where lectins were present compared to lane 5 where they are absent. This means that the 
interactions of the BSA-GlcNAc oligmoers is predominantly non-specfic. It could be that the 
high density of proteins in the oligomer sterically hinders the GlcNAc residue from binding. 
However, since this is sold as a standard for GSL II and WGA it would be unusual. There are no 
P. falciparum proteins present in lane 6 where lectin was present nor lane 7 where it was 
absent. In a way, this is a positive result since it means that the proteins do not interact with 
the beads in a non-specific manner. However, no glycoproteins were enriched. The band in 
lanes 4 and 6 just above 25 Da is biotin. GSL II has a molecular weight of 113 kDa and WGA 38 
kDa. The action of boiling in laemmli buffer breaks the streptavidin bond releasing the lectins 
from the beads, but there are no bands of this Mw seen on the gel. Both lectins exist as dimers 
and although they were subjected to reducing conditions it is possible that they have 
remained as dimers (GSL II at 226 kDa, WGA at 76 kDa). There are bands at these molecular 
weights but they match those from the control lane of BSA-GlcNAc so are unlikely to be from 
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 the lectins. It could be that the lectins needed longer than what they were given to react with 
the dynabeads. 
 
11.1.5 Chemical modification of P. falciparum N-glycans to enable their enrichment 
After trying numerous methods to pull down GlcNAc and GlcNAc2 residues from P. falciparum 
lysates without being able to identify any glycoproteins, chemically modifying the N-glycans 
to allow for a different pull down was considered. As previously described, -1,4-
galactosyltransferase adds a galactose to a terminal GlcNAc. If this enzyme was able to 
galactosylate P. falciparum N-glycans then they could be enriched with ricin instead of GSL II 
and WGA. This would serve two purposes; first ricin might improve the enrichment protocol 
by binding with a higher affinity to Gal residues than GSL II and WGA do to GlcNAc, secondly 
it provides a way to validate the GlcNAc peptides found previously. If a GalGlcNAc peptide is 
present in the ricin pull down and the GlcNAc present in pull down then it is almost certainly 
glycosylated. R. communis seeds contain two galactose binding lectins: ricin and Ricinus 
communis agglutinin I (RCA-I). RCA-I is a tetramer, therefore it binds with a higher avidity to 
terminal galactose residues than ricin (Liener, Sharon and Goldstein, 1986). 
 
Dieckmann-schupper et al. used a similar technique to try and prove the presence of O-GlcNAc 
residues in blood stage form P. falciparum with radiolabeled UDP(14C)Gal but they did not 
perform any glycoprotein enrichment. They found the amount of Gal labelled GlcNAc was 
almost the same in infected and non-infected erythrocytes but after many repeats the 
infected cells always had a higher quantity, suggesting the parasite is contributing to their 
presence. However, they were unable to identify any proteins with a GlcNAc modification 
(Dieckmann-Schuppert, Bause and Schwarz, 1993). 
11.1.5.1 Using -1,4-Galactosyltransferase to produce GalGlcNAc residues for characterisation 
The reaction of -1,4-Galactosyltransferase (-1,4-GalT) with GlcNAc is very sensitive and 
requires optimisation before it can be used on a large scale with P. falciparum. The previously 
mentioned BSA-GlcNAc was used to optimise conditions. In order to visualise GlcNAc or Gal 
residues, dot blots were performed: samples of proteins are pipetted on to a nitrocellulose 
membrane and dried. The membrane can then be labelled with a biotinylated lectin and 
revealed by chemiluminescence. This technique allows rapid visualisation of the glycans 
present in the sample. By performing dot blots with GSL II and ricin of each sample the extent 
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of reaction with -1,4-GalT will be determined. For all dot blots shown in this chapter, if a dot 
of protein is present but there is no signal or the signal is weak then it is circled. If the dot is 
clearly labelled, then it is not circled. 
 
In this first dot blot are samples of BSA-GlcNAc incubated with either different amounts of -
1,4-GalT or UDP-Gal or a different buffer, figure 62. The exact conditions used can be found in 
annex table 18. The absence of signal in the GSL II blot is most likely because the membrane 
was contaminated with something that lead to a large increase in non-specific signal across 
the membrane. Only two conditions produced Gal-GlcNAc, giving rise to the signal at positions 
5 and 6 on the ricin dot blot. These conditions used either an increase in concentration of 
HEPES or Tris-HCl and had no NP-40 present which may have been interfering with the 
enzyme’s interactions. 
Figure 62 - Dot blots of BSA-GlcNAc revealed to -1,4-GalT and UDP-Gal in different buffers. Blot A 
was exposed with GSL II and blot B was revealed with ricin. Dot 1: 1.7 µg GalT, 125 µm UDP-Gal, 4°C, 
o/n. Compared to dot 1: dot 2: less UDP-Gal, dot 3: less GalT and less UDP-Gal, dot 4: less time, 
higher temperature, dot 5: more concentrated HEPES and no NP-40, dot 6: 50 mM TrisHCl and no 
HEPES. 
 
-1,4-GalT is known to autogalactosylate and if this reaction is faster than that with the 
desired substrate it can drastically reduce the efficiency of reaction (Whiteheart et al., 1989). 
Therefore, using 100 mM HEPES, the next dot blot was performed to assess if pre-incubating 
-1,4-GalT before reacting it with our BSA-GlcNAc substrate would improve the efficiency of 
the reaction. The effect of increasing [MnCl2], [UDP-Gal] and Gal-T were also assessed. Control 
blots were made of identical samples but incubated with added GlcNAc or Galactose and 
lactose for GSL II and ricin respectively. These sugars block the action of the lectin and 
therefore show if any labelling in the corresponding blot is specific or not. The full set of 
conditions are found in annex 19. 
1        2        3 
 
4        5        6 
A B 
 1       2         3 
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Control blots B and D show no non-specific binding of the lectins to the blots, figure 63. Blot 
C shows that all conditions produced galactosylated BSA-GlcNAc. However, blot A shows that 
for conditions 2, 6, 7 and 10 a small amount remains ungalactosyalted. Conditions 6, 7 and 10 
are all pre-incubated before the addition of BSA-GlcNAc to encourage auto-galactosylation 
before the intended reaction ot improve efficiency. However, the fact that 3 of the 5 pre-
incubated conditions still had non-galactosylated BSA-GlcNAc present suggests that the 
enzyme used up all of the UDP-Gal galactosylating itself. Conditions 8 and 9 had an increased 
amount of UDP-Gal and therefore were able to galactosylated BSA-GlcNAc as well as auto-
galactosylated -1,4-GalT. MnCl2 is required for the enzyme to bind to its substrates. Adding 
a higher concentration of MnCl2 (conditions 2 and 7) seems detrimental to the enzymes 
activity. MnCl2 is known to be required for the binding of UDP-Gal and for stabilisation of the 
transition states on the formation of the glycosidic bond and the increase in activity on its 
addition is well described (Boeggeman and Qasba, 2002). MnCl2 is slightly acidic, therefore 
increasing its concentration could have made the buffer too acidic and out of the optimal pH 
range of -1,4-GalT. 
 
 
Figure 63 – Dot blots of BSA-GlcNAc exposed to -1,4-GalT and UDP-Gal with varying [MnCl2], [UDP-
Gal] and [GalT], with (dots 6 to 10) and without (dots 1 to 5) pre-incubation of -1,4-GalT with UDP-
A: GSL II 
C: Ricin 
Before GT 
No pre inc. GT 
GT pre inc. 
Before GT 
No pre inc GT 
GT pre inc. 
B: GLS II + 44 mg/ml GlcNAc 
D: Ricin + 30 mg/ml Gal and 
60 mg/ml lactose 
  1 2      3       4        5  
 
  6 7      8       9    10 
  1 2      3       4        5  
 
  6 7      8       9    10 
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Gal. Blots A and B were revealed with GSL II and blots C and D were revealed with ricin. Compared 
to conditions for dot 1: dots 2 and 7: more MnCl2, dots 3 and 8: more UDP-Gal, dots 4 and 5: more 
UDP-Gal and more GalT and dots 5 and 10: more GalT. Dots 1 to 5 were incubated at 37 °C  for an 
hour before addition of BSA-GlcNAc. All were incubated for an hour at 37 °C with BSA-GlcNAc. 
After the addition of Gal to GlcNAc, UDP remains and is a known inhibitor of 
galactosyltransferases. Alkaline phosphatase is an enzyme that degrades UDP and can be used 
in situ to remove this inhibitory effect (Sujino et al., 2000). A number of concentrations of 
alkaline phosphatase were tested but there was no major change in the conversion of BSA-
GlcNAc to BSA-GlcNAcGal. Perhaps on a different scale (less -1,4-GalT used or more 
substrate) alkaline phosphatase would prove more useful. 
 
To optimise the amount of UDP-Gal and -1,4-GalT used, two assays were preformed where 
the UDP-Gal or -1,4-GalT concentrations were changed, figure 64. This was performed on a 
much larger scale than before (100 µg or 500 µg compared to 1 µg of BSA GlcNAc used 
previously) in order to mimic conditions with P.  falciparum lysates where far more protein is 
present. 
 
Figure 64: Blots A and C stained with GSLII. Blots B and D stained with Ricin. For blots A and B: 
Decreasing amount of UDP-Gal used for dots 1 to 6, no enzyme used in 7 (control) and 100 µg of BSA-
GlcNAc is present in all dots. For blots C and D: 500 µg of BSA-GlcNAc is present in all dots, dots 1 to 
3 used 1.7 µg of -1,4-GalT and dots 4 to 6 used 2.5 µg of -1,4-GalT. Dots 1 and 4 used 18 µL of UDP-
Gal stock, dots 2 and 5 used 20 µL of UDP-Gal stock and dots 3 and 6 used 22 µL of UDP-Gal stock. 
Dot 7 was not exposed to-1,4-GalT (UDP-Gal stock at 8.19 mM). 
Ricin 
Reducing 
amount of 
UDP-Gal for 
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BSAGlcNAc 
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 Blot B shows that all conditions where -1,4-GalT was present produced BSA-GlcNAc as there 
is a signal for dots 1 to 6 and not for 7. However, blot A shows that at least 12 µL of the stock 
solution of UDP-Gal is required for complete conversion of 100 µg of BSA-GlcNAc as a faint 
signal is still seen in dot 3 indicating an incomplete conversion as the source of UDP-Gal was 
not sufficient or the concentration was not high enough for a 1 hour conversion. 
 
Blot D shows that all conditions where -1,4-GalT was present produced BSA-GlcNAc and in 
its absence, dot 7, no signal is produced. Blot C shows that almost all conditions are 
incomplete except dot 6. Although it had the same amounts of -1,4-GalT as dot 4 and 5, there 
was more UDP-Gal present, driving the reaction to completion. Therefore, for every 500 µg of 
BSA-GlcNAc, 2.5 µg of -1,4-GalT and 22 µL of UDP-Gal stock is required for the reaction to 
complete in 1 hour. The remaining signal seen in the other lanes could also be from non-
galactosylated -1,4-GalT rather than BSA-GlcNAc. On a dot blot it is not possible to 
differentiate. If the conditions are optimised so that both -1,4-GalT and BSA-GlcNAc are fully 
galactosylated then the probability that all P. falciparum GlcNAcs are galactosylated under the 
same conditions is increased. 
 
Using the optimised conditions, P. falciparum lysates were galactosylated and subjected to 
the FASP FACE conditions described previously except this time the pull down was performed 
with ricin in place of GSL II and WGA. It was not clear if the galactosylation would be more 
efficient before or after trypsinisation, both conditions were tested, figure 65. 
Figure 65- Illustration of the two methods by which P. falciparum lysates could be galactosylated. 
Top: galactosylation of proteins, bottom: galalcosylation of peptides. 
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Unfortunately, the TIC profiles of both pre- and post- trypsin galactosylation showed that no 
enrichment of peptides had occurred as there was no late-elution profile as seen with the GSL 
I and WGA pull down, figure 66. 
Figure 66 – TIC profiles illustrating the poor enrichment by ricin. Top: Peptides that were 
galactosylated after being trypsinised. Bottom: Proteins that were galactosylated before being 
trypsinised. 
 
There are a couple of possibilities as to why the enrichment with ricin did not work. The 
addition of galactose might not have occurred or only occurred in small quantities. This could 
have been confirmed by dot blot analysis however dot blots of P. falciparum lysates suffer 
from contamination with red blood cell proteins that are labelled by both ricin and GSL II. It 
could be that there are simply too few, or no, GlcNAc terminating glycans to be galactosylated. 
This would, however, contradict our previous evidence. Perhaps ricin was not binding with 
enough affinity to enrich, but this seems unlikely as it is well used in pull downs of galactose 
containing glycoproteins from lysates (Izquierdo, Schulz, et al., 2009). 
 
11.2 Chapter summary 
To identify N-glycosylated proteins in P. falciparum various methods based on lectin 
enrichment were used in order to prepare a sample for mass spectrometry analysis. Although 
there was evidence of truncated N-glycosylation (GlcNAc or GlcNAc2), the resolution of the 
corresponding peptides was too poor to allow identification of the protein. Chemical 
modification using a GalT to theoretically produce GalGlcNAc or GalGlcNAc2 followed by 
139 
 enrichment with ricin was ineffective. Future work will involve improving the sample 
preparation so that the peptides can be resolved. This may be achieved by increasing the 
parasitemia to decrease the background of proteins from red blood cells.  
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11.3 Materials and methods 
Plasmodium falciparum strain 3D7 was cultured in O+ RBCs in RPMI medium with glutamine 
and HEPES added until 1 ml RBCs at between 15 and 20% parasitemia were obtained. The 
culture was pelleted and the pellet frozen at -20 C. After defrosting, the pellet was washed 
with 3 x 40 mL PBS (centrifuging at 4,000 rpm for 10 min each wash). The pellet was then 
transferred to an Eppendorf and washed with a further 3 x 1 mL PBS (centrifuging at 13,000 
rpm for 5 min each wash). The pellet was re-suspended in 480 L lysis buffer with 20 L pic (1 
mL of lysis buffer = 0.4 mL 20% SDS, 0.1 mL 1 M DTT, 0.5 mL 2 % TX-114, 1 mL Tris-HCl pH 7.6 
and pic = 1 pill in 400 L H2O). The dissolved pellet was heated at 95 C for 1 min x 3 with 1 
min pause on ice, sonicated on ice (2 min 30 sec at 10 microhertz then 30 sec pause x 3) and 
centrifuged for 20 min at 4 C. The pellet was discarded and the supernatant kept for FASP. 
 
11.3.1 Filter aided sample preparation (FASP) 
Samples were prepared using a modified version of a published FASP procedure (Wiśniewski 
et al., 2009). An Amicon 30kda column was pre-washed with 400 L of ddH2O. The sample 
was loaded on to the column (200 g) before 200 L of UA (8M urea in 0.1 M Tris HCl pH 
8.5) was added and the column centrifuged at 14,000 g for 15 min. Another 200 L of UA was 
added and the column centrifuged at 14,000 g for 15 min. The flow through was discarded 
and 100 L of 0.05 M iodoacetamide in UA was added to the column. It was incubated in the 
dark for 20 min then centrifuged at 14,000 g for 10 min. The filter unit was washed twice with 
100 L of UA, each time centrifuging at 14,000 g for 15 min and discarding the flow through. 
It was then washed 4 x 100 L 40 mM NH4HCO3, each time centrifuging at 14,000 g for 10 min 
and discarding the flow through. The filter unit was transferred to a new collection tube, 
trypsin-Lys-C added (promega, use 25:1 protein: protease, w: w) in 40 mM NH4HCO3 (0.4 g 
trypsin/L) and incubated overnight at 37 C. The filter unit was centrifuged at 14,000 g for 
10 min. The filter was washed twice with 40 L of BB (40 mM Tris/HCl pH 7.6, 2mM MnCl2, 
2mM CaCl2, 1 M NaCl) and centrifuged at 14,000 g for 10 mins. The filtrate was collected for 
FACE. 
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 11.3.2 Filter aided capture and elution (FACE) 
The filtrate from the FASP protocol (Pf peptides) was added to an amicon 30kda column (pre-
washed with 400 L of ddH2O) and 36 L GSLII (5 mg in 1 ml of 2 x BB) and 36 L WGA (10 mg 
in 2 ml of 2 x BB) was added. The column was mixed at 550 rpm in a thermomix for 1 min and 
incubated without mixing for 60 min. The column was centrifuged at 14,000 g for 10 min and 
then washed with 200 L of 1xBB with centrifuging the at 14, 000 g for 8 min three times. The 
flow-through from the collection tubes was put to one side (unbound and shouldn’t have 
sugar, but kept for analysis) and the filter transferred to new collection tube. The column was 
washed twice with 200 L of 1xBB followed by centrifugation at 14, 000 g for 8 min. It was 
then washed twice with 50 L ABC centrifuging at 14,000 g for 8 min. The filter units were 
transferred to a new collection tube and 0.5 M GlcNAc in 40 ul ABC was added. The column 
was mixed at 550 rpm for 1 min and incubated in thermo-mixer for 1 h at room temperature. 
The filter units were centrifuged at 14, 000 g for 8 min and then washed twice with 40 L ABC 
centrifuging the filter units at 14, 000 g for 8 min. The filtrate, containing enriched 
glycopeptides, was dried on a speed vac and kept for C18 purification. 
 
11.3.3 Addition of UDP-Gal to GlcNAc residues of P. falciparum 
P. falciparum peptides or lysates (500 µg) were incubated with -1,4-GalT (2.55 µg), UDP-
Galactose (25 µl of 8.19 mM stock) in 10 mM HEPES with 10 mM MnCl2 and alkaline 
phosphatase (5 U) for 1 hour at 37 °C. The peptides were then used in the FACE protocol and 
the lysates in the FASP then FACE protocol. 
11.3.3.1 C18 purification 
All solvents used in this purification were of mass spectrometry grade. The solutions used 
were as follows:  
Conditioning solution: 90/10 MeOH/H2O with 0.1% TFA (v/v/v) (10 ul TFA per 10 ml) 
Equilibration solution: 0.1% TFA in H2O (v/v) 
Desalting solution: 5% MeOH/ H2O with 0.1% TFA (v/v/v) 
Elution solution: 50/50 AcCN/ H2O with 0.1% TFA (v/v/v) 
The C18 SPE cartridge was conditioned by passing 3 ml conditioning solution through the 
packing bed. It was then equilibrated by passing 2 ml equilibration solution through the 
packing bed. The sample was reconstituted in up to 1 ml of 0.1-0.5% TFA. The pH was adjusted 
to <3 with formic acid if needed. The sample was loaded by passing slowly (1 drop/ sec) into 
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the cartridge. Loading was completed by passing 1 ml of equilibration solution into the 
cartridge. The sample was desalted by passing 1 ml desalting solution through cartridge. A 
new was placed below the cartridge for collection of the sample. The sample was eluted by 
slowly (1 drop/ sec) passing 1 ml of elution solution through cartridge. The sample was dried 
on a speed vac overnight. 
11.3.4 Enrichment of glycopeptides using magnetic bead-bound lectins 
Dynabeads (25 µL, 0.25 mg) were washed with PBS (3 x 1 mL, 7.4 pH) and then incubated in 
100 µL of PBS with 25 µg of WGA or 25 µg of GSL II or 12.5 µg of each for 1 h at 4 °C. The beads 
were then washed with PBS (3 x 1 mL, 7.4 pH). Plasmodium falciparum lysates (as prepared 
above, 300 µL ≈ 600 µg) or BSA-GlcNAc (10 µg) were incubated in PBS (1 ml total for P. 
falciparum or 100 µL total for BSA-GlcNAc) for 1 h at 4 °C. The beads were then washed with 
PBS (3 x 1 mL, 7.4 pH). Bound proteins were eluted by boiling the beads in 50 µL laemmli buffer 
for 10 min at 95 °C and run on an SDS gel for visualisation. 
11.3.5 Mass spectrometry 
The samples were analyzed on a calibrated LTQ-Orbitrap Velos mass spectrometer (Thermo 
Fischer Scientific, Bremen, Germany) coupled to an Eksigent-Nano-HPLC system (Eksigent 
Technologies, Dublin (CA), USA). The peptides were resuspended in 3% acetonitrile and 0.1% 
formic acid and loaded onto the self-made tip column (75 μm × 80 mm) packed with reverse 
phase C18 material (AQ, 3 μm 200 Å, Bischoff GmbH, Leonberg, Germany) and eluted with a 
flow rate of 300 nl per min by a gradient from 10 to 31.6% of solution B (99.9% ACN, 0.1% FA) 
applied for 28.5 min, from 31.6 to 44.8 % of solution B (99.9% ACN, 0.1% FA) applied for 25.5 
min, from 44.8  to 98 % of solution B (99.9% ACN, 0.1% FA) applied for 2.5 min, and 98% B 
applied for 11.5 min. One scan cycle comprised of a full scan MS survey spectrum, followed 
by up to 10 sequential HCD MS/MS on the most intense signals above a threshold of 2000. 
The full-scan MS spectra (400–2000 m/z) were acquired in the FT-Orbitrap at a resolution of 
60,000 at 400 m/z, while the HCD MS/MS spectra were recorded in FT-Orbitrap at a resolution 
of 15,000 at 400 m/z. HCD was performed with a target value of 1e5 and a collision energy 
from 35 V was applied. The AGC target values were 5e5 for full FTMS. For all experiments, 
dynamic exclusion was used with 1 repeat count, 15 s repeat duration, and 60 s exclusion 
duration. 
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 The data was processed using MaxQuant15 version 1.3.0.5 which incorporates the 
Andromeda search engine. Proteins were identified by comparing against a protein sequence 
database containing Plasmodium falciparum and human annotated proteins and frequently 
observed contaminants. A peptide tolerance of 10 ppm, an MS/MS tolerance at 0.5 Da and 
full trypsin specificity, allowing for up to one missed cleavages were specified. Fixed 
modifications were set to carbamidomethylation of cysteine. Variable modifications were set 
to oxidation (M) and N-glycosylation (HexNAc and 2HexNAc). 
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 12 Conclusions and future perspectives 
With the field of glycobiology rapidly growing and the importance of N-glycosylation becoming 
widely recognised, tools to study rare glycosylation are highly sought after. This thesis has 
focussed on three aspects of profiling glycosylation; characterising glycosyltransferases 
responsible for building glycans; inhibiting an oligosaccharide that is responsible for the 
transfer of a glycan to proteins; characterising the proteins together with their glycans. Many 
pathogens require glycosylation to proliferate and cause disease. Ultimately, understanding 
in detail how they glycosylate could lead to new therapeutic targets. 
 
Current methods to characterise glycosyltransferases involve finding homologous enzymes in 
other organisms. When this approach fails, there are no other methods to fall back on. Many 
pathogens synthesise unique glycans, therefore a method that can capture and subsequently 
characterise a glycosyltransferase involved in its synthesis could be invaluable to 
understanding these pathogens. These enzymes could serve as suitable drug targets in many 
diseases if well characterised. 
 
In Chapter 1 of this thesis, the first synthesis of a resin bound nucleotide sugar has been 
described. Starting with methyl galactosylpyranoside, resin bound UDP-galactose was 
successfully bound to tentagel resin via and SMCC linker over 9 steps. Resin bound UDP-(4F)-
galactose was then synthesised in 12 steps starting from glucose. The synthesis involved a 
modular approach whereby the phosphorylated sugar was produced with an alkyl chain 
terminating in a thiol at position 6. Tentagel resin was bound to SMCC and uridine phosphate 
was activated with the morpholidate. In doing so, we believe this strategy can be applied to 
almost any nucleotide sugar and these resin-bound nucleotide sugars could be used as probes 
for a wide range of enzymes. Tentagel is a versatile resin that has both hydrophobic and 
hydrophilic character making it the perfect support to use in chemistry and biology. 
 
These particular UDP-Gal based resins can potentially act as affinity probes for the discovery 
and identification of unknown galactosyltransferases through our incorporation of the 
galactose moiety in the probe design. UDP-agarose is a well described affinity probe for 
glycosyltransferases but it is unable to distinguish between the different UDP-sugars therefore 
the designed probes would be of a great advantage. Initial biological assays using -1,4-
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galactosyltransferase indicate that the resin has an affinity for this UDP-Gal processing enzyme 
and that the affinity is higher for the fluorinated probe. However, the evidence was not 
conclusive as further experiments need to be performed with alternative controls. The most 
obvious being a control for extraction of proteins from the SDS gel. Furthermore, since the 
probes were designed to be an improvement upon UDP-agarose, a future experiment should 
be performed with the now optimised conditions to test these resins in parallel to UDP-
agarose. Another interesting experiment would be to compare the resin’s ability to bind to 
galactosyltransferases compared to other UDP-sugar processing enzymes such as α-1,3N-
acetyl-galactosaminyltransferase (UDP-GalNAc) or β-1,3-N-Acetyl-Hexosaminyl-transferase 
(UDP-GlcNAc). This would investigate their selectivity to UDP-Galactose processing 
transferases. Equally, a test to see whether GDP-sugar transferases have an affinity would give 
invaluable insight into the probes specificity. -1,4-galactosyltransferase is an inverting 
transferase and as inverting and retaining transferases operate by different mechanisms it 
would have been advantageous to prove the probe works in both cases. Future work could 
therefore involve the testing of -1,3-GalT with the resins and analogues. 
 
Future probe designs should focus on the inhibitors previously described in the introduction. 
Modification of the uridine moiety to produce strong inhibitors perhaps wouldn’t retain the 
selectivity for galactosyltransferases and would create a general UDP-sugar transferase 
affinity probe. Therefore, modifications of galactose could be performed such as fluorination 
of C2 or introduction of the C-glycosyl moiety. Alternatively, combinations of the two 
modifications could be synthesised which could further increase the binding. 
 
T. brucei synthesises an enormous array of glycans containing linkages that are unique to the 
parasite. Homologues of UDP-Gal/GlcNAc transferases have been identified but so far they 
have not been characterised. Galactosyltransferases are of particular importance to the 
parasite as shown by the essentiality of UDP-Gal and the prevalence of galactose in its glycans. 
An affinity probe that can distinguish between Gal and GlcNAc transferases and enrich 
galactosyltransferases for characterisation would provide a better understanding of the 
mechanisms behind and functions of T. brucei glycosylation. These enzymes are in an 
incredibly low abundance making affinity purification challenging. However, with the right 
probe design it should be possible. 
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In chapter 2, resin bound UDP-Gal proved unable to enrich galactosyltransferases from 
procyclic form Trypanosoma brucei lysates but it did show an affinity for GALE and a UDP-Gal 
transporter. Resin bound UDP-(4F)-Gal also had an affinity towards these two UDP-Gal 
processing enzymes. However, it also enriched GT3 3.5 fold compared to the UDP-Gal resin. 
This is a very positive result as GT3 is the only characterised galactosyltransferase of T. brucei. 
Disappointingly, no other enriched protein showed any GalT like properties. 
 
The enrichment protocol with UDP-(4F)-Gal was only performed once. Therefore, with 
optimisation of incubation times or increased washing of the resin the protocol could be 
improved and the background noise of non-specifically binding proteins should be reduced. 
GalTs are low in abundance, therefore a reduction in background noise could reveal 
uncharacterised GalTs that were not present in previous trials. Furthermore, UDP-Gal was 
used as the control due to its proven low affinity in the previous experiments. The ideal control 
would be the UDP-(4F)-Gal resin with free UDP-(4F)-Gal to block any interactions of the 
galactosyltransferases. This is not a commercially available product therefore the next best 
control of UDP-Gal resin was used. 
 
In future, an alternate strategy could be to synthesise affinity probes based on acceptors to 
target GalTs. For GPI anchor galactosyltransferases this would require only tri or tetra 
saccharide. The affinity might not be sufficient enough to bind the enzymes as they require 
the presence of the donor first, but perhaps with careful design or by using an irreversible 
inhibitor this could be successful. 
 
GlcNAc is prevalent in many unique linkages of T. brucei therefore immobilised analogues of 
GlcNAc could make powerful probes and could help determine the specificity of the UDP-
Gal/GlcNAc transferases. Future work could involve the synthesis of resin bound UDP-GlcNAc 
and the subsequent biological validation assays to ensure these resins have an affinity to 
GlcNAc-transferases. For example, 5-bromo-UTP is a known inhibitor of α-1,3-mannosyl-
glycoprotein 2-β-N-acetylglucosaminyltransferase (Nishikawast et al., 1988). They could then 
be used to characterise the missing N-acetylglucosaminyltransferases of T. brucei. 
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Moving away from biochemistry techniques, systematic knockdowns of the putative 
transferases or over expression could be performed. In doing so, the change in glycan 
structure can be determined and the identity of the transferase revealed. There are groups 
already performing these knock-downs, but the process is slow. Recombinant expression of 
these GTs could also be performed and their specificity tested in a glycan array type 
experiment. A major problem with recombinant expression is that the GT would not be 
glycosylated which can change its folding, affecting its enzymatic activity and rendering it 
dysfunctional. 
 
In chapter 3, studies on the effects of NGI-1 with T. brucei showed that it reduces the parasites 
growth in blood stream forms in vitro and has an IC50 of 75.73 µM. Below 50 µM, the parasite’s 
growth is comparable to those grown in the absence of NGI-1. Therefore, the study of NGI-1’s 
predicted inhibition of STT3B was performed at low concentrations without toxic effects. 
Lectin blots performed on whole cell lysates indicate a change in N-glycosylation, with a 
reduction in high mannose structures and an increase in complex. This is in agreement with 
the predicated inhibition of STT3B that transfers the precursor to high mannose glycans. To 
confirm the change in glycosylation, VSG was extracted from cultures grown in the presence 
or absence of NGI-1. The VSGs were visualised on an SDS page gel and prepared for mass 
spectrometry analysis. The gel alone was not of high enough resolution to draw conclusions 
and the mass spectrometry analysis is still in progress. Once the mass spectrometry data has 
been processed, it should be clear if NGI-1 has inhibited STT3B. 
 
An interesting experiment to perform would be to culture STT3A knock-down T. brucei blood 
stage forms with NGI-1. In vitro, the parasite requires Stt3a or Stt3b. If NGI-1 is specific to 
Stt3b, the effect of NGI-1 should be much greater when applied to the Stt3a knock-down as 
the mutant has a higher dependency on Stt3b. Alternatively, in vivo experiments could be 
performed in mice to try and use NGI-1 to treat a T. brucei infection. At low concentrations, 
NGI-1 is not toxic to mammalian cells nor T. brucei in vitro. However, in vivo, Stt3B is essential 
to the parasite. Therefore, the IC50 of NGI-1 in vivo is likely to be much lower than the 75.73 
µM calculated in vitro. As such, NGI-1 remains an interesting small molecule with potential 
therapeutic value. However, mutations that reduce expression of STT3A and STT3B are known 
causes of congenital disorders of glycosylation in humans (Shrimal et al., 2013). These 
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 disorders are present from birth, therefore the effect of Stt3b inhibition in adults might be 
less severe. Although NGI-1 did not completely inhibit mammalian STT3B, studies would have 
to be performed to evaluate its toxicity to mammals in vivo before NGI-1 could be considered 
as a treatment for Trypanosomiasis. The huge economic burden of Trypanosomiasis in cattle 
demands more effective treatments. Targeting Stt3b with a small molecule inhibitor such as 
NGI-1 could lead to cheaper and more effective treatment methods. 
 
The N-glycosylation of Plasmodium remains a mystery. Although there is strong evidence 
published that the parasite can synthesise short N-glycans, no glycoprotein with this motif has 
so far been characterised. From chapter 4, the mass spectrometry results from the FASP FACE 
protocol with GSL II and WGA were promising and showed that GlcNAc and GlcNAc2 were 
present and successfully enriched, but without the identity of the peptide to which they were 
attached no more is known than before. The presence of the GlcNAc2Fuc motif suggests the 
use of GDP-fucose in N-glycosylation most likely as core fucosylation. Future work could 
involve performing a pull down using a fucose binding lectin such as CCL2, AAL or LEA to 
elucidate further the nature of this modification. The use of -1,4-GalT to galactosylate was 
not successful probably due to the complexity of the lysates. Another approach would be to 
target specific proteins that have the N-X-S/T motif and are present in enriched samples and 
to perform an antibody based pull down of these proteins and analyse them alone (e.g. MESA 
and RMP1 appear often in enriched samples). Although this approach is lengthy, by combining 
the results from our experiments and similar published lists, the chances of enriching an N-
glycoprotein should be improved. The main draw-back of this is that there are no commercial 
antibodies against these proteins, so proteins with already commercialised antibodies would 
be easier to enrich. Finding a method to produce good enough quality MS/MS to resolve the 
peptide structures remains a problem for the identification of glycopeptides. 
 
In short, this work allowed the development of new methods for the discovery of 
carbohydrate processing enzymes and N-glycosylated proteins in two parasites with 
glycosylation pathways that are different from other eukaryotes. These methods require 
optimisation but, considering that these parasites have non-canonical glycosylation pathways, 
the experimental approaches followed in this work should be an effective way of discovering 
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and characterizing the N-glycosylation of their proteins. They can also be applied to other 
organisms who also display unusual glycosylation. 
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13 Annexes 
 
 
 
Figure 67 – Gel to determine the optimal amount of -1,4-GalT and BSA to use. *Heated at 50 C. 
 
 
 
  
------------------------1,4-GalT------------------------    ------------- BSA------------ 
g of protein: 
1    2       4          6          10       10* 1   4   10
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 Mass spectrometry results, Gel A: 
Here each resin was incubated with VSG and BSA. If these proteins bound non-specifically to 
the resins, they should be detected in the elution. However, only the common contaminant 
Keratin was found. 
 
Table 7 - Mass spectrometry results, Gel A (Both resins incubated with condition A) 
Band Type Resin used Proteins found 
A1 Wash 1 UDPGal Serum albumin, Bos taurus 
A2 Wash 1 UDPGal 
Variant surface glycoprotein, Trypanosoma brucei; Keratin, Homo 
sapiens 
Observed peptides, but no significant protein score:  Serum 
albumin, Bos taurus 
A3 Elution UDPGal Keratin, Homo sapiens 
A4 Elution UDPGal Keratin, Homo sapiens 
A5 Standard - Serum albumin, Bos taurus 
A6 Standard - 
Variant surface glycoprotein, Trypanosoma brucei 
Observed peptides, but no significant protein score:  Serum 
albumin, Bos taurus;  Keratin, Homo sapiens 
A7 Wash 1 UDP-4F(Gal) 
Serum albumin, Bos Taurus 
Observed peptides, but no significant protein score:  Keratin, Homo 
sapiens 
A8 Wash 1 UDP-4F(Gal) 
Variant surface glycoprotein, Trypanosoma brucei;  Keratin, Homo 
sapiens 
Observed peptides, but no significant protein score:  Serum 
albumin, Bos taurus 
A9 Elution UDP-4F(Gal) Keratin, Homo sapiens 
A10 Elution UDP-4F(Gal) Keratin, Homo sapiens 
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Mass spectrometry results, Gel B: 
Here each resin was incubated with 1,4)-GalT, VSG and BSA. If (1,4)-GalT bound specifically 
to the resins, it should be detected in the elution. For the UDP-Gal resin, (1,4)-GalT was found 
in the elution, but not in a large quantity. For the UDP-4F(Gal) resin, (1,4)-GalT was found in 
the elution (along with the contaminant keratin. Neither VSG nor BSA were found in the 
elutions, supporting our hypothesis that the resins bind specifically to 1,4)-GalT. 
Table 8 – Mass spectrometry results, gel B 
 
  
Band Type Resin used Proteins found 
B1 Wash 1 UDPGal 
Serum albumin, Bos Taurus. Observed peptides, but no significant 
protein score:  Keratin, Homo sapiens. 
B2 Wash 1 UDPGal Beta-1,4-galactosyltransferase 1, Bos taurus; Serum albumin, Bos taurus 
B3 Wash 1 UDPGal Beta-1,4-galactosyltransferase 1, Bos taurus 
B4 Elution UDPGal Keratin, Homo sapiens 
B5 Elution UDPGal Keratin, Homo sapien 
B6 Elution UDPGal 
Keratin, Homo sapiens. Observed peptides, but no significant protein 
score: Beta-1,4-galactosyltransferase 1, Bos taurus 
B7 Standard - Serum albumin, Bos taurus 
B8 Standard - 
Serum albumin, Bos taurus; Beta-1,4-galactosyltransferase 1, Bos 
Taurus. Observed peptides, but no significant protein score:  Keratin, 
Homo sapiens 
B9 Standard - 
Beta-1,4-galactosyltransferase 1, Bos taurus. Observed peptides, but no 
significant protein score:  Serum albumin, Bos taurus 
B10 Wash 1 UDP-4F(Gal) Serum albumin, Bos taurus 
B11 Wash 1 UDP-4F(Gal) Beta-1,4-galactosyltransferase 1, Bos taurus; Serum albumin, Bos taurus 
B12 Wash 1 UDP-4F(Gal) 
Beta-1,4-galactosyltransferase 1, Bos taurus;  Serum albumin, Bos 
Taurus. Observed peptides, but no significant protein score:   Keratin, 
Homo sapiens 
B13 Elution UDP-4F(Gal) Keratin, Homo sapiens 
B14 Elution UDP-4F(Gal) Keratin, Homo sapiens 
B15 Elution UDP-4F(Gal) Beta-1,4-galactosyltransferase 1, Bos taurus;  Keratin, Homo sapiens 
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 Table 9 – Summary of NSAF counts for Control and Elution of Conditions 1 to 3 
  
Control Elution 
Spectrum Counting NSAF [fmol] 
Protein Description 1 2 3 1 2 3 
Alpha-1-antiproteinase (A1AT_BOVIN) 0 388 340 0 0 0 
Alpha-2-macroglobulin (A2MG_BOVIN) 242 270 233 0 0 0 
Serpin A3-3 (SPA33_BOVIN) 0 0 248 0 0 0 
Sesquipedalian-2 (SESQ2_BOVIN) 0 0 350 0 0 0 
Alpha-2-HS-glycoprotein (FETUA_BOVIN) 1960 1746 2683 2093 1334 5314 
Fetuin-B (FETUB_BOVIN) 640 1253 920 0 0 0 
Green fluorescent protein (GFP_AEQVI) 26415 20618 20582 11232 10919 16520 
Keratin, type II cytoskeletal 5 (K2C5_BOVIN) 0 599 210 0 0 0 
Protein AMBP (AMBP_BOVIN) 0 0 288 0 0 0 
Inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4_BOVIN) 0 0 196 0 0 0 
Lactotransferrin (TRFL_BOVIN) 684 321 202 414 0 0 
Antithrombin-III (ANT3_BOVIN) 0 223 293 0 0 0 
Bovine Serum albumin (ALBU_BOVIN) 3324 4404 4555 4763 2074 3262 
Alpha-1B-glycoprotein (A1BG_BOVIN) 0 602 644 0 0 0 
Variant Surface Glycoprotein 6961 5527 8124 2157 9178 5345 
Ribonuclease pancreatic (RNAS1_BOVIN) 981 6340 11287 0 0 4839 
Beta-1,4-galactosyltransferase 1 (B4GT1_BOVIN) 3738 5765 1127 6179 2977 1827 
Cationic trypsin (TRY1_BOVIN) 1088 1590 2360 0 0 0 
Complement C3 (CO3_BOVIN) 239 65 161 0 0 0 
Chitinase-3-like protein 1 (CH3L1_BOVIN) 661 0 0 0 0 0 
Inter-alpha-trypsin inhibitor heavy chain H3 (ITIH3_BOVIN) 224 0 0 0 0 0 
Polyubiquitin-B (UBB_BOVIN) 121 85 0 0 0 0 
Polymeric immunoglobulin receptor (PIGR_BOVIN) 227 0 0 0 0 0 
Hemoglobin subunit alpha (HBA_BOVIN) 1036 0 0 1960 4998 4035 
Alpha-S1-casein (CASA1_BOVIN) 856 0 0 0 0 0 
Transthyretin (TTHY_BOVIN) 0 704 0 0 0 0 
Alpha-1-acid glycoprotein (A1AG_BOVIN) 0 1294 0 0 0 0 
Polymeric immunoglobulin receptor (PIGR_BOVIN) 0 320 0 0 0 0 
Kininogen-1 (KNG1_BOVIN) 0 196 0 0 0 0 
Keratin, type II cytoskeletal 79 (K2C79_BOVIN) 0 472 0 0 0 0 
Keratin, type I cytoskeletal 10 (K1C10_BOVIN) 0 555 0 0 0 0 
Lysozyme C, milk isozyme (LYSM_BOVIN) 0 0 0 1881 3197 0 
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Hemoglobin subunit beta (HBB_BOVIN) 0 0 0 1920 1632 0 
Hemoglobin fetal subunit beta (HBBF_BOVIN) 0 0 0 0 1632 0 
Annexin A2 (ANXA2_BOVIN) 0 0 0 0 698 0 
Arginase-1 (ARGI1_BOVIN) 0 0 0 0 813 0 
 
 
 
Figure 68 - Predicted glycosyltransferases of Trypanosoma brucei from Izquierdo, Nakanishi, Mehlert, Machray, Geoffrey 
J Barton, et al., 2009 
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Fig. S1
A
Fig. S1. Putative UDP-Gal/UDP-GlcNAc-dependent glycosyltransferases in T. 
brucei genome. (A) Phylogenetic analysis of putative GlcNAc/Galactosyltransferases 
in the T. brucei genome. The box marks the gene studied in this paper. The results of 
Semi-quntitative RT-PCR analysis (see Figure S2) are summarised on the right. No or low 
expression at the mRNA level is indicated by (-). Expression at the mRNA level is indicated 
by (+) and greater expression by (++). (B) Multiple sequence aligment of the predicted 
amino acid sequences of the putative glycosyltransferases shown in panel A visualised by 
Jalview (Clamp et al., 2004). The putative transmembrane domains and DXD motifs of 
the ORFs are indicated by filled blue and green boxes respectively. The predicted amino 
acid sequence of Tb10.389.1450, the gene studied in this paper, is marked with an open 
red box. A scheme of the predicted secondary structure of this ORF, predicted by the Jnet 
algorithm (Cole et al., 2008, Cuff & Barton, 2000), is included and aligned at the bottom.
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Figure 69 -Predicted glycosyltransferases of Trypanosoma brucei from Izquierdo, Nakanishi, Mehlert, Machray, 
Geoffrey J Barton, et al., 2009 
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Table 10 - UDP-Gal probe 1st trial: Enriched proteins 
Protein IDs Product of lead protein Ratio H/L 
Tb927.11.12220 Catalytic subunit of the vacuolar transporter chaperone 4 5.34 
Tb927.10.10170 Predicted WD40 repeat protein 2.84 
Tb927.10.4440 
Tb927.9.8210 
Predicted SAP domain protein 2.70 
Tb927.4.1240 Hypothetical protein 2.14 
Tb927.2.3080 Conserved protein 2.13 
Tb927.2.4110 Mitochondrial-processing peptidase subunit alpha (MPPA) 2.12 
Tb927.11.6790 Predicted WD40 repeat protein 2.11 
Tb927.10.16120 Inosine-5-monophosphate dehydrogenase 2.11 
Tb927.1.4550 Unspecified product 2.10 
Tb927.7.1130 
Tb927.7.1140 
Tb927.7.1550 
Trypanothione/tryparedoxin dependent peroxidase 2 
(TDPX2) 
2.05 
Tb927.3.5250 Zinc finger CCCH domain-containing protein 8 (ZC3H8) 2.02 
Tb927.9.11900 
Tb927.4.5330 
Acyl transferase-like protein 2.01 
Tb927.11.1820 Guanine nucleotide exchange factor subunit GCD2 2.01 
Tb927.7.3440 
Tb927.7.3450 
I/6 autoantigen 2.00 
Tb11.1550 
Tb927.8.4490 
Tb10.v4.0258 
Tb927.10.1510 
Tb927.8.2050 
Hypothetical protein 2.00 
Tb927.10.11990 RNA-binding protein 2.00 
Tb927.10.7500 
Tb927.10.8230 
Fibrillarin (NOP1) 1.90 
Tb927.9.4190 Fatty acyl coa syntetase 1 (ACS1) 1.88 
Tb927.4.3420 Wee1-like protein kinase 1.88 
Tb927.9.3070 Unspecified product 1.87 
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Table 11 - UDP-Gal probe 2nd trial: Enriched proteins 
Protein IDs Product of lead protein 
Ratio H/L 
UDP-Gal-
Rep1 
Ratio H/L 
UDP-Gal-
Rep2 
Tb927.11.7060 Acidocalcisomal pyrophosphatase 9.94 5.01 
Tb927.11.3560 Hypothetical protein 8.84 4.62 
Tb927.11.1490 Unspecified product 6.66 3.70 
Tb927.11.2990 Krepb4 (krepb4) 6.25 2.79 
Tb927.7.7350 Hypothetical protein 5.99 3.62 
Tb927.9.5660 Unspecified product 5.68 3.18 
Tb927.9.11980 Unspecified product 5.45 3.99 
Tb927.11.4450 Alba-domain protein (alba2) 5.23 2.91 
Tb927.1.3500 Unspecified product 5.16 3.32 
Tb927.11.9330 Helicase-like protein 5.00 3.51 
Tb927.3.1920 NOT5 protein (NOT5) 4.87 2.78 
Tb927.10.2910 Splicing factor PTSR1 interacting protein (TSR1IP) 4.85 2.28 
Tb927.8.2450 5-AMP-activated protein kinase subunit beta (AMPKB) 4.82 2.04 
Tb927.9.12120 
Tb927.9.4100 
Tb927.8.1760 
Tb927.6.1300 
Unspecified product 4.66 2.50 
Tb927.6.4370 Eukaryotic translation initiation factor 3 subunit 7-like protein 4.59 1.84 
Tb927.10.14950 Zinc finger CCCH domain-containing protein 40 (ZC3H40) 4.52 2.41 
Tb927.9.9080 
Present in the outer mitochondrial membrane proteome 5 
(POMP5) 
4.40 2.31 
Tb927.8.3330 Mitochondrial carrier protein (MCP18) 4.13 2.90 
Tb927.11.12410 
Tb927.11.12420 
Kinetoplastid kinetochore protein 10 (kkt10) 4.02 1.44 
Tb927.8.3860 WD-repeat containing protein 3.92 - 
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Table 12 –UDP-(4F)-Gal probe, enriched proteins 
Protein IDs Product of lead protein Ratio H/L 
Tb927.6.720 40S ribosomal protein L14, putative 30.87 
Tb927.3.3320 60S ribosomal protein L13, putative 29.91 
Tb927.3.5050 60S ribosomal protein L4 28.10 
Tb927.11.14130 ribosomal protein L18, putative 27.88 
Tb927.9.7620 60S ribosomal protein L11, putative 27.75 
Tb927.10.11390 60S ribosomal protein L6, putative 26.33 
Tb927.9.8420 QM-like protein 24.13 
Tb927.10.15410 glycosomal malate dehydrogenase 23.57 
Tb927.10.4120.
2 
60S ribosomal protein L30 22.98 
Tb927.9.14000 60S ribosomal protein L12, putative 21.79 
Tb927.11.7685 ribosomal protein S10p/S20 20.98 
Tb927.9.15170 60S ribosomal protein L5, putative 20.03 
Tb927.11.10910 40S ribosomal protein SA, putative 19.92 
Tb927.7.1050 40S ribosomal protein S16, putative 19.67 
Tb927.10.1100 60S ribosomal protein L9, putative 19.36 
Tb927.8.1340 60S ribosomal protein L7a, putative 18.90 
Tb927.9.6070 40S ribosomal protein S3, putative 18.15 
Tb927.8.1110 40S ribosomal protein S9, putative 17.83 
Tb927.9.15420 60S ribosomal protein L32 17.75 
Tb927.11.6440 hypothetical protein, conserved 17.21 
 
 
Table 13 - GT3 enrichment result 
GENE RATIO H/L INTENSITY L INTENSITY H 
TB927.2.3370  N/A 0 1352000 
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  Alignment of Sequence_1: TbSTT3B with  Sequence_2: STT3B, Homo sapiens 
 
Similarity : 538/787 (68.36 %) 
 
Seq_1  1     -------------------------MTKGGKVAVTKGSAQSD-GAGEGGMSKAKSSTTFV  34 
                                        :::::::  | ||:: :| :||:   |    :: 
Seq_2  1     MAEPSAPESKHKSSLNSSPWSGLMALGNSRHGHHGPG-AQCAHKA-AGGAAPPK-PAPAG  57 
 
Seq_1  35    ATGGGSLPAWALKAVSTVVSAVILIYSVHRA-YDIRLTSVRLYGELIHEFDPWFNYRATQ  93 
                || ::  | :: |   |  ||:  :: |  ::||  | :  |:| ::  :: :  :: 
Seq_2  58    LS-GGLSQP-A-GWQS-LLSFTILFL-AWLAGFSSRLFAVIR-FESIIHEF-DP-WF-NY  108 
 
Seq_1  94    YLSDNGWRAFFQWYDYMSWYPLGRPVGTTIFPGMQLTGVAIHRVLEMLGRGMSINNICVY  153 
              : :: ::::|:   :: : ::  | |  ::: :::  : ::: :::: :  :|::: :: 
Seq_2  109   RSTHHLASHGFYEFLNWFDERAWYPLGRIVGGTVYPGLMITAGLIHWILNTLNITVHIRD  168 
 
Seq_1  154   IPAWFGSIATVLAALIAYESSNSLSVMAFTAYFFSIVPAHLMRSMAGEFDNECVAMAAML  213 
             ::: :  :  :|  ::  :  : | :  :   :::: :| : ::  ::: ::: ::   : 
Seq_2  169   VCVFLAPTFSGLTSISTFLLTRELWNQGAGLLAACF-IAIVPGYISRSV-AGSFDNEGIA  226 
 
Seq_1  214   LTFYMWVRSLRSSSSWPIGALAGVAYGYMVSTWGGYIFVLNMVAFHASVCVLLDWARGTY  273 
             : :     :|:::|:::::::: : :  ::  :  :::::::| : :    :: :      
Seq_2  227   IFALQFTYYLWVKSVKTGSVFWTMCCCLSYF-YM-VSAWGGYVFIINLIPLHVFVLLLMQ  284 
 
Seq_1  274   SVSLLRAYSLFFVIGTALAICVPPVEWTPFRSLEQLTALFVFVFMWALHYSEYLRERARA  333 
             ::|:::   ::: :   | ::::: :: ::  ::::::::::||:  ::| : : :|:|  
Seq_2  285   RYSKRVYIAYSTFYIVGLILSMQIPFVGFQPIRTSEHMAAAGVFALLQAYAFLQYLRDRL  344 
 
Seq_1  334   PIHSSKALQIRARIFMGTLSLLLIVAIYLFSTGYFRPFSSRVRALFVKHTRTGN-PLVDS  392 
             ::     |::  ::::  ::: |:| |||::|||::|:|:|   |::: ::: : |: :| 
Seq_2  345   TKQEFQTLFFLGVSLAAGAVF-LSV-IYLTYTGYIAPWSGRFYSLWDTGYAKIHIPIIAS  402 
 
Seq_1  393   VAEHHPASNDDFFGYLHVCYNGWIIGFFFMSVSCFFHCTPGMSFLLLYSILAYYFSLKMS  452 
             | || |  ::: |  : :  :  :: :::: :  :::  :: ::  || |:  :: :::: 
Seq_2  403   VSEHQPTTWVS-FFFDLHILV-CTFPAGLWFCIKNINDERVFVA--LYAIS-AVYFAGVM  457 
 
Seq_1  453   RLLLLSAPVASILTGYVVGSIVDLAADCFAASGTEHADSKEHQGKARGK-GQKEQITVEC  511 
             ::|:|  : :::: :  : |:| ::   ::::: | :  :|:::: ::| :| ::::::  
Seq_2  458   VRLMLTLTPVVCMLSAIAFSNVFEHY-LGDDMKRE-NPPVEDSSDEDDKRNQ-GNLYDKA  514 
 
Seq_1  512   GCHNPFYKLWCNSFSSRL-VVGKFFVVVVLSICGPTFLGSNFRIYSEQFADSMSSPQIIM  570 
             | ::::: :   ::  :|  : |:: | :| :  : ::  :: ::::::|:|: |::::: 
Seq_2  515   G-KVRKHATEQEKTEEGLGPNIKSI-VTML-MLMLLMMFAVHCTWVTSNAYSSPSVVLAS  571 
 
Seq_1  571   RATVGGRRVILDDYYVSYLWLRNNTPEDARILSWWDYGYQITGIGNRTTLADGNTWNHEH  630 
              ::: | |:||||    |:||| ||:|:||::||||||||| |: |||||:|:||||::| 
Seq_2  572   YNHD-GTRNILDDFREAYFWLRQNTDEHARVMSWWDYGYQIAGMANRTTLVDNNTWNNSH  630 
 
Seq_1  631   IATIGKMLTSPVKESHALIRHLAD-YVLIWAGYD-GSDLLKSPHMARIG---NSVYRD-I  684 
             || :||:: |: :: : ::|:|:: |||:  | : |::::: ::  :::    : : : | 
Seq_2  631   IALVGKAMSSNETAAYKIMRTLDVDYVLVIFGGVIGYSGDDINKFLWMVRIAEGEHPKDI  690 
 
Seq_1  685   CSEDDPLCTQFGFYSGDFSKPTPMMQRSLLYNLHRFGTDGGKTQLDKNMFQLAYVSKYGL  744 
               |:|::  |: | ::::::||: :: :::::::||| :  : ::  : ::::::   |: 
Seq_2  691   R-ESDYFTPQGEFRVDKAGSPTLLNCLMYKMSYYRFGEMQLDFRTPPGFDRTRNAEI-GN  748 
 
Seq_1  745   VKIYKVMNVSEESKAWVADPKNRKCDAPGSWICTGQYPPAKEIQDMLAKRIDYEQLEDFN  804 
             ::|: ::    |     ::::: : : : ::: | :::|:::::  : | :::::::::: 
Seq_2  749   KDIKFKHLE--EAFTSEHWLVRIYKVKAPDNRETLDHKPRVTNIFPKQKYLSKKTTKRKR  806 
 
Seq_1  805   RRNRSDAYYRAYMRQMG---  821 
             :  ::: : :   ::::    
Seq_2  807   GYIKNKLVFKKGKKISKKTV  826 
 
Figure 71 – Sequence aligment of TbStt3b and Homo Sapien Stt3b 
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Table 14 - Peptides with N-Glycans from ETD trap run, MASCOT analysis with PlasmoDB database 
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 Table 15 - - Peptides with N-Glycans from ETD trap run, MASCOT analysis with PlasmoDB database 
 
 
 
 
 
Table 16 - Peptides with N-Glycans from HCD, MaxQuant analysis with UniProt database search for O- and N-Glycans 
 
Gene	ID Protein	Description Peptide	sequence Modification
PF3D7_1350100 lysine-tRNA	ligase,	putative	(KRS1) ITMFLTNKNSIK HexNAc	(N);	Phospho	(ST)
PF3D7_0928200 conserved	Plasmodium	protein,	unknown	function RGGSFENT NYT NDCLLYIYKE 2	HexNAc	(N);	Phospho	(ST)
Proteins Modified	sequence Modifications
PF3D7_0807800 _(he)NDENKLET(he)SK_ HexNAc	(ST),HexNAc	(N)
PF3D7_1017300 _(he)NDSNSNSHSS(he)NGS(he)SK_ 2	HexNAc	(ST),HexNAc	(N)
PF3D7_1041300 _(he)NGAT(he)GEKS(he)K_ 2	HexNAc	(ST),HexNAc	(N)
PF3D7_0103800 _(he)NGHLFNTSSEMEVVK_ HexNAc	(N)
PF3D7_1116000 _(he)NGIDS(he)FKGK_ HexNAc	(ST),HexNAc	(N)
PF3D7_0418000 _(he)NIDIDLLCDMIKRDVTYS(he)CK_ HexNAc	(ST),HexNAc	(N)
PF3D7_1226500 _(he)NIEMS(he)NLANS(he)LVR_ 2	HexNAc	(ST),HexNAc	(N)
PF3D7_1020600 _(he)NIES(he)FFNYM(ox)KS(he)K_ Oxidation	(M),2	HexNAc	(ST),HexNAc	(N)
PF3D7_1145600 _(he)NINTNVRNTFK_ HexNAc	(N)
PF3D7_0425800 _(he)NKDILSDNPK_ HexNAc	(N)
PF3D7_1457400 _(he)NKETEFS(he)SILKSFNTHK_ HexNAc	(ST),HexNAc	(N)
PF3D7_0503500 _(he)NNDS(he)VHREDK_ HexNAc	(ST),HexNAc	(N)
PF3D7_0619800 _(he)NNEIHYK_ HexNAc	(N)
PF3D7_0415200 _(he)NNKQNNVT(he)HK_ HexNAc	(ST),HexNAc	(N)
PF3D7_0410800 _(he)NNLHMNS(he)FNK_ HexNAc	(ST),HexNAc	(N)
PF3D7_1431100 _(he)NNPKCKIDPK_ HexNAc	(N)
PF3D7_0307700 _(he)NNYNM(ox)SDKQNIPS(he)IDEK_ Oxidation	(M),HexNAc	(ST),HexNAc	(N)
PF3D7_1322200 _(he)NS(he)DNT(he)EGNSK_ 2	HexNAc	(ST),HexNAc	(N)
PF3D7_1010200 _(he)NT(he)KESIDCK_ HexNAc	(ST),HexNAc	(N)
PF3D7_0805300 _(he)NVETCTS(he)SS(he)K_ 2	HexNAc	(ST),HexNAc	(N)
PF3D7_1025900 _(he)NYMNES(he)STQTS(he)TETSSK_ 2	HexNAc	(ST),HexNAc	(N)
PF3D7_1013600 _(he)NYREILRS(he)HK_ HexNAc	(ST),HexNAc	(N)
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Table 17 - Peptides with N-Glycans from HCD, MaxQuant analysis with UniProt database, search for N-glycans 
 
Table 18 - Standard buffer = 20 mM HEPES, 45 mM NaCl, 4 mM CaCl2 and 2% NP-40. All conditions contained 6 mM 
MnCl2, and 1 µg BSA-GlcNAc. 
Sample Buffer GalT (µg) UDP-Gal (µM) Temp (°C) Time 
1 Standard 1.70 125 4 o/n 
2 Standard 1.70 62.5 4 o/n 
3 Standard 0.85 62.5 4 o/n 
4 Standard 1.70 125 37 1 h 
5 100 mM HEPES 1.70 62.5 37 1 h 
6 50 mM TrisHCl 1.70 62.5 37 1 h 
 
 
Table 19 - Optimisation of UDP-gal and GalT quantities. 
Sample 1 2 3 4 5 6 7 8 9 10 
MnCl2 (mM) 6.7 33.3 6.7 6.7 6.7 6.7 33.3 6.7 6.7 6.7 
UDP-Gal (mM) 0.55 0.55 1.10 1.10 0.55 0.55 0.55 1.10 1.10 0.55 
GalT (µg) 0.85 0.85 0.85 1.70 1.70 0.85 0.85 0.85 1.70 1.70 
Conditions 37 °C for 1 h 
Pre-incubation  
then 37 °C for 1 h 
 
 
Gene	Name Modified	sequence Modifications
PF11_0246 _(he)NDNTGNNHLDIGK_ HexNAc	(N)
PFL1240c _(he)NEDKENVVNINIQK_ HexNAc	(N)
PFL1800w _(he)NFYIIKKM(ox)FK_ Oxidation	(M),HexNAc	(N)
PFA_0190c _(he)NGHLF NTS SEMEVVK_ HexNAc	(N)
PF08_0118 _(he)NHVM(ox)NSINKK_ Oxidation	(M),HexNAc	(N)
PFL1475w _(he)NIHEYKK_ HexNAc	(N)
Rh3 _(he)NIM(ox)NELM(ox)RK_ 2	Oxidation	(M),HexNAc	(N)
Oxidation	(M),2	HexNAc	(ST),HexNAc	(N) PF11_0467 _(he)NINTNVRNTFK_ HexNAc	(N)
PF11_0226 _(he)NM(ox)N NST EK_ Oxidation	(M),HexNAc	(N)
PFD0555c _(he)NNIVNKNNELK_ HexNAc	(N)
PFL1990c _(he)NTPHLFNNQQK_ HexNAc	(N)
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